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Introduction
Colonization of the human body by microorganisms occurs at the very beginning of life. 
Most of these microorganisms are commensals, and as such play a major role in bodily 
functions such as digestion and protection against disease [1, 2]. The skin is the largest 
organ in the human body and acts as a physical barrier with the environment, protecting 
the body against bacterial invasion. Unfortunately, this barrier does not always suffice and 
when breached may result in the development of skin and skin structure infections (SSSIs). 
SSSIs encompass a spectrum of clinical conditions with varying presentation, etiology and 
severity, caused by microbial invasion of the epidermis, dermis and subcutaneous tissues 
[3]. In clinical practice, SSSIs are among the most commonly observed human infections. 
Most often, presentation is mild and resolves either without antibiotic treatment or with 
oral antimicrobial therapy. However, severe cases result in either long-lasting or acute, 
life-threatening infections, which require immediate medical and surgical intervention. 
Perhaps due to this diversity in clinical conditions and duration of symptoms, the 
prevalence of SSSIs has been difficult to determine. Studies from the USA estimated 
increasing health care visits for SSSIs, with 48.1 per 1000 population per year in 2005, 
reaching a total of 14.2 million health care visits [4]. Incidence of hospital admissions due 
to SSSIs is also increasing and are estimated to account for ~10% of all hospitalizations 
[5-7].
Classification of skin and skin structure infections
There is, to date, no universally accepted terminology and classification for SSSIs. Synonyms 
for SSSIs are skin and soft-tissue infections and acute bacterial skin and skin structure 
infections. Various attempts have been made to classify SSSIs based on: primary (infection 
of the otherwise normal skin) and secondary infection (complication of a chronic skin 
condition), acute versus chronic infection, local versus systemic infection, focal versus 
diffuse location, depth of the invasion, community-acquired versus nosocomial infection, 
or causative organism [3, 8-12]. 
In this thesis we will adhere to the classification developed by the US Food and Drug 
Administration (FDA) [3]. In their 1998 guidance document for developing antimicrobial 
drugs for treatment of SSSIs, the FDA classified the different conditions in 2 broad 
categories: uncomplicated (uSSSIs) and complicated skin and skin structure infections 
(cSSSIs). The FDA based this classification on the observation that SSSIs tend to share 
common pathogens and show comparable responses to antimicrobial therapy. uSSSIs 
included superficial conditions such as minor abscesses, impetigo, ecthyma, folliculitis, 
furunculosis, erysipelas and cellulitis. cSSSIs included infections of the deeper soft tissue, 
involving surgical intervention or a significant underlying disease state that complicates 
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the response to treatment, such as major abscesses, infected ischemic or diabetic foot 
ulcers, wound and burn infections. Superficial infections located in an anatomical site in 
which the chance of involvement of anaerobic or gram-negative pathogens is high should 
also be considered as cSSSIs [3, 7]. 
Clinical presentation of skin and skin structure infections
The hallmark of SSSIs is redness, warmth, edema and tenderness of the skin, often 
accompanied by (purulent) discharge. At the more severe end of the spectrum of SSSIs, 
infections involve the deeper soft tissue, including the subcutaneous fat and/or fascia and 
muscle, requiring surgical intervention or involving a significant underlying disease state 
that complicates the response to treatment [3]. These deeper SSSIs can be subdivided 
based on clinical presentation in major abscesses, wound and burn infections or infected 
ischemic and diabetic foot ulcers. Major abscesses are characterized by collections of pus 
within the deeper skin and soft tissues, often surrounded by extensive cellulitis. Wound 
infections can originate from a variety of wounds such as post-surgical, post-traumatic, 
human or animal bite wounds, whereas burn infections occur after thermal injury of the 
skin. Infected ischemic ulcers occur in peripheral vascular disease, and diabetic foot ulcers 
are defined as infections occurring below the ankle in patients with confirmed diabetes 
mellitus [3].
Causative organisms of skin and skin structure infections
The microbiology of SSSIs is diverse, with presence of gram-positive, gram-negative aerobic 
or anaerobic bacteria, either alone or as part of a polymicrobial infection. Reviewing the 
major clinical trials for antibiotic registration over the last 15 years, performed according 
to the FDA guidance documents for developing antimicrobial drugs for treatment of SSSIs 
indicated that the large majority of SSSIs are caused by gram-positive bacteria, mainly 
Staphylococcus aureus followed by Streptococcus species (S. pyogenes, S. agalactiae, S. 
dysgalactiae and S. anginosus group) and Enterococcus faecalis. When reported, gram-
negatives Escherichia coli and Pseudomonas aeruginosa are also frequently found in 
the top 5 of causative organisms. Other bacteria, including Bacteroides fragilis, Proteus 
mirabilis, Enterobacter cloacae and Staphylococcus epidermidis only incidentally reached 
the top 5 of causative organisms [13-24]. 
Pathogenesis
The skin is of crucial importance for fluid and temperature regulation, sensation, 
metabolism of vitamin D and defense against bacterial invasion. It consists of 2 distinct 
layers, the epidermis and dermis. The epidermis is the outermost layer of the skin which 
comprises several strata of epithelium and forms the main layer of protection against 
bacterial invasion. The dermis is the layer underneath the epidermis and contains 
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the connective tissue responsible for strength and elasticity of the skin. This layer also 
contains the hair follicles, glands, blood and lymphatic vessels. Beneath these layers of the 
skin, the subcutaneous tissues (fat and fascia), muscle, and bone are positioned (Figure 1). 
The skin controls bacterial invasion by maintaining a low pH, secreting sebum (containing 
antioxidants and antimicrobial peptides) and salty sweat, limiting the presence of 
moisture and maintaining a low surface temperature to prevent growth of pathogens [25, 
26]. In addition, the skin is covered with its own microflora, thereby preventing unwanted 
pathogenic colonization [27]. Upon breaching of this physical barrier, microorganisms 
may invade below the skin and result in the development of SSSIs. Often, these infections 
are caused by commensal bacteria that have escaped their normal habitat and invade 
after physical or chemical trauma to the skin surface. Spread from other invasive bacterial 
infections to the skin rarely occurs, except for septic emboli from certain bloodstream 
infections and endocarditis. Depending on the depth of the microbial invasion and the 
degree of tissue damage, different clinical entities can be described ranging from mild 
superficial infection to deep life-threatening disease (Figure 1) [3]. The pathogenesis of 
SSSIs is an interplay between virulence of the pathogen and the immune response of the 
host.
Bacterial virulence
In order for bacteria to successfully induce SSSIs, they have to overcome several obstacles: 
first, they must be able to adhere to and colonize the skin; secondly, they have to invade 
and cause disease to the skin and underlying tissue; and finally, they need to escape 
Figure 1. Schematic representation of the skin and presence of skin and skin structure infections.
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destruction by the host immune response. Virulence factors are small molecules that 
are expressed or secreted by bacteria that help the bacteria to induce SSSIs. According 
to function, virulence factors can be divided in several classes, such as: factors that 
assist in adherence and invasion, the capsule which protects against opsonization and 
phagocytosis, cell-surface endotoxins and secreted exotoxins. Each species possesses 
their own set of virulence factors as extensively reviewed for major cSSSI pathogens S. 
aureus (O’Riordan et al. [28], Dinges et al. [29] and Foster et al. [30]) and Streptococcus 
species (Cuningham et al. [31], Walker et al. [32] and Lindahl et al. [33]).
Host immune response 
When a pathogen breaches the physical barrier of the skin, cells of the host immune system 
come into play. The immune system can be divided into innate and adaptive immunity. 
Cells of the innate immune system are first to respond after invasion of microbes. They 
recognize these invaders by conserved microbial structures, called pathogen-associated 
molecular patterns (PAMPs), using specific pattern-recognition receptors (PRRs). Five 
different classes have been described to date: Toll-like receptors (TLRs), Nucleotide-
binding domain (NOD)-like receptors (NLRs), C-type lectin receptors, Retinoic acid-
inducible gene I (RIG-I) like receptors and absent in melanoma 2 (AIM2)-like cytoplasmic 
DNA receptors. Activation of PRRs, induces downstream intracellular signal transduction 
cascades which result in gene transcription, synthesis and secretion of effector molecules 
such as cytokines, chemokines and antimicrobial peptides, recruitment of other innate 
immune cells (e.g. neutrophils), and activation of an adaptive immune response [34]. 
Each microbe, depending on its composition, activates a distinct set of PRRs, resulting 
in tailored immune responses for each pathogen, for example as reviewed for cSSSI 
pathogen S. aureus (Fournier et al. [35], Krishna et al. [36], Miller et al. [37]). 
Outline of this thesis 
The overall aim of this thesis is to study the contribution of the innate immunity diversity 
of the host and presence of relevant pathogens in the development of complicated skin 
and skin structure infections.
 
The first part of this thesis focuses on the role of the innate immune system of the host 
during complicated skin and skin structure infections (Chapters 2-6). Following breaches 
of the skin, microorganisms can invade and cause infection. Cells of the innate immune 
system recognize through PRRs and phagocytose these microorganisms. In Chapter 2, 
we provide an overview of the different PRR families (Toll-like receptors, C-type lectin 
receptors, NOD-like receptors, RIG-I-like receptors and AIM2-like receptors), describe 
their signaling pathways and roles during infection. We also reviewed the influence of 
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variation in genes encoding these PRRs on their function and susceptibility to infectious 
disease. Bacteroides fragilis, a commensal of the human gut microbiome, is the most 
frequently isolated anaerobic microorganism from SSSIs [38], but evidence regarding 
the pattern recognition of B. fragilis is lacking. In Chapter 3, we investigated the PRRs 
involved in the recognition of B. fragilis and characterised the cytokine profile induced 
by this microorganism. Although several genes have been associated with susceptibility 
to infectious disease (Chapter 2), the role of genetic variation in susceptibility to 
complicated skin and skin structure infections remained to be clarified. In Chapters 4 
and 5, we investigated the influence of genetic variation in genes encoding PRRs on the 
susceptibility to cSSSIs in a cohort of cSSSI patients versus healthy, and the functional 
consequences of sequence variants associated with disease were studied. In addition, the 
role of TLR10, recently proposed as an anti-inflammatory receptor [39], was studied in the 
innate immune response to frequent cSSSI pathogens in Chapter 5. Recognition of the 
microorganism by cells of the innate immune system results in activation of an immune 
response and production of various pro- and anti-inflammatory cytokines [34]. In Chapter 
6, the influence of sequence variants in genes encoding cytokines on the susceptibility to 
cSSSIs, and the functional consequences of sequence variants associated with disease, 
were studied.
The second part of this thesis focuses on the identification of pathogens present in cSSSIs 
(Chapters 7 and 8). Routine assessment of bacterial presence currently relies upon culture 
of biopsies. However, in recent years various molecular methods have been developed to 
improve the detection of pathogens, as reviewed by [40, 41]. In Chapters 7 and 8 we 
evaluate the potential benefit of direct, pathogen-specific real-time PCR assays on clinical 
samples in the detection of the causative organisms of cSSSIs for the gram-positive S. 
aureus and Streptocccus species and for the gram-negative B. fragilis, respectively. 
A summary of the findings and conclusions described in this thesis is presented in Chapter 
9.
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Abstract
 
Cells of the innate immune system are equipped with surface and cytoplasmic receptors 
for microorganisms called pattern-recognition receptors (PRRs). PRRs recognize specific 
pathogen-associated molecular patterns and as such are crucial for the activation of 
the immune system. Currently, 5 different classes of PRRs have been described: Toll-
like receptors, C-type lectin receptors, nucleotide-binding oligomerization domain-like 
receptors, retinoic acid-inducible gene I-like receptors and absent in melanoma 2-like 
receptors. Following their discovery, many sequence variants in PRR genes have been 
uncovered and shown to be implicated in human infectious diseases. In this review, 
we will discuss the effect of genetic variation in PRRs and their signalling pathways on 
susceptibility to infectious diseases in humans.
Genetic variation in pattern-recognition receptors | 21
2
Introduction
Infectious diseases are a major cause of morbidity and mortality worldwide [1]. The 
genetic makeup of an individual has a strong influence on the risk of death from infection, 
as demonstrated by studies correlating the cause of death in adopted children with 
biological or adoptive parents [2]. To defend the host against infections, components of 
the innate and adaptive immune system collaborate to eliminate intruding pathogens. 
Genetic variation in both components of the immune system influences the susceptibility 
to infectious disease. For example, individuals with severe combined immunodeficiency 
suffer from recalcitrant opportunistic infections due to deficiencies in T and B cells of the 
adaptive immune system [3], and defects in the innate interferon-γ pathway are associated 
with recurrent infections with mycobacteria and Salmonella spp. [4].
In this review, we will discuss the major findings concerning genetic variation in 
pattern-recognition receptors of the innate immune system and molecules involved in 
their signalling pathways. We will focus on the relation between genetic variation and 
susceptibility to infectious disease and review the functional consequences induced by 
these genetic variants.
Pattern recognition of the innate immune system
The human body is constantly exposed to potential harmful threats such as bacteria, 
fungi, viruses, parasites and protozoa. Upon intrusion of a pathogen in a normally sterile 
environment, the innate immune system is the first line of defense against these invaders. 
Cells of the innate immune system are equipped with membrane and cytoplasmic 
receptors called pattern-recognition receptors (PRRs), a concept first proposed by Charles 
Janeway Jr. [5]. These highly conserved, germ-line encoded receptors are able to recognize 
specific pathogen-associated molecular patterns (PAMPs) that are essential structures 
of microorganisms [6, 7]. Although highly conserved, small interspecies variation in 
PAMPs have been shown to result in altered immune responses mediated by the same 
PRR. One relevant example in that respect is that of bacterial muramyl dipeptide (MDP): 
it has been shown that the glycolyl-MDP from mycobacteria and other Actinomycetes is 
much more active for stimulation of immune responses compared to acetyl-MDP from 
other bacterial species [8-10]. Recognition of PAMPs by PRRs activates intracellular signal 
transduction cascades followed by gene transcription, secretion of distinctive effector 
molecules and generation of an adaptive immune response. Depending on the structure 
and composition of the microbe, different combinations of PRRs are activated, inducing 
specific signaling pathways, which results in tailored responses to infectious agents [6, 
7]. At present, 5 main classes of PRRs have been described: Toll-like receptors (TLRs), 
22 | Chapter 2
C-type lectin receptors (CLRs), nucleotide-binding domain (NOD)-like receptors (NLRs), 
retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) and absent in melanoma 2 
(AIM2)-like receptors (ALRs) (Figure 1) [7, 11]. Most PRRs recognize cell wall components 
of microorganisms, but DNA, RNA or metabolites of microbial origin can also act as PAMPs 
[7]. Table 1 summarizes important PRRs of the innate immune system with corresponding 
PAMPs and their microbial sources.
Genetic variation in pattern-recognition receptors
Changes in the nucleotide sequence of genes encoding PRRs can affect the susceptibility 
to infectious disease. Most often, the susceptibility to infections is multifactorial, with the 
odds of developing the disease increasing with every risk sequence variant. In a minority 
of cases, single sequence variants are able to induce a strong increase in susceptibility 
to certain infections. The presence of such a mutation thus results in a monogenetic or 
primary immunodeficiency.
 
Figure 1. Overview of pattern-recognition receptors and downstream signalling pathways.
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Table 1. Overview of pattern-recognition receptors and corresponding pathogen-associated molecular patterns.
Receptor PAMP Source
Toll-like receptors
TLR2/TLR1 Triacyl lipopeptides Bacteria
TLR2 Peptidoglycans
Glycolipids
Envelope proteins
Bacteria
Bacteria, fungi
Viruses
TLR2/TLR6 Diacyl lipopeptides
Lipoteichoic acid
Zymosan
Bacteria
Bacteria
Fungi
TLR2/TLR10 Unknown Unknown
TLR3 Single-stranded RNA
Double-stranded RNA
Viruses
Viruses
TLR4 Lipopolysaccharide
Mannans
Envelope proteins
Bacteria
Fungi 
Viruses
TLR5 Flagellin Bacteria
TLR7 Single-stranded RNA Viruses
TLR8 Single-stranded RNA Viruses
TLR9 Unmethylated CpG motifs
Double-stranded DNA
Bacteria, fungi, viruses
Viruses
C-type lectin receptors
Dectin-1 Beta (linked)-glucans Fungi, bacteria
Dectin-2 High mannose structures Fungi, bacteria
Mannose receptor Mannose, fucose Fungi, bacteria, viruses
DC-SIGN Mannan, high mannose structures Fungi, bacteria, viruses
Mannose-binding lectin High mannose,
N-acetylglucosamine structures
Fungi, bacteria, viruses
NOD-like receptors
NOD1 Muramyl tripeptide Bacteria
NOD2 Muramyl dipeptide Bacteria
NLRP3 Uric acid crystals, silica, different 
PAMPs
Bacteria, fungi, viruses
RIG-I-like receptors
RIG-I Short double-stranded RNA Viruses
MDA5 Long double-stranded RNA Viruses
AIM2-like receptors
AIM2 Double-stranded DNA Bacteria, viruses, host
PAMP, pathogen-associated molecular pattern.
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The majority of genetic variation is represented by variants such as substitutions (single-
nucleotide polymorphisms), insertions, deletions, inversions and duplications and micro- 
and minisatellites, in which only 1 or a few nucleotides are affected. Less often, large-scale 
variants in which whole chromosomes or regions are altered can also be encountered 
[12]. Depending on the type of sequence variant and its location in the gene, it can have 
different functional consequences. Variants in the coding region can affect the amino acid 
sequence, and as such, the potential to influence the function of the protein. By contrast, 
variation in the noncoding region of the gene can still affect the functionality of the gene 
by alterations in promoter binding sites, splicing of the gene, stability and degradation of 
the messenger RNA.
As a result, one may expect that genetic variation in genes encoding for PRRs, key mediators 
in innate immune recognition, affects susceptibility to infectious disease, a hypothesis 
confirmed in recent years. Here we will discuss the major genetic polymorphisms in TLR, 
CLR, NLR, RLR and ALR genes, their association in susceptibility to infectious disease and 
functional consequences for activation of the innate immune response.
Toll-like receptors
Following the discovery of the Toll-signaling pathway in Drosophila, implicated in the 
host defense against fungal infections [13], 10 Toll homologues termed TLRs (TLR1-10) 
have been characterized in humans. TLRs are primarily expressed in cells of the immune 
system such as monocytes, neutrophils, basophils, eosinophils and NK cells, but also cells 
of epithelial, endothelial and stromal origin [14]. TLRs recognize a variety of different 
microbes based on the presence of specific PAMPs (Table 1). A broad division can be made 
between TLRs primarily expressed on the surface of cells (TLR1, TLR2, TLR4, TLR5, TLR6 and 
TLR10), mainly targeting microbial lipids and proteins; and those located in intracellular 
compartments of the endocytic pathway (TLR3, TLR7, TLR8 and TLR9), mainly involved in 
the recognition of microbial nucleic acids (Table 1).
All TLRs consist of an extracellular domain with varying amounts of leucine-rich repeats 
for recognition of PAMPs, a transmembrane region, and a cytoplasmic Toll/Interleukin-1R 
(TIR) homology domain involved in signal transduction. Recognition of its ligand induces 
the formation of homo- or heterodimers between TLRs and subsequent recruitment 
of downstream adaptor proteins, activation of transcription factors, resulting in the 
production of cytokines and interferons and induction of an adaptive immune response. 
Most TLRs depend on the activation of adaptor protein myeloid differentiation primary 
response gene 88 (MyD88), which via Interleukin-1 receptor-associated kinase (IRAK) 
induces activation of transcription factors such as nuclear factor kappa-light-chain-
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enhancer of activated B-cells (NF-κB) and activating protein-1 (AP1). In contrast, TLR3 
signals via the TIR domain containing adaptor protein inducing IFN-β (TRIF). TLR4 has, 
besides MyD88, a second signalling pathway via TRIF-related adaptor molecule (TRAM). 
Both TRIF and TRAM pathways activate TNF receptor associated factor (TRAF)3, resulting 
in the activation of IFN-stimulated response elements (ISRE) [15]. For the last discovered 
member, TLR10, the exact signaling pathway remains to be elucidated. Table 2 summarizes 
the sequence variants in TLRs and their association in susceptibility to infectious diseases.
Toll-like receptor 2 subfamily
TLR1, TLR2, TLR6 and TLR10 are located in a cluster on chromosome 4, and for convenience 
are termed the TLR2 subfamily. Besides significant sequence similarity [16], members of 
the TLR2 subfamily form heterodimers that cooperate for the recognition of microbes. 
TLR2 is the key receptor in this process, due to its ability to form homodimers as well as 
heterodimers with TLR1 and TLR6 for the recognition of various ligands from bacterial, 
fungal and viral origin (Table 1). Until recently, TLR10 was the only TLR without known 
ligand and function. However, molecular modelling indicated Pam3Cys as a possible 
ligand for the TLR10/2 heterodimer and PamCysPam for the TLR10/1 heterodimer and 
TLR10 homodimer [17]. Recent studies have suggested that the function of TLR10 differs 
from other TLRs, as it was shown to inhibit TLR2-driven innate immune activation [18-20]. 
By contrast, TLR10 has also been described as a stimulatory receptor in the innate immune 
recognition [21, 22]. 
Toll-like receptor 1
TLR1 sequence variant rs5743618 (Ile602Ser) leads to the substitution of isoleucine for 
serine at amino-acid position 602 of the TLR1 protein. Presence of the 602Ser variant 
results in aberrant trafficking of TLR1 to the cell surface and results in decreased NF-
κB activation and proinflammatory cytokine responses to TLR1 agonists [23, 24]. TLR1 
sequence variant rs5743618 is associated with susceptibility to tuberculosis [25], leprosy 
[23, 26], candidemia [27] and malaria [28]. 
TLR1 sequence variant rs4833095 (Ser248Asn) leads to the substitution of serine for 
asparagine at amino-acid position 248 of the TLR1 protein. TLR1 rs4833095 is in strong 
linkage with the above described TLR1 rs5743618 in populations of European descent 
[24, 27], which may partially explain why the 248Asn variant is associated with reduced 
cytokine responses after exposure to TLR2 ligand Pam3Cys and Staphylococcus aureus [27, 
29]. However, slight reduction of NF-κB activation was detected in the presence of 248Asn, 
irrespective of the presence of TLR1 rs5743618 [30]. TLR1 sequence variant rs4833095 is 
associated with susceptibility to tuberculosis [25], leprosy [31], complicated skin and skin 
structure infections [29], aspergillosis [32] and candidemia [27]. 
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Table 2. Overview of genetic variation in Toll-like receptors and susceptibility to infectious diseases.
Gene Sequence variant Disease Risk allele Reference
Rs-number Nucleotide
change#
Amino acid 
change#
TLR1 rs5743618 T > G Ile602Ser Tuberculosis
Leprosy
Candidemia
Malaria
T
T
G
G
[25]
[23, 26]
[27]
[28]
TLR1 rs4833095 C > T Ser248Asn Tuberculosis
Leprosy
Complicated skin and 
skin structure infection
Aspergillosis
Candidemia
C
C
T
C
T
[25]
[31]
[29]
[32]
[27]
TLR2 rs5743708 G > A Arg753Gln Tuberculosis
Lyme disease
CMV infection
A
G
A
[35, 36]
[37]
[38, 39]
TLR2 rs5743704 C > A Pro631His Tuberculosis
Complicated skin and 
skin structure infection
Recurrent vulvo vaginal 
candidiasis
A
A
A
[40]
[29]
[41]
TLR6 rs5743810 C > T Pro249Ser Tuberculosis
Complicated skin and 
skin structure infection
Aspergillosis
Malaria
T
T
T
T
[25]
[29]
[32]
[28]
TLR10 rs4129009 & 
rs11096955
A > C &
A > C
Ile775Leu & 
Ile369Leu
Complicated skin and 
skin structure infection
A & A [44]
TLR4 rs4986790 & 
rs4986791
A > G &
C > T
Asp299Gly & 
Thr399Ile
Sepsis
Urinary tract infection
Brucellosis
Legionnaires´ disease
Meningococcal disease
Tuberculosis
Leprosy
Aspergillosis
Candidiasis
RSV infection
Malaria
G & T
A & C
G & T
A & C
G & T
G & T
A & C
G & T
G & T
G & T
G & T
[57-59]
[60]
[61]
[62]
[63, 64]
[65, 66]
[67]
[68-71]
[72]
[75]
[73, 74]
TLR5 rs5744168 C > T Arg392Ter Legionnaires’ disease
Urinary tract infection
T
T
[76]
[60]
TLR3 rs3775291 G > A Leu412Phe HCV infection 
HSV infection
HIV infection
Tick-borne encephalitis 
virus infection 
A
G
G
G
[82]
[83]
[81]
[84]
TLR7 rs179008 A > T Gln11Leu HCV infection
HIV infection
T
T
[86]
[85]
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Toll-like receptor 2
TLR2 sequence variant rs5743708 (Arg753Gln) leads to the substitution of arginine 
for glutamine at amino-acid position 753 of the TLR2 protein. Presence of the 753Gln 
variant does not influence the expression of TLR2, but instead causes deficient tyrosine 
phosphorylation, compromises the assembly of the TLR2-TLR6 complex and impairs 
recruitment of transcription factors MyD88 and Mal [33]. Engagement of a receptor 
encoded by TLR2 753Gln results in decreased NF-κB activation and proinflammatory 
cytokine secretion after exposure to specific TLR2 ligands (Pam3Cys, lipoteichoic acid 
and macrophage-activating lipopetide-2) and whole cell stimuli such as Mycobacterium 
tuberculosis or S. aureus [33, 34]. TLR2 sequence variant rs5743708 is associated with 
susceptibility to tuberculosis [35, 36], Lyme disease [37] and cytomegalovirus infection 
[38, 39]. 
TLR2 sequence variant rs5743704 (Pro631His) leads to the substitution of proline for 
histidine at amino-acid position 631 of the TLR2 protein. Presence of the 631His variant 
is associated with decreased internalization of the TLR2 complex after recognition of its 
ligand [40], attenuated NF-κB activation and proinflammatory cytokine secretion after 
exposure to specific TLR2 ligands (Pam3Cys, lipoteichoic acid, lipomannan and follistatin-
like 1) and Mycobacterium avium [30, 40]. TLR2 sequence variant rs5743704 is associated 
with susceptibility to tuberculosis [40], complicated skin and skin structure infections [29], 
and recurrent vulvovaginal infections with C. albicans (RVVC) [41].
Toll-like receptor 6
TLR6 sequence variant rs5743810 (Pro249Ser) leads to the substitution of proline for serine 
at amino-acid position 249 of the TLR6 protein. Presence of the 249Ser variant resulted 
in decreased NF-κB activation and cytokine secretion after exposure to TLR6/2 ligands 
and Mycobacterium tuberculosis [42]. The Pro249Ser variant is located in the extracellular 
domain of TLR6. Therefore, this variant may influence ligand recognition or affect assembly 
of a TLR6/2 heterodimer, but the exact mechanism remains unknown. TLR6 sequence 
variant rs5743810 is associated with susceptibility to tuberculosis [25], complicated skin 
TLR8 rs3764880 G > A Val1Met Tuberculosis
Crimean-Congo 
hemorrhagic fever 
HCV infection
A
G
A
[90, 91]
[93]
[89, 92]
TLR9 rs5743836 C > T N/A Tuberculosis
Aspergillosis
Malaria
T
C
C
[96]
[69]
[97, 98]
# The first nucleotide (and corresponding amino acid) is the ancestral nucleotide and therefore is considered 
the wild-type allele. N/A, not applicable; CMV, cytomegalovirus; RSV, respiratory syncytial virus; HCV, hepatitis C 
virus; HSV, herpes simplex virus; HIV, human immunodeficiency virus.
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and skin structure infections [29], aspergillosis [32] and malaria [28].
Toll-like receptor 10
TLR10 sequence variant rs4129009 (Ile775Leu) leads to the substitution of isoleucine 
to leucine at amino-acid position 775 of the TLR10 protein. TLR10 sequence variant 
rs11096955 (Ile369Leu) also leads to the substitution of isoleucine to leucine at amino-acid 
position 369 of the TLR10 protein. Presence of the 775Leu or 369Leu variant is associated 
with increased cytokine secretion in the presence of TLR1/2 ligand Pam3Cys, TLR6/2 ligand 
follistatin-like 1 and various pathogens [19, 20, 43]. How these TLR10 sequence variants 
precisely exert their effect remains unknown, but the location of rs4129009 in the LRR 
region and rs11096955 in the TIR domain could indicate involvement in the recognition 
of PAMPs or signal transduction, respectively. Both these TLR10 sequence variants have 
been associated with susceptibility to complicated skin and skin structure infections [44].
Toll-like receptor 4
TLR4 forms homodimers for the recognition of various ligands of bacterial, fungal and 
viral origin (Table 1). The TLR4 gene is located on chromosome 9. TLR4 sequence variant 
rs4986790 (Asp299Gly) leads to the substitution of aspartic acid for glycine at amino-acid 
position 299 of the TLR4 protein. TLR4 sequence variant rs4986791 (Thr399Ile) leads to the 
substitution of threonine for isoleucine at amino-acid position 399 of the TLR4 protein. 
Both TLR4 sequence variants lead to alterations in the leucine-rich repeat region of the 
protein, and as such, possible influence ligand recognition [45]. The presence of both 
TLR4 variants differs between populations [46]. In populations from European descent, 
TLR4 rs4986790 and rs4986791 are found to be present in cosegregation, whereas in 
African populations mainly presence of 299Gly and almost no 399Ile is observed. In Asian 
populations both 299Gly and 399Ile are practically absent [46]. Several studies have 
investigated the functional consequences of TLR4 sequence variants rs4986790 and/or 
rs4986791. Presence of the TLR4 299Gly allele, but not the 399Ile allele, is associated with 
diminished recruitment of MyD88 and TRIF, decreased NF-κB activation and cytokine 
responses after exposure to LPS in transfection experiments with different cell lines [47-
49]. On the other hand, most studies investigating the effect of TLR4 299Gly and/or 399Ile 
on LPS-stimulated whole-blood or isolated primary cells, showed no differences [50-55]. 
These contrasting results are possibly due to type of stimulation used or the fact that the 
cosegregated nature of these variants in different populations was not taken into account 
[56]. TLR4 sequence variants rs4986790 and rs4986791 are associated with susceptibility 
to sepsis [57-59], urinary tract infections [60], brucellosis [61], Legionnaires’ disease [62], 
meningococcal disease [63, 64], tuberculosis [65, 66], leprosy [67], aspergillosis [68-71], 
candidiasis [72], malaria [73, 74], respiratory syncytial virus infection [75].
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Toll-like receptor 5
TLR5 forms homodimers for the recognition of bacterial flagellin (Table 1). The TLR5 gene 
is located on chromosome 1. TLR5 sequence variant rs5744168 (Arg392Ter) leads to the 
substitution of arginine to a stop codon at amino-acid position 392 of the TLR5 protein. 
Presence of the 392Ter variant results in premature truncation in the extracellular domain 
of the TLR5 protein with complete loss of the transmembrane and cytoplasmic region. 
Cells expressing the 392Ter variant were not able to induce NF-κB activation and reduced 
cytokine secretion was observed in response to TLR5 ligand flagellin [76]. TLR5 sequence 
variant rs5744168 is associated with susceptibility to Legionnaires’ disease [76] and urinary 
tract infections [60]. 
TLRs recognizing nucleic acids
TLR3, TLR7, TLR8 and TLR9 are all located in intracellular compartments of the cell where 
they recognize different microbial nucleic acids structures (Table 1). TLR3, TLR7 and TLR8, 
as homodimers, recognize single-stranded RNA of viral origin. In addition, TLR3 is also 
involved in the recognition of viral double-stranded RNA. TLR9 forms homodimers for the 
recognition of DNA motifs of bacterial, fungal or viral origin. The TLR3 gene is located on 
chromosome 4, and the TLR9 gene is located on chromosome 3. The TLR7 and TLR8 genes 
are located in close proximity of one other on chromosome X.
Toll-like receptor 3
TLR3 sequence variant rs3775291 (Leu412Phe) leads to the substitution of leucine for 
phenylalanine at amino-acid position 412 of the TLR3 protein. Presence of the 412Phe 
variant is associated with decreased NF-κB activation and proinflammatory cytokine 
secretion after exposure to TLR3 ligand Poly I:C [77-79]. Decreased intracellular expression 
of TLR3 [79], deficient cell surface expression and receptor shedding [77, 80] have all 
been suggested as possible mechanisms for the described functional consequences 
of the 412Phe variant. By contrast, 1 study reported increased cytokine responses after 
exposure to Poly I:C in the presence of the 412Phe variant [81]. TLR3 sequence variant 
rs3775291 is associated with susceptibility to hepatitis C virus (HCV) infection [82], human 
immunodeficiency virus (HIV) infection [81], herpes simplex virus (HSV) infection [83] and 
tick-borne encephalitis virus infection [84].
Toll-like receptor 7
TLR7 sequence variant rs179008 (Gln11Leu) leads to the substitution of glutamine for 
leucine at amino-acid position 11 of the TLR7 protein. Presence of the 11Leu variant is 
associated with decreased IFNα secretion after exposure to TLR7 ligand Imiquimod, 
whereas IL-6 remained unaltered [85]. Although the exact mechanism remains unknown, 
it is speculated that due to its location in the signal sequence region, sequence variant 
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rs179008 could influence post-translational modification, localization, quantity and 
therefore functionality of TLR7 [85]. TLR7 sequence variant rs179008 is associated with 
susceptibility to HCV infection [86] and HIV infection [85].
Toll-like receptor 8
The TLR8 gene encodes 2 different splice variants, TLR8v1 and TLR8v2, which share a 
similar sequence, with the exception of the longer N-terminal section of TLR8v1 [87]. TLR8 
sequence variant rs3764880 (Val1Met) influences TLR8v2, but not TLR8v1, and leads to 
the substitution of valine for methionine at amino-acid position 1, resulting in alteration 
of the start codon and truncation of the TLR8 protein. Different functional consequences 
have been described for TLR8 sequence variant rs3764880. Presence of the variant 1Val 
is associated with decreased NF-κB activation, but increased cytokine secretion, after 
exposure to TLR8 ligands CL075 and R848 [88, 89]. By contrast, another study reported no 
differences in TLR8 function and cellular distribution for TLR8 sequence variant rs3764880 
[87]. This study suggested that the TLR8 sequence variant rs3764880 influences fine-tuning 
of translation of both TLR8 isoforms, indicated by decreased TLR8v2 and increased TLR8v1 
[87]. TLR8 sequence variant rs3764880 is associated with susceptibility to tuberculosis [90, 
91], HCV infection [89, 92], and Crimean-Congo hemorrhagic fever [93].
Toll-like receptor 9
TLR9 sequence variant rs5743836 (-1237C/T) is located in the promoter region of the 
TLR9 gene. Presence of the -1237C variant is associated with increased transcription of 
the TLR9 gene after exposure to proinflammatory cytokines or TLR ligands [94, 95]. The 
incorporation of cytosine is suggested to create a novel NF-κB transcriptional binding 
site [94] or IL-6 binding site [95] in the promoter region of the TLR9 gene. TLR9 sequence 
variant rs5743836 is associated with susceptibility to tuberculosis [96], aspergillosis [69] 
and malaria [97, 98].
Primary immunodeficiencies in the TLR pathway
Primary immunodeficiencies in the TLR signaling pathway are rare, but novel genetic 
variants are continuously discovered. Some of the most important examples are the 
deficiencies in MyD88 and IRAK4 of the TLR signaling pathway [99, 100]. Different 
sequence variants have been described in both genes including deletions, insertions 
and substitutions resulting in loss-of-expression or loss-of-function phenotypes [99]. 
Deficiencies in the MyD88/IRAK4 pathway result in defective downstream signaling 
of most TLRs and failure to induce proinflammatory cytokines in response to known 
TLR ligands and whole organisms [101, 102]. Patients with MyD88 or IRAK4 deficiency 
are predisposed to life-threatening infections with invasive pyogenic bacteria, such as 
Streptococcus pneumoniae, S. aureus and Pseudomonas aeruginosa [99]. Despite antibiotic 
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treatment, these infections lead to a mortality up to 30 - 40% during infancy and childhood, 
but decrease in frequency and severity of infections after adolescence [103].
Another cluster of primary immunodeficiencies discovered over the last decade are 
the defects in the TLR3/TRIF/TRAF3/UNC93B pathway [104-107]. The TLR3 pathway 
is important for the recognition of single- and double stranded RNA of viral origin 
(Table 1), and patients with primary immunodeficiencies in this pathway have loss-of-
expression or loss-of-function phenotypes, due to sequence variations such as deletions 
and substitutions. TLR3 pathway deficiencies are characterized by a failure to induce 
interferons after stimulation with HSV-1. Patients with TLR3 pathway deficiencies are 
predisposed to development of recurrent herpes simplex encephalitis, a rare complication 
of the common viral infection HSV-1.
C-type lectin receptors
A prominent role in host immunity in general and antifungal immunity in particular has 
been attributed to CLRs, as they are able to recognize fungal cell wall components as 
β-glucans or mannans [108]. Most, but not all, CLRs are Ca2+ dependent and recognize 
carbohydrate-containing PAMPs through a C-type-lectin-like-domain. Recognition leads 
to subsequent signaling via Src and spleen tyrosine kinase (Syk), which in turn signal 
downstream adaptor molecules to induce a NF-κB dependent immune response through 
secretion of cytokines such as (pro-)IL-1β, IL-6, IL-10 and TNFα [109-111]. Moreover, 
signaling leads to reactive oxygen species (ROS) production and subsequent activation 
of inflammasomes, which in turn process the inactive pro-IL-1β and pro-IL-18 into their 
biologically active forms [112]. Although most CLRs are membrane-bound, there are 
also soluble CLRs such as the complement activating mannose-binding-lectin (MBL) and 
pentraxin-3. Table 3 summarizes the sequence variants in CLRs and their association in 
susceptibility to infectious diseases.
Dectin-1
The β-glucan receptor Dectin-1 (C-type lectin domain family 7 member A, CLEC7A) 
is a prominent member of the CLR family. By recognizing its ligand, different adaptor 
proteins such as Caspase recruitment domain-containing protein 9 (CARD9), Syk, as well 
as Bcl-10 and Malt-1 are recruited which leads to the activation of NF-κB and subsequent 
transcription of proinflammatory cytokines. In addition, Dectin-1 is known to synergize 
with TLRs to amplify cytokine production after pathogen recognition in both humans and 
mice [108, 113-115].
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Table 3. Overview of genetic variation in C-type lectin receptors and susceptibility to infectious diseases.
Gene Sequence variant Disease Risk allele Reference
Rs-number Nucleotide
change#
Amino acid 
change#
CLEC7A rs16910526 T > G Tyr238Ter Candida colonization 
Recurrent vulvovaginal 
candidiasis
Onychomycosis
G
G
G
[119] 
[118]
[118]
CLEC7A rs16910527 A > C Ile223Ser Oropharyngeal 
candidiasis 
Aspergillosis
A
C
[124]
[121, 122]
CLEC7A rs7309123 G > C N/A Aspergillosis G [123]
CLEC7A rs3901533 G > T N/A Aspergillosis T [123]
CD209 rs4804803 G > A N/A Tuberculosis 
HIV infection
Dengue fever 
G
G
G
[127]
[128]
[129]
CD209 rs735239 A > G N/A Tuberculosis A [127]
CD209 rs4804800 A > G Unknown Aspergillosis G [123]
CD209 rs11465384 C > T Unknown Aspergillosis T [123]
CD209 rs7248637 G > A Unknown Aspergillosis A [123]
CD209 rs7252229 G > C Unknown Aspergillosis C [123]
CD206 rs1926736 C > T Gly396Ser Tuberculosis 
Leprosy
C
T
[133]
[132, 134]
CD206 rs692527 T > C Unknown Leprosy C [134]
CD206 rs34856358 C > T Unknown Leprosy T [134]
PTX3 h2/h2 
(G-A/G-A)
Aspergillosis h2/h2 
haplotype
[140]
PTX3 rs2305619 A > G Tuberculosis Haplotype [142]
PTX3 rs1840680 C > T Tuberculosis 
Pseudomonas aeruginosa 
colonization
Haplotype 
Haplotype
[142]
[143]
MBL rs1800450,
rs5030737,
rs1800451
Arg52Cys, 
Gly54Asp, 
Gly57Glu 
Recurrent vulvovaginal 
candidiasis
Haplotype [149-152]
CARD9 rs121918338 C > T Gln295Ter Chronic mucocutaneous 
candidiasis
T [116]
CARD9 rs398122363 C > T Gln289Ter Dermatophytic
disease
T [157]
CARD9 rs398122364 C > T Arg101Cys Dermatophytic
disease
T [157]
CARD9 Unknown T > C Tyr91His C. albicans 
meningoencephalitis
C [158]
# The first nucleotide (and corresponding amino acid) is the ancestral nucleotide and therefore is considered the 
wild-type allele. N/A, not applicable; HIV, human immunodeficiency virus.
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Dectin-1’s importance in β-glucan recognition was shown in different mice knock-out 
studies as well as in patients with fungal infections who carried a specific mutation in the 
CLEC7A gene [116, 117]. The sequence variant responsible for the altered phenotypes is 
rs16910526 (Tyr238Ter) in the CLEC7A gene, located in exon 6 of chromosome 12. The 
sequence variant leads to a change from tyrosine into a stop codon resulting in the loss 
of amino acids within the carbohydrate-recognition domain [118]. Subsequently, this 
sequence variant results in decreased surface expression of the receptor accompanied 
by low levels of IL-17 and IL-23 after stimulation with either β-glucan or C. albicans [118].
Contradictory results regarding susceptibility to different infectious diseases have been 
observed for CLEC7A sequence variant Y238X. However, independent studies show an 
increase in mucosal and gastrointestinal fungal colonization as a consequence of the 
sequence variant [118-120]. In addition, several studies show a correlation between 
this sequence variant and invasive as well as pulmonary aspergillosis [121-123]. Finally, 
Sainz et al. observe a correlation with susceptibility to aspergillosis in 2 other intronic 
CLEC7A sequence variants (rs7309123 and rs3901533). Presence of the GG genotype for 
sequence variant rs7309123 leads to decreased Dectin-1 mRNA expression, whereas the 
functional consequences of rs3901533 remains unknown [123]. Plantinga et al. observed 
an association of rs16910527 (Ile223Ser) and oropharyngeal candidiasis in HIV patients 
which is accompanied with lower IFNγ levels as well as a reduced capacity to bind zymosan 
[124]. 
DC-SIGN
DC-SIGN (CD209) is mainly present in dendritic cells and macrophages and recognizes 
mannose glycoproteins. In addition, it has an important function in the process of 
adhesion and was shown to modulate TLR function [125]. Several studies link genetic 
variation in DC-SIGN to various infectious diseases. DC-SIGN sequence variant rs4804803 
(336A/G), located in the promoter region is linked with susceptibility to tuberculosis, HIV 
and dengue fever [126-129]. By contrast, both -336A as well as -871G (rs735239) have 
been shown to have a protective effect in the development of tuberculosis [130]. These 
sequence variants most likely affect transcription levels leading to lower expression of 
CD209 [127, 129]. However, 1 meta-analysis of the -336A/G polymorphism of DC-SIGN did 
not show any association with susceptibility to tuberculosis [131]. Sainz et al. observed 
4 sequence variants in DC-SIGN (rs4804800, rs11465384, rs7248637, rs7252229) that are 
associated with increased risk to develop invasive pulmonary aspergillosis [123]. 
Mannose receptor 
The mannose receptor (CD206) recognizes different high mannose structures present on 
the surface of various pathogens. After recognition and subsequent internalization, the 
pathogen is degraded in the lysosome and an immune response is initiated. Very little 
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is known about sequence variants in CD206 and susceptibility to infectious disease in 
humans. Nevertheless, sequence variant rs1926736 (Gly396Ser) in exon 7 of the MRC1 
gene on chromosome 10 is suggested to be associated in susceptibility to leprosy and 
tuberculosis [132-134].
Soluble C-type lectin receptors 
Pentraxin-3 
The soluble and circular pentraxin-3 (PTX3) belongs to the pentraxin superfamily that also 
includes C-reactive protein as well as serum amyloid P component. It is released by several 
immune and nonimmune cells, such as dendritic cells and endothelial cells. By forming 
complexes with different pathogenic antigens and components of the complement 
system it enhances cellular processes as antigen recognition and phagocytosis. Interaction 
of PTX3 with Aspergillus fumigatus and Candida albicans has been reported [135-139]. In 
a cohort of patients with hematopoietic stem-cell transplantation Cunha et al. showed 
that the h2/h2 haplotype (G-A/G-A) in PTX3 is associated with invasive aspergillosis 
[140], whereas another study did not find an association for PTX3 with susceptibility to 
aspergillosis [141]. The increased risk for aspergillosis is most likely due to a reduced 
expression of PTX3 in neutrophils, which might therefore lead to reduced phagocytosis of 
the fungus [140]. In a study of African tuberculosis cases and controls, Olesen et al. found an 
association between sequence variants rs2305619 and rs1840680 in PTX3 and pulmonary 
tuberculosis [142]. In addition, a haplotype containing these 2 sequence variants has been 
shown to be associated with P. aeruginosa colonization in patients suffering from cystic 
fibrosis [143].
Mannose-binding-lectin 
Mannose-binding-lectin (MBL) is able to recognize carbohydrate patterns present on the 
surface of different microorganisms. Upon binding to its ligand, MBL activates the lectin 
pathway of the complement system, initiating a cascade of complement activation [144, 
145]. Three polymorphisms located in exon 1 of the MBL2 gene rs5030737 (Arg52Cys), 
rs1800450 (Gly54Asp) and rs1800451 (Gly57Glu) have been shown to decrease circulating 
levels of MBL2 [146, 147]. All 3 polymorphisms are linked to recurrent vulvovaginal 
infections with C. albicans (RVVC), although there is still some debate for the role of 
MBL2 as a marker for this disease since genotype distribution strongly depends on 
ethnic background [148-153]. Decreased levels of MBL and complete MBL deficiency are 
associated with invasive and pulmonary aspergillosis [154, 155]. Moreover, Hibberd et 
al. showed that homo and/or heterozygous combinations of MBL2 genotypes are more 
frequently present in patients suffering from meningococcal disease [156].
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CARD9
CARD9 functions as adapter protein downstream of most CLRs, for example, Dectin-1, 
Dectin-2 and Mincle. Upon engagement of these CLRs with their ligands typically 
present on the cell walls of various fungi, signaling via CARD9 leads to the production of 
proinflammatory cytokines. Several sequence variants in the CARD9 gene are associated 
with fungal infections in humans [116, 157]. Sequence variants rs121918338 (Gln295Ter) 
and rs398122363 (Gln289Ter) lead to the incorporation of a stop codon, whereas 
rs398122364 (Arg101Cys) leads to the substitution of arginine for cysteine. Homozygosity 
for these variants results in absence (289Ter, 295Ter) or decreased levels of CARD9 protein 
(101Cys), and it is associated with reduced numbers of Th17 cells and altered cytokine 
profiles, essential for the antifungal defense [116, 157]. Gavino et al. recently reported 
a novel mutation in the CARD domain of CARD9 (Tyr91His) in a patient with relapsing 
C. albicans meningoencephalitis. Interestingly, presence of 91His is associated with 
decreased levels of CARD9 protein and impaired GM-CSF expression but not reduced 
numbers of Th17 cells [158].
NOD-like receptors
NOD-like receptors are intracellular receptors that recognize mainly bacterial PAMPs, 
and they are able to induce proinflammatory cytokines and activation of host defense. 
Interestingly, it has also been shown that NLRs also participate in the antiviral immune 
response [159]. Moreover, a central role in the induction of autophagy was ascribed to 
members of this receptor family. Although NLRs form a heterozygous group of receptors, 
in general they contain a C-terminal leucine-rich repeat (LRR) domain, a NACHT (and 
NACHT associated domain, NAD) and an effector domain. Based on the N-terminal effector 
domain, which can be either PYD, CARD or BIR2, several subfamilies can be distinguished 
[160]. However, regarding phylogenetic aspects of NLRs, 3 subfamilies (NALPs, IPAF/NAIP 
and NODs) have been proposed [161, 162].
Besides their role in the direct signaling and stimulation of cytokine production, some 
family members form molecular complexes known as inflammasomes that are able to 
recruit inflammatory caspases. The classical example is the recruitment of caspase-1 into 
the NLRP3 inflammasome that processes the inactive pro-IL-1β and pro-IL-18 into their 
bioactive forms. Two well-known cytosolic NLRs are NOD1 (CARD4) and NOD2 (CARD15). 
Both recognize different parts of the bacterial cell wall component peptidoglycan 
[163, 164]. Table 4 summarizes the sequence variants in NLRs and their association in 
susceptibility to infectious diseases.
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NOD2
Frameshift variant rs2066847 (Leu1007fsinsC) in CARD15 encoding the leucine-rich repeat 
of NOD2, as well as 2 sequence variants in CARD15 rs2066844 (Arg702Trp) and rs2066845 
(Gly908Arg) are associated with susceptibility to Crohn’s disease and sepsis [163, 165-
168]. These sequence variants most likely affect antigen binding at the site of the LRR 
and, therefore, downstream signaling via NF-κB. This, in turn, may lead to a diminished 
production of proinflammatory cytokines. Genome-wide association studies suggest 
that genetic variants in CARD15 (also CARD4) may affect autophagy function and thereby 
contribute to the development and severity of various diseases, such as Crohn’s disease 
[169, 170].
In addition, sequence variants in CARD15 (NOD2) are linked to susceptibility to leprosy 
and tuberculosis. Using a genome-wide association study approach, a couple of sequence 
variants in CARD15 (rs9302752, rs7194886, rs8057341, rs3135499) and downstream genes 
were identified to be associated with the susceptibility to leprosy [171, 172]. In addition, 
Berrington et al. identified an intronic sequence variant rs5743289 that is also associated 
Table 4. Overview of genetic variation in NOD-like receptors and susceptibility to infectious diseases.
Gene Sequence variant Disease Risk allele Reference
Rs-number Nucleotide
change#
Amino acid 
change#
CARD15 rs2066845 G > C Gly908Arg Crohn’s disease C [165, 166]
CARD15 rs2066844 C > T Arg702Trp Sepsis
Tuberculosis 
T
C
[167]
[168]
CARD15 rs2066847 insC Leu1007insC Crohn’s disease 1007C [165, 166]
CARD15 rs9302752 A > G Unknown Leprosy G [171, 172]
CARD15 rs7194886 G > A Unknown Leprosy A [171]
CARD15 rs8057341 A > G Unknown Leprosy G [171]
CARD15 rs3135499 A > C Unknown Leprosy C [171]
CARD15 rs5743289 C > T Unknown Leprosy T [173]
CARD15 rs2066842 C > T Pro268Ser Tuberculosis C [168]
CARD15 rs5743278 C > G Ala725Gly Tuberculosis G [168]
CARD4 rs2075820 
(E266K)
G > A Glu796Lys H. pylori gastric 
inflammation
A [180]
CIAS1 rs74163773 12,9,7,6 Tandem 
repeat
Mycoplasma infection-
associated infertility
Recurrent vulvovaginal 
candidiasis
Allele 7
Allele 7
[184]
[183]
CIAS1 rs4925663 C > T Gly223Asp Chlamydia trachomatis 
infection
T [185]
# The first nucleotide (and corresponding amino acid) is the ancestral nucleotide and therefore is considered the 
wild-type allele. N/A, not applicable.
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with susceptibility to leprosy [173]. Finally, rs5743278 (Ala725Gly) is shown to increase the 
risk for tuberculosis, whereas rs2066842 (Pro268Ser) as well as rs2066844 (Arg702Trp) are 
shown to have a protective effect [168]. The protective effect is most likely due to a more 
stable NOD2 protein with increased functionality [168]. 
NOD1
Two different sequence variants rs2075820 (G796A) and +32656 (rs number unknown) 
have linked CARD4 (NOD1) to various inflammatory diseases such as inflammatory bowel 
disease, Crohn’s disease and asthma [174-179]. In addition, Kim et al. found an association 
with sequence variant rs2075820 (Gly796Ala) and H. pylori associated gastric mucosal 
inflammation [180]. 
NACHT, LRR and PYD domains-containing protein 3
NLRP3 is encoded by the CIAS1 gene and was extensively studied due to its capacity to 
form active inflammasomes. Several danger signals can activate the NLRP3 inflammasome, 
leading to activation of caspase-1, which in turn processes the inactive forms of pro-IL-1β 
and pro-IL-18 into their biologically active forms [160, 181]. Numerous genetic variations 
have been described within the CIAS1 locus that lead to various different diseases, 
commonly summarized as cryopyrin-associated periodic syndrome. Depending on the 
genetic variant, most (but not all) share an increased inflammasome activity that leads to 
excessive IL-1β production and tissue damage [181, 182]. 
A few genetic variants in NLRP3 have been described that are associated with bacterial 
or fungal infections. Lev-Sagie et al. showed that presence of allele 7 of tandem repeat 
rs74163773 in intron 4 of the CIAS1 gene is increased in patients suffering from recurrent 
vulvovaginal infections with C. albicans. Furthermore, the risk genotype is associated 
with reduced levels of IL-1β, pointing toward a reduced inflammasome activity [183]. 
In addition, the same variant was described by Witkin et al. who showed a significant 
correlation with mycoplasma infection-associated infertility [184]. Wang et al. proposed a 
negative correlation between rs4925663 in NLRP3 and the course of Chlamydia trachomatis 
infections [185].
RIG-I-like receptors 
RLRs are intracellular DEAD-box containing RNA helicases that are important for antiviral 
defense [186, 187]. RIG-I and melanoma differentiation-associated protein 5 (MDA5) 
recognize double stranded RNA (dsRNA) of viral origin. RIG-I is known to recognize 
relatively short dsRNA strands, whereas MDA5 recognizes longer dsRNA strands [188]. 
Recognition and downstream signaling through mitochondrial antiviral-signaling protein 
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followed by interferon regulatory factors leads to the production of type 1 interferons. 
Laboratory of genetics and physiology 2 (LGP2), the third member of the RLR family, is 
thought to have a regulatory function on RIG-I and MDA5, as it misses the N-terminal 
CARD domain essential for downstream signaling [189, 190]. Table 5 summarizes the 
sequence variants in RLRs and their association in susceptibility to infectious diseases.
RIG-I
RIG-I is encoded by DDX58 (DEAD (Asp-Glu-Ala-Asp) box polypeptide 58) which is 
located on chromosome 9. A sequence variant in the CARD domain of RIG-I rs10813831 
(Arg7Cys) has been shown to increase transcription of IFNB1 and DDX58 [191]. In addition, 
Ovsyannikova et al. showed that the same variant and RIG-1 sequence variant rs669260 
is associated with differences in rubella antibody levels [192]. A frameshift mutation 
in DDX58 rs36055726 (p229fs) was reported to lead to a truncated and constitutively 
active protein, resulting in excessive cytokine production. In addition, sequence variant 
rs11795404 (Ser183Ile) leads to impaired antiviral signaling due to disrupted interactions 
of RIG-I with downstream molecules. Both sequence variants most likely lead to an altered 
immune response against dsRNA viruses [193]. 
MDA5
MDA is encoded by the IFIH1 gene located on chromosome 2. MDA5 polymorphisms 
have been mainly associated with autoimmune diseases such as Type-1 diabetes 
mellitus and SLE, or with IgA deficiency [194-197]. In this context, the sequence variant 
rs1990760 (Ala946Thr) is proposed to have a major contribution to disease development 
and progression, due to increased (baseline) expression levels of MDA5 [198]. Recently, 2 
MDA5 variants rs1990760 (Ala946Thr) and rs3747517 (His843Arg) have been associated 
with susceptibility to candidemia [199]. However, it remains to be investigated which 
Table 5. Overview of genetic variation in RIG-1-like receptors and susceptibility to infectious diseases.
Gene Sequence variant Disease Risk allele Reference
Rs-number Nucleotide
change#
Amino acid 
change#
DDX58 rs10813831 G > A Arg7Cys IgG antibody levels A [191]
DDX58 rs669260 A > G Unknown IgG antibody levels G [192]
DDX58 rs36055726 Frameshift p229fs Immune response 
against viruses
[193]
DDX58 rs11795404 G > T Ser183Ile Immune response 
against viruses
T [193]
IFIH1 rs1990760 C > T Ala946Thr Candidemia T [199]
IFIH1 rs3747517 T > C His843Arg Candidemia C [199]
# The first nucleotide (and corresponding amino acid) is the ancestral nucleotide and therefore is considered the 
wild-type allele. N/A, not applicable.
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PAMP of C. albicans is recognized by MDA5.
AIM2-like receptors 
The AIM2 protein is encoded by the AIM2 gene located on chromosome 1. It recognizes 
cytosolic DNA derived from the host, bacterial and viral origin [200, 201]. Antigen 
recognition by a specific C-terminal domain of AIM2 is followed by formation of an 
inflammasome platform. The pyrin domain of AIM2 interacts with ASC, which contains 
a CARD domain that subsequently recruits caspase-1 to the complex responsible for 
processing of pro-IL-1β and pro-IL-18 [11, 202]. Although no specific polymorphisms have 
been found that link AIM2 to infectious diseases so far, it is likely that more research on 
this recently discovered receptor will identify genetic variants that contribute to infectious 
disease susceptibility.
 
Conclusion 
Since the discovery of PRRs, sequence variants in the genes encoding them have been 
recorded, and evidence regarding their associations with susceptibility to infectious 
disease has mounted. In this review, we have discussed major examples of genetic 
variation in PRRs, their association with susceptibility to infectious diseases, with a specific 
focus on their functional consequences. As such, this review provides strong arguments 
that genetic variation in PRRs has a profound impact on innate immune responses to 
infectious stimuli and affects infectious disease susceptibility.
However, this review is subject to several limitations. Although very important for the 
understanding of the consequences of sequence variants, negative associations and 
numerous attempts to validate sequence variants received less prominence. In addition, 
generalization of the results of individual studies is difficult and reproducibility often fails 
in independent validation studies. At least part of the differences between studies may be 
due to variations in ethnic background of the populations, often the small sample sizes of 
patient cohorts, the type of analyses performed, as well as possible confounding factors 
such as age, gender and co-morbidities which were not always taken into account. 
Nonetheless, the study of genetic variation in PRRs has been of crucial importance for 
several reasons. First, genetic variation in PRRs has increased our understanding of the role 
that these receptors play in infectious diseases. Second, this information may represent a 
first step in an approach toward personalized diagnosis and treatment. Finally, this type 
of research provides a human model to study PRR pathways to complement experimental 
animal models of infection.
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Future perspective
Within the last decades extensive research in the field of immunogenetics has led to a 
better understanding of the functional immune pathways and interactions underlying 
infectious diseases. Studying the genetic background of patients with infections has 
allowed us to pinpoint components of the immune system that contribute to disease 
susceptibility, as well as the influence on disease progression and outcome. Advances in 
technology, such as next generation sequencing, will enable the extensive study of large-
scale genomic information rather than single sequence variants. Moreover, structural 
variation as well as gene-gene interactions and gene expression changes will be more 
easily detected and may be linked to different diseases. Finally, technical improvement will 
allow the study of the epigenetic changes, and add an additional layer of complexity to the 
field of immunogenetics. Understanding the multiple pathways and factors that underlie 
susceptibility to infectious disease may lead to personalized diagnosis and treatment 
in the future. Such personalized treatment might involve patient-adjusted prophylaxis 
in those deemed at high risk of developing a severe infection due to a combination of 
genetic risk factors, or inhibition of an overactive immune system due to genetic variants 
in order to restore a normal cytokine balance. 
Executive summary
• Pattern-recognition receptors (PRRs) recognize specific pathogen-associated 
molecular patterns (PAMPs) and are involved in the initiation of the immune response 
against microorganisms.
• Five different classes of PRRs have been described: Toll-like receptors, C-type lectin 
receptors, NOD-like receptors, RIG-1-like receptors and AIM2-like receptors.
• Sequence variants are changes in the nucleotide sequence of DNA.
• Depending on the type of sequence variant and its location in the gene, it can have 
different functional consequences. 
• Genetic variation in PRRs influences susceptibility to infectious disease.
• Genetic variation in PRRs has increased our understanding in the pathological 
mechanism of infectious diseases and may lead toward personalized diagnosis and 
treatment in the future.
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Abstract
Bacteroides fragilis, an intestinal flora commensal microorganism, is frequently isolated 
from abscesses and soft tissue infections. This study aimed to identify pattern-recognition 
receptors (PRRs) involved in B. fragilis recognition and to characterize the induced cytokine 
profile. Human PBMCs were stimulated with heat-killed B. fragilis and cytokine levels were 
determined by ELISA. Roles of individual PRRs were assessed using specific blockers of 
receptor signaling pathways and PBMCs carrying single-nucleotide polymorphisms of PRR 
genes. Cell lines expressing human TLR2 or TLR4 were employed to assess TLR-specificity 
of B. fragilis. TLR1, TLR2 and NOD2 were the main PRRs responsible for recognition of B. 
fragilis, while TLR4, TLR6, NOD1 and Dectin-1 were not involved. B. fragilis induced strong 
IL-6 and IL-8, moderate IL-1β and TNFα, and poor IL-10, IL-17, IL-23 and IFNγ production. 
This study identifies the receptor pathways of the innate immune response to B. fragilis, 
and thus provides new insights in the host defense against B. fragilis.
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Introduction
The gram-negative, obligate anaerobic, rod-shaped bacterium Bacteroides fragilis normally 
resides within the colon as part of the commensal flora and is present in the majority of 
humans [1]. Species of the genus Bacteroides account for 20 - 30% of the species in human 
fecal flora and are an important component of the human microbiome [2]. As such, B. fragilis 
plays important biological roles in the induction but also modulation of the gut immune 
response. An immunomodulatory feature of B. fragilis has been shown to be mediated by 
one of its capsular components, polysaccharide A (PSA) [3, 4]. However, when B. fragilis 
spreads to normally sterile body sites, it can lead to serious infections with high associated 
mortality unless treated [5, 6]. This potential is underlined by the fact that B. fragilis is 
the most common anaerobic organism isolated from clinical infections [6, 7], e.g. intra-
abdominal abscesses, bacteraemia and complicated skin and skin structure infections 
[8]. Furthermore, B. fragilis shows increasing resistance against several antibiotics [9, 10]. 
Abscesses caused by B. fragilis are often polymicrobial and it has been shown that live B. 
fragilis and Escherichia coli act synergistically in promoting larger abscesses and bacterial 
persistence in a rat model [11]. 
On the side of the host encountering B. fragilis, the innate immune system is an early line 
of defense against invading microorganisms. Cells of the innate immune system recognize 
pathogen-associated molecular patterns (PAMPs) on the surface of these microorganisms 
through pattern-recognition receptors (PRRs). PRR families include the Toll-like receptors 
(TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) and 
C-type lectin receptors (CLRs), which recognize specific microbial ligands and lead to 
specific innate immune responses such as cytokine production [12]. A fourth family of 
PRRs, the RIG-I-helicases, are believed to be mainly involved in antiviral host defense [13].
Apart from the intriguing immunological characteristics of B. fragilis mentioned above, 
not much is known about its interactions with the innate immune system at a molecular 
level. Despite studies showing that heat-killed B. fragilis is able to induce tumour necrosis 
factor (TNF)α, interleukin-6 (IL-6), IL-10 and transforming growth factor (TGF)β production 
from mononuclear cells [14, 15], only fragmentary information is available regarding the 
pattern recognition of B. fragilis. Lipopolysaccharide (LPS) and polysaccharide A (PSA) 
isolated from B. fragilis are recognized by TLR2 [15-18], and a biased proinflammatory 
cytokine response induced by B. fragilis is observed in cells from Crohn’s disease patients 
with NOD2 mutations [15]. 
The aim of this study was to systematically explore the PRRs recognizing B. fragilis, 
characterize the cytokine profile induced by B. fragilis, and assess the impact of known 
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loss of function PRR single-nucleotide polymorphisms (SNPs) on cytokine production 
induced by B. fragilis.
Materials and methods
Bacterial strains and culture methods
Six different strains of B. fragilis were used: ATCC 25285, ATCC 23745, NCTC 10584 and 
3 clinically isolated strains JY 1032005, JY 3042143 and JY 2033990, selected randomly 
from 95 B. fragilis isolates obtained in a recent clinical trial on complicated skin and 
skin structure infections [8]. All strains were confirmed to be B. fragilis by 16S rRNA 
polymerase chain reaction. Briefly, DNA was isolated using an automated DNA extraction 
platform (MagNA Pure, Roche Diagnostics, Almere, The Netherlands). Isolated DNA 
was amplified using primers targeting part(s) of the ribosomal gene cassette (forward: 
5’-CCTAACACATGCAAGTCGARCG-3’, reverse: 5’-CGTATTACCGCGGCTGCT-3’, Eurogentec, 
Seraing, Belgium). Amplified products were purified using SPRI chemistry (Beckman 
Coulter, Mijdrecht, The Netherlands) and subjected to DNA sequence analysis using the 
DYEnamic ET dye terminator kit (GE Healthcare, Diegem, Belgium) and a MegaBACE 
500 automated DNA analysis platform (GE Healthcare). Identification of the isolates was 
performed by BLAST analysis of the obtained DNA sequences.
B. fragilis, grown anaerobically overnight at 37°C on Brucella blood agar plates (BD 
Biosciences, Franklin Lakes, NJ, USA), was inoculated in 20 mL pre-warmed and pre-
reduced Brain Heart Infusion broth (BD Diagnostics, Basel, Switzerland) and again grown 
anaerobically overnight at 37°C until reaching stationary growth phase mimicking growth 
conditions in abscesses. Bacterial suspensions were washed 3 times in phosphate-buffered 
saline (PBS; B. Braun Medical B.V., Melsungen, Germany) and heat-killed at 95°C for 30 
minutes. Before heat-killing, aliquots of bacterial suspensions were taken to determine 
colony-forming unit (cfu) counts. Heat-killed bacteria were washed again and after 
adjusting the concentration in PBS to 1 x 108 cfu/mL, stored at -80°C. When comparing 
B. fragilis with other microorganisms, an inoculum of 1 x 106 cfu/mL was used. All other 
experiments were performed with an inoculum of 1 x 107 cfu/mL.
Isolation of peripheral blood mononuclear cells and cytokine induction
Peripheral blood mononuclear cells (PBMCs) were isolated from either freshly obtained 
venous blood in EDTA tubes (Monoject, s-Hertogenbosch, The Netherlands) or from buffy 
coats of healthy individuals (after informed consent), as described earlier [19]. Briefly, 
PBMCs were isolated by density gradient centrifugation using Ficoll-Paque PLUS (GE 
Healthcare) and collecting the white interphase. Next, PBMCs were washed twice in cold 
PBS and concentrations were adjusted to 5 x 106 cells/mL for experiments in RPMI-1640 
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Dutch Modified culture medium (RPMI supplemented with 2 mM L-glutamine, 1 mM 
pyruvate and 50 μg/mL gentamicin; GIBCO Invitrogen, Carlsbad, CA, USA). PBMCs (5 x 105 
cells) and stimuli were added to wells of a 96-well round-bottom plate (Greiner, Nurnberg, 
Germany) in a final volume of 200 µL. For induction of IL-1β, TNFα, IL-6, IL-8, IL-10 and IL-
23, PBMCs were incubated for 24 hours at 37°C and 5% CO2, after which the plates were 
centrifuged and supernatants were collected. For induction of IL-17 and interferon (IFN)
γ, PBMCs and stimuli were supplemented with 10% pooled human serum and incubated 
for 7 days at 37°C and 5% CO2 before supernatant collection. All supernatants were 
stored at -20°C. In addition to stimulations with B. fragilis strains, the following specific 
PRR ligands were used, in various concentrations depending on the experiment: Pam3Cys 
(EMC Microcollections Tϋbingen, Germany) for TLR2/1, E. coli LPS (Sigma-Aldrich, St Louis, 
MO, USA) for TLR4, FSL-1 (EMC Microcollections) for TLR2/6 and MDP (Sigma-Aldrich) for 
NOD2.
Blocking pattern-recognition receptors and receptor signaling
PRR-mediated recognition was blocked using Bartonella quintana LPS (obtained as 
described previously [20]) for TLR4, anti-TLR2 blocking antibody (eBioscience, Halle-
Zoersel, Belgium) for TLR2, anti-TLR1 blocking antibody (eBioscience) for TLR1, anti-TLR6 
blocking antibody (Biolegend, San Diego, CA, USA) for TLR6, glucan-phosphate (kindly 
provided by Dr. David Williams, University of Tennessee, Knoxville, TN, USA) for blocking 
Dectin-1 and the RICK-inhibitor SB202190 (Sigma-Aldrich, St Louis, MO, USA) as an 
inhibitor of NOD1/2-induced stimulation. In these experiments, PBMCs (5 x 105 cells) were 
pre-incubated for 1 hour (30 min for RICK inhibitor) at 37°C and 5% CO2 with the various 
blocking reagents in 96-well round-bottom plates. Thereafter, stimuli were added (among 
which B. fragilis) and plates were incubated for 24 hours before collection of supernatants.
Measurement of cytokine concentrations
Cytokine concentrations were determined by commercially available enzyme-
linked immunosorbent assay (ELISA) kits according to manufacturer’s instructions. 
Concentrations of IL-1β, TNFα, IL-17 (R&D Systems, Inc., Minneapolis, MN, USA), IL-6, IL-8, 
IL-10, IFNγ (Sanquin Reagents, Amsterdam, The Netherlands) and IL-23 (eBioscience) were 
measured. 
Transfected Chinese hamster ovary cell line stimulation experiments
Chinese hamster ovary (CHO) cell lines stably transfected with human CD14 alone (3E10), 
human CD14 and TLR2 (3E10/TLR2) and human CD14 and TLR4 (3E10/TLR4) were kindly 
provided by Robin R. Ingalls (Boston University, Boston, MA, USA). These cell lines have 
been transfected with a reporter gene (Tac/CD25) under transcriptional control of a 
segment of the human ELAM promoter, which contains a binding site for nuclear factor 
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κB (NF-κB). Upon TLR recognition of the microorganism, the subsequent TLR signaling 
cascade results in NF-κB translocation to the nucleus of the CHO cell. In the nucleus, NF-
κB activates transcription of the reporter gene Tac/CD25 and drives the expression of 
membrane-bound CD25. Upregulation of membrane bound CD25 is detected by flow 
cytometry using anti-CD25 antibodies and represents recognition of the microorganism 
by the transfected TLR [21, 22]. Cells were grown at 37°C and 5% CO2 in Ham’s F-12 
medium (GIBCO Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum 
(GIBCO Invitrogen), 50 μg/mL gentamicin, 400 U/mL hygromycin B, and either 500 µg/mL 
G418 (geneticin) (for 3E10/TLR2) or 50 µg/mL puromycin (for 3E10/TLR4) as an additional 
selection antibiotic, as described previously [15]. For stimulation experiments, 5 x 104 
cells in 500 µL culture medium were plated in 24-well tissue culture plates (Greiner) and 
incubated overnight. Next, cells were incubated with control culture medium, 10 µg/
mL Pam3Cys (EMC Microcollections Tϋbingen, Germany), 1 µg/mL purified E. coli LPS 
(Sigma-Aldrich) or 1 x 107 cfu/mL of heat-killed B. fragilis for 20 hours at 37°C and 5% CO2. 
Subsequently, cells were harvested using trypsin-EDTA (GIBCO Invitrogen), prepared for 
flow cytometry and stained for CD25 expression with FITC-labeled mouse anti-human 
CD25 monoclonal antibody (Dako, Glostrup, Denmark). CD25 expression was assessed 
using a Coulter Epics XL-MCL flow cytometer (Beckman Coulter). 
Genomic DNA isolation and single-nucleotide polymorphism analysis
Venous blood was obtained after informed consent from a cohort of 74 healthy foresters 
from the ‘Geldersch Landschap’ department in The Netherlands (cohort details: 23-
73 years of age, 77% male, 23% female). DNA was isolated using the Gentra Pure Gene 
Blood kit (Qiagen, Hilden, Germany), according to the manufacturer’s protocol. SNPs 
of the analyzed PRR genes were selected upon previously published functional effects 
on protein function and/or gene expression and characteristics are described in detail 
in Table 1 [23-26]. PCR amplification of TLR1, TLR6, Dectin-1, NOD1 and NOD2 gene 
fragments bearing the polymorphisms S248N (TLR1), P249S (TLR6), Y238X (Dectin1), ND1 
+32656 (NOD1) and 1007finsC (NOD2) was performed using a pre-designed TaqMan® SNP 
genotyping assay (Applied Biosystems Inc., Carlsbad, CA, USA). Fluorescence intensities 
were corrected using a pre-read/post-read method for 1 min at 60°C before and after the 
amplification. The software used automatically plotted genotypes based on a 2-parameter 
plot with an overall success rate of >95%. Intermediate samples were excluded from 
analysis. Conventional PCR amplification of the TLR1 gene fragment containing SNP I602S 
and TLR2 gene fragment containing SNP R753Q was performed on a iCycler detection 
system (Bio-Rad Laboratories, Hercules, CA, USA). After sequencing using the Sanger 
method, samples were analyzed using the 3730 Sequence analyzer and Chromas 2.33 
software (Technelysium Pty Ltd., Tewantin, QLD, Australia). PCR amplification of TLR4 gene 
fragments containing SNPs D299G and T399I was performed as described previously [27]. 
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Statistical analysis
Paired cytokine data from PRR blocking experiments were analyzed using the Wilcoxon 
signed rank test. Comparison of cytokine levels between different genotype/SNP groups 
was performed using either the Mann-Whitney U test or the Kruskal-Wallis test with 
Dunns post-test comparison. A P-value <0.05 was considered to be statistically significant. 
All statistical analyses were performed using GraphPad Prism 4.00 software (GraphPad 
Software Inc., La Jolla, CA, USA). Data are presented as means + SEM, unless stated 
otherwise.
Table 1. Genotyped single-nucleotide polymorphisms (SNPs) in genes coding for pattern-recognition receptors. 
Gene SNP ID Mutation Amino acid change# Function
TLR1 rs4833095 Missense S248N Loss of function [23]
TLR1 rs5743618 Missense I602S Loss of function [23]
TLR2 rs5743708 Missense R753Q Loss of function [23]
TLR4 rs4986790 Missense D299G Loss of function [26]
TLR4 rs4986791 Missense T399I Loss of function [26]
TLR6 rs5743810 Missense P249S Loss of function [23]
NOD1 * - Ins/Del ND1+32656 - Loss of function [25]
NOD2 rs5743293 Frameshift 1007finsC - Loss of function [25]
Dectin1 rs16910526 Nonsense Y238X Loss of function [24]
# First described amino acid (AA) is considered wild-type.
* NOD1 insertion/deletion (Ins/Del) polymorphism ND1+32656, partially identified as rs6958571.
Results
Cytokine induction by B. fragilis
In order to characterize the cytokine profile induced by B. fragilis, PBMCs of 74 healthy 
individuals were stimulated with an inoculum of heat-killed 1 x 106 cfu/mL B. fragilis, E. coli 
(gram-negative bacterium) or S. aureus (gram-positive bacterium, also a potent abscess 
inducer) and medium as a control. B. fragilis stimulated PBMCs induced a significantly 
higher response for each cytokine, except for IFNγ compared to the negative control. B. 
fragilis was a strong inducer of IL-6 and IL-8, a moderate inducer of IL-1β and TNFα and a 
poor inducer of IL-10 and IFNγ. For each of these cytokines, the B. fragilis response was 
in between both positive controls, significantly higher than S. aureus, but lower than E. 
coli. In addition, recognition of B. fragilis resulted in an unexpected low IL-17 induction 
compared to other cytokines, with a higher response than E. coli, but significantly lower 
than the known IL-17 inducer S. aureus (Figure 1A). To further investigate the cause of 
the low IL-17 induction by B. fragilis, dose-response curves were obtained by stimulating 
PBMCs with increasing concentrations of 6 different B. fragilis strains and IL-17 (after 7 
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Figure 1. Cytokine induction by B. fragilis. (A) PBMCs (5 x 106/mL) were incubated with heat-killed B. fragilis NCTC 
10584 (1 x 106 cfu/mL), heat-killed S. aureus ATCC 29213 (1 x 106 cfu/mL), E. coli ATCC 25922 (1 x 106 cfu/mL) or 
culture medium (negative control). After incubation for 24 hours (IL-1β, IL-6, IL-8, TNFα and IL-10) or 7 days (IL-
17 and IFNγ), cytokine levels were measured in supernatants by ELISA (n=74). (B - D) PBMCs (5 x 106/mL) were 
incubated with increasing concentrations of 6 different strains of heat-killed B. fragilis (ATCC 25285, ATCC 23745, 
JY 1032005, JY 3042143, JY 2033990 and NCTC 10584) and cytokine levels of IL-1β (B), IL-17 (C) and IL-23 (D) were 
measured in supernatants by ELISA (n=4).
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Figure 2. Role of Toll-like receptors in immune recognition of B. fragilis. (A) CHO 3E10 cells (1 x 105/mL) stably 
transfected with CD14 alone (3E10), human CD14 and TLR2 (3E10/TLR2) or human CD14 and TLR4 (3E10/TLR4) 
were incubated with medium, Pam3Cys (10 µg/mL), E. coli LPS (1 µg/mL) or heat-killed B. fragilis JY 1032005 (1 x 10
7 
cfu/mL) for 20 hours. Subsequently, cells were stained with FITC-labeled mouse anti-human CD25 monoclonal 
antibody, a measure for TLR signaling, and the percentage of CD25 positive cells was assessed by flow cytometry. 
Data are representative of an experiment performed in duplicate. (B - E) PBMCs (5 x 106/mL) were pre-incubated 
for 1 hour with TLR inhibitors, followed by 24 hours incubation with heat-killed B. fragilis JY 1032005 (1 x 107 cfu/
mL). Subsequently, levels of IL-6 were measured in supernatants by ELISA. Wilcoxon signed-rank test; * P<0.05. 
Individual data are presented. TLR inhibitors: (B) α-TLR2 (10 µg/mL) or isotype control antibody (10 µg/mL), n=6. 
(C) α-TLR1 (10 µg/mL) or isotype control antibody (10 µg/mL), n=6. (D) α-TLR6 (10 µg/mL) or isotype control 
antibody (10 µg/mL), n=6. (E) B. quintana LPS (TLR4 inhibitor; 1 µg/mL) or medium control, n=8.
days) and IL-17 inducing cytokines IL-1β and IL-23 (after 24 hours) were measured. Again, 
a moderate induction of IL-1β (Figure 1B) and poor induction of IL-17 (Figure 1C) was 
confirmed for all strains, although the IL-1β induction was variable between strains. In 
addition, B. fragilis proved to be a very poor inducer of IL-23 (Figure 1D), providing the 
most likely explanation for its low IL-17 inducing potential.
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Role of Toll-like receptors in immune recognition of B. fragilis
To determine which TLRs are involved in immune recognition of B. fragilis, CHO cells 
transfected with human (h)CD14 alone, with hCD14 and hTLR2, or with hCD14 and hTLR4 
were stimulated with medium (negative control), Pam3Cys (TLR2 agonist), E. coli LPS 
(TLR4 agonist) or heat-killed B. fragilis. Induction of TLR signaling in these cells leads to 
translocation of NF-κB to the nucleus which drives the expression of membrane-bound 
CD25. B. fragilis strongly induced CD25 expression in hTLR2 transfected cells. In contrast, 
CHO cells transfected with hTLR4 and hCD14 or hCD14 alone did not respond to B. 
fragilis (Figure 2A). CD25 expression represents immune recognition of B. fragilis by the 
transfected TLR suggesting that TLR2, but not TLR4, has a major role in the binding and 
recognition of B. fragilis. However, they are not informative concerning the effects of this 
recognition on the induced cytokine responses. 
In a subsequent set of experiments, we performed PRR and receptor signaling blocking 
experiments using IL-6 as a read-out cytokine. Using anti-TLR2 antibodies in order to 
inhibit TLR2 resulted in a significant decrease of IL-6 production by PBMCs stimulated 
with B. fragilis (Figure 2B). Recognition of TLR2 ligands can occur through heterodimeric 
association of TLR2 with either TLR1 or TLR6, therefore we also studied blocking these 
receptors with anti-TLR1 and anti-TLR6 antibodies. IL-6 production was significantly 
inhibited using anti-TLR1 antibodies, but not by anti-TLR6 antibodies (Figure 2C, D). 
Inhibiting TLR4 using B. quintana LPS had no significant effect on induction of IL-6 (Figure 
2E) in PBMCs stimulated with B. fragilis, whereas production of IL-6 (data not shown) was 
significantly reduced in E. coli LPS stimulated PBMCs in the presence of B. quintana LPS. 
These findings suggest that TLR1 and TLR2, but not TLR4 and TLR6, are involved in the 
recognition of B. fragilis. 
Figure 3. Role of Dectin-1 and NOD-like receptors in immune recognition of B. fragilis. (A) PBMCs (5 x 106/mL) 
were pre-incubated for 1 hour with medium or glucan-phosphate (200 µg/mL) followed by 24 hours incubation 
with heat-killed B. fragilis JY 1032005 (1 x 107 cfu/mL). Subsequently, levels of IL-6 were measured in supernatants 
by ELISA (n=6). (B) PBMCs (5 x 106/mL) were pre-incubated for 30 min with medium or RICK inhibitor SB202190 
(1 µM) and incubated with heat-killed B. fragilis JY 1032005 (1 x 107 cfu/mL) for 24 hours. Subsequently, levels 
of IL-6 were measured in supernatants by ELISA (n=6). Wilcoxon signed-rank test; * P<0.05. Individual data are 
presented.
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Role of Dectin-1 and NOD-like receptors in immune recognition of B. fragilis
TLR2 has been previously demonstrated to interact with Dectin-1 [28, 29] and NOD-like 
receptors [30] for the induction of cytokines. Production of IL-6 (Figure 3A) in response to B. 
fragilis was not significantly affected by the Dectin-1 inhibitor glucan-phosphate, whereas 
glucan-phosphate significantly decreased levels of IL-6 (data not shown) in response to 
Candida albicans. To investigate the role of NOD-like receptors, we stimulated PBMCs 
with heat-killed B. fragilis in the presence of the RICK inhibitor SB202190, which is an 
adaptor molecule mediating NOD1/2-dependent signals. The RICK inhibitor significantly 
decreased production of IL-6 (Figure 3B), indicating that NOD-like receptors recognize B. 
fragilis and induce proinflammatory cytokine production. 
Impact of Toll-like receptor single-nucleotide polymorphisms on immune 
recognition of B. fragilis
In the cohort of healthy individuals, SNPs of TLR2, TLR1, TLR6 and TLR4 were determined 
and PBMCs were stimulated with B. fragilis to assess IL-6 and IL-1β cytokine production. 
PBMCs from individuals bearing the TLR2 SNP R753Q displayed no difference in IL-6 
production in response to B. fragilis (Figure 4A). However, PBMCs from individuals 
homozygous for the TLR1 SNP S248N produced significantly less IL-6 (Figure 4B) compared 
to those from heterozygous individuals. Similar results were found for the genetically 
linked TLR1 SNP I602S (93% linkage between these 2 polymorphisms; data not shown). No 
significant differences in IL-6 production were present in B. fragilis stimulated PBMCs from 
individuals homozygous for the TLR6 SNP P249S compared to those from wild-type and 
heterozygous individuals (Figure 4C). PBMCs from individuals heterozygous for the TLR4 
SNPs D299G and T399I (100% cosegregation) produced similar levels of IL-6 in response to 
B. fragilis (Figure 4D) compared to PBMCs from wild-type individuals. In addition, cytokine 
induction by E. coli LPS stimulated PBMCs did not differ between groups. 
In contrast to the IL-6 cytokine production, PBMCs from individuals bearing the TLR2 
SNP R753Q polymorphism displayed significantly increased IL-1β in response to B. fragilis 
compared to those from wild-type individuals (Figure 4E). Similar to the IL-6 results, IL-
1β was significantly decreased in PBMCs from individuals homozygous for the TLR1 
SNP S248N compared to heterozygous individuals in response to B. fragilis (Figure 4F). 
No significant differences in IL-1β production were observed in the genotype groups for 
TLR6 SNP P249S and TLR4 SNPs D299G and T399I (Figures 4G, H). These results show that 
SNPs in TLR1 and TLR2, in contrast to SNPs in TLR6 and TLR4, affect cytokine induction by 
B. fragilis. Furthermore, in contrast to SNPs in TLR1, the TLR2 SNP R753Q leads to higher 
production of IL-1β.
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Figure 4. Impact of Toll-like receptor single-nucleotide polymorphisms on immune recognition of B. fragilis. 
(A - H) PBMCs (5 x 106/mL) from individuals carrying various TLR SNPs were incubated for 24 hours with B. fragilis 
or various control TLR ligands. Subsequently, levels of IL-6 (left panel) and IL-1β (right panel) were measured in 
supernatants by ELISA. Wt, wild-type; He, heterozygous; Ho, homozygous. (A and E) PBMCs (5 x 106/mL) from 
individuals not carrying the TLR2 SNP R753Q (Wt, n=59) and individuals carrying the TLR2 SNP R753Q (He, n=5 
and Ho, n=1) were incubated with medium, Pam3Cys (10 µg/mL) or heat-killed B. fragilis NCTC 10584 (1 x 10
6 
cfu/mL). Mann-Whitney U Test * P<0.05. (B and F) PBMCs (5 x 106/mL) from individuals not carrying the TLR1 
SNP S248N (Wt, n=3) and individuals carrying the TLR1 SNP S248N (He, n=29; Ho, n=41) were incubated with 
medium, Pam3Cys (10 µg/mL) or heat-killed B. fragilis NCTC 10584 (1 x 10
6 cfu/mL). Kruskal-Wallis test; ** P<0.01, 
*** P<0.001. (C and G) PBMCs (5 x 106/mL) from individuals not carrying the TLR6 SNP P249S (Wt, n=23) and 
individuals carrying the TLR6 SNP P249S (He, n=39; Ho, n=11) were incubated with medium, FSL-1 (1 µg/mL) or 
heat-killed B. fragilis NCTC 10584 (1 x 106 cfu/mL). (D and H) PBMCs (5 x 106/mL) from individuals not carrying the 
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Impact of NOD-like receptor and Dectin-1 single-nucleotide polymorphisms on 
immune recognition of B. fragilis
PBMCs from individuals heterozygous for the NOD2 SNP 1007finsC produced significantly 
lower levels of IL-6 (Figure 5A), in response to B. fragilis compared to wild-type PBMCs. 
Muramyl dipeptide (MDP), a specific NOD2 ligand, showed a similar response (Figure 5A). 
In contrast, B. fragilis stimulated PBMCs from individuals heterozygous and homozygous 
for the NOD1 SNP ND1 +32656 displayed similar levels of IL-6 (Figure 5B), compared to 
those from wild-type individuals. Both NOD2 SNP 1007finsC and NOD1 SNP ND1 +32656 
genotype groups produced IL-1β cytokine profiles comparable to those observed for 
IL-6 (Figure 5C, D). These results confirm a role for NOD2, but not NOD1, in the immune 
recognition of B. fragilis. Furthermore, no differences in IL-6 and IL-1β production (data 
not shown) were observed between PBMCs heterozygous for the Dectin-1 SNP Y238X 
compared to wild-type PBMCs in response to B. fragilis, confirming that Dectin-1 is not 
involved in immune recognition of B. fragilis.
Figure 5. Impact of NOD-like receptor single-nucleotide polymorphisms on immune recognition of B. fragilis. 
(A - D) PBMCs from individuals carrying various NLR SNPs were incubated for 24 hours with B. fragilis or various 
control NLR ligands. Subsequently, levels of IL-6 (left panel) and IL-1β (right panel) were measured in supernatants 
by ELISA. Wt, wild-type; He, heterozygous; Ho, homozygous. (A and C) PBMCs (5 x 106/mL) from individuals not 
carrying the NOD2 SNP 1007finsC (Wt, n=60) and individuals carrying the NOD2 SNP 1007finsC (He and Ho, n=5) 
were incubated with medium, muramyl dipeptide (MDP; 10 µg/mL) or heat-killed B. fragilis NCTC 10584 (1 x 106 
cfu/mL). Mann-Whitney U test; * P<0.05, ** P<0.01. (B and D) PBMCs (5 x 106/mL) from individuals not carrying 
the NOD1 SNP ND1 +32656 (Wt, n=39) and individuals carrying the NOD1 SNP ND1 +32656 (He, n=20; Ho, n=6) 
were incubated with medium or heat-killed B. fragilis NCTC 10584 (1 x 106 cfu/mL).
TLR4 SNPs D299G and T399I (Wt, n=59) and individuals carrying the TLR4 SNPs D299G and T399I (He, n=5) were 
incubated with medium, E. coli LPS (10 ng/mL) or heat-killed B. fragilis NCTC 10584 (1 x 106 cfu/mL).
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Discussion
In the present study, we show that B. fragilis has potent stimulatory effects on innate 
immunity, with strong induction of IL-6 and IL-8 production, and a moderate stimulation 
of IL-1β and TNFα. In contrast, B. fragilis poorly induced IL-10, IFNγ, IL-23 and IL-17 cytokine 
responses in human peripheral blood mononuclear cells. In addition, we demonstrate that 
TLR2, TLR1 and NOD2, but not TLR4, TLR6, Dectin-1 or NOD1, mediate pattern recognition 
of B. fragilis by human PBMCs. 
The strong IL-6 and TNFα cytokine responses induced in PBMCs by whole B. fragilis are in 
line with the findings of Nagy et al., who observed significant induction of IL-6 and TNFα 
in human mononuclear cells stimulated with B. fragilis [14]. Other studies exploring the 
host response to B. fragilis have been conducted on specific cell wall components of this 
bacterium. Mice injected with B. fragilis LPS displayed slightly increased blood levels of 
IL-6, TNFα and IFNγ [31]. B. fragilis outer membrane protein A (OmpA), one of its major 
outer-membrane components, induced the release of IL-1α, TNFα, IFNγ and IL-6 by murine 
splenocytes [32]. However, most research has focused on B. fragilis capsular polysaccharide 
A (PSA) of B. fragilis strain ATCC 25285. In line with our findings showing a poor induction 
of Th17 responses by B. fragilis, PSA suppressed IL-17 production in mice and induced 
IL-10 and TGF-β2 production by CD4+Foxp3+ regulatory T cells, resulting in protection 
against experimental colitis [4, 33] and experimental autoimmune encephalomyelitis 
[34]. In contrast, IL-17 was a critical component of the response to B. fragilis ATCC 25285 
or capsular polysaccharide from Streptococcus pneumoniae type 1 and blockade of IL-
17 inhibited abscess formation in mice [35]. These different observations are likely to be 
explained by variation in host, body site and experimental setup (in vivo/in vitro).
The poor IL-17 induction by B. fragilis may seem unexpected. IL-17 is a potent chemotactic 
peptide of neutrophils to sites of inflammation [36], and the majority of cells present in 
mixed infection abscesses in which B. fragilis is a participant are neutrophils. A possible 
explanation for the poor IL-17 induction in our findings is the absence of IL-23 induction 
by B. fragilis, a cytokine necessary for the maintenance of an IL-17 producing Th17 cell 
population [37]. On the other hand, B. fragilis strongly induced IL-8, which is another 
important chemotactic factor for recruiting neutrophils to sites of infection. The strong 
induction of IL-8 is likely to explain the ability of B. fragilis to induce abscess formation 
[38]. In contrast, B. fragilis enterotoxin (BFT) has previously been shown to induce IL-8 and 
TGF-β in human colonic epithelial cell lines [39, 40] and, more recently, to induce IL-17 
producing Th17 cells in mice [41]. However, BFT has no role in our system, as we used 
washed heat-killed bacteria in all experiments.
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We have assessed the role of major PRRs for the recognition of B. fragilis through several 
complementary approaches. Firstly, using stable CHO cell lines expressing either TLR2 or 
TLR4, we demonstrate that B. fragilis is recognized by TLR2, but not by TLR4. CHO cells 
constitutively express functional hamster TLR4, but not TLR2 [42], explaining the relatively 
strong CD25 induction in E. coli LPS stimulated CHO cells even without the presence of 
hTLR4. The conclusions from CHO cells were strengthened by experiments in human 
primary cells in which TLR2 or TLR4 were blocked by specific inhibitors during B. fragilis 
stimulation. Previous studies, using whole heat-killed B. fragilis [15] or B. fragilis LPS and 
PSA [16-18, 43], are in line with our results and may suggest that either the B. fragilis LPS 
or PSA are responsible for its recognition by TLR2. In contrast, 1 study found TLR4, but 
not TLR2, to be important in immune recognition of B. fragilis LPS [44] and reasons for 
this discrepancy are unclear so far. Through heterodimeric association with either TLR1 or 
TLR6, TLR2 can recognize distinct substrates [45]. To the best of our knowledge, this is the 
first study investigating the role of TLR1 and TLR6 in the immune recognition of B. fragilis. 
Blocking TLR1 and TLR6 clearly showed that TLR1, but not TLR6, is involved in immune 
recognition of B. fragilis. 
In addition to the effect of TLRs, we have also assessed the role of other PRR families for 
the recognition of B. fragilis. Dectin-1 has been previously shown to collaborate with TLR2 
for the induction of cytokine production [28, 29]. However, in line with the absence of 
known Dectin-1 ligands in the structure of the Bacteroides cell wall, blockade of Dectin-1 
did not influence cytokine production induced by B. fragilis. In contrast, bacterial cell 
wall contains an important amount of peptidoglycans, components recognized by the 
NLR receptors NOD1 and NOD2 [46, 47]. Blocking NOD1/NOD2 signaling using the RICK 
inhibitor SB202190 resulted in a decreased production of proinflammatory cytokines after 
stimulation of cells with B. fragilis. However, SB202190 is a non-specific RICK inhibitor and 
has been shown to inhibit other targets [48], indicating a possible role for either NOD1 or 
NOD2 for the recognition of the microorganism.
An additional methodology we employed was to investigate the effect of loss-of-function 
SNPs in PRR genes on cytokine responses induced by B. fragilis. SNPs were selected upon 
previously published functional effects on protein function and/or gene expression. In 
other studies, SNPs in TLR1 (S248N, I602S), TLR2 (R753Q), TLR6 (P249S) demonstrated 
to have a reduced potential to activate NF-κB after stimulation in HEK293T cells [23]. 
Decreased cytokine responses were observed after PBMC stimulation in the presence 
of SNPs in NOD2 (1007finsC) [25] and Dectin-1 (Y238X) [24], whereas increased cytokine 
responses were observed in the presence of SNPs in NOD1 [25]. SNPs in TLR4 (D299G, 
T399I) are associated with a blunted response to inhaled LPS [26].
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The finding that SNP R753Q in TLR2 affected cytokine induction by B. fragilis, whereas 
SNPs in TLR4 did not, confirmed the importance of TLR2 and not TLR4 in B. fragilis immune 
recognition. Interestingly, recognition by TLR2 leads to down regulation of IL-1β induction, 
suggesting a possible immunomodulatory role, which has been previously reported for 
TLR2 [49]. Furthermore, these results confirm that heterozygosity for both SNPs D299G and 
T399I in the TLR4 gene does not lead to a phenotype different from that of wild-type TLR4 
[27, 50]. Polymorphisms in TLR1 and TLR6 confirmed results from blocking experiments 
and indicated that TLR1, but not TLR6, is important for B. fragilis pattern recognition and 
proinflammatory cytokine production. Furthermore, by investigating the influence of 
SNPs in NOD-like receptors on cytokine responses, we demonstrate that NOD2, but not 
NOD1, is important in the pattern recognition of B. fragilis, and this in line with earlier 
observations from our group [15]. 
In conclusion, in the present study we have systematically assessed major classes of PRRs 
and cytokines regarding their involvement in the innate immune response against B. 
fragilis. TLR2, TLR1 and NOD2, but not TLR4, TLR6, Dectin-1 and NOD1, are important in 
the pattern recognition of B. fragilis in human PBMCs. This leads to a strong induction of 
IL-6 and IL-8, the moderate stimulation of IL-1β and TNFα production, but a poor IL-10, 
IFNγ, IL-23 and IL-17 cytokine response. With the increasing ability of bacteria to resist 
antibiotic treatment, the need for new targets to control infections caused by B. fragilis 
will arise, and an immunotherapeutic approach has been advocated. This study suggests 
such targets and future research is needed to explore their role in the management of B. 
fragilis infections.
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Abstract
Background. Complicated skin and skin structure infections (cSSSIs) are characterized by 
infections with either gram-positive and gram-negative aerobic or anaerobic bacteria, 
as well as a polymicrobial etiology. These invading microorganisms are recognized by 
pattern-recognition receptors (PRRs) of the innate immune system. This study assessed 
whether genetic variation in genes encoding PRRs influences the susceptibility to cSSSIs. 
Methods. A total of 318 patients with cSSSI and 328 healthy controls were genotyped for 
9 nonsynonymous single-nucleotide polymorphisms (SNPs) in PRR genes coding for Toll-
like receptors (TLRs) 1, 2, 4, 6; NOD-like receptor 2; and the signaling adaptor molecule 
TIRAP. Associations between susceptibility to cSSSIs and a SNP were investigated by 
means of logistic regression models. In an additional cohort of 74 healthy individuals in 
whom the same SNPs were genotyped, peripheral blood mononuclear cells (PBMCs) were 
obtained and stimulated with Staphylococcus aureus. Interleukin 6 (IL-6) concentrations 
were determined in supernatants by enzyme-linked immunosorbent assay to determine 
the correlation between genotypes and levels of IL-6 secretion. 
Results. In the genetic association analysis, polymorphisms in TLR1 (S248N and R80T), 
TLR2 (P631H) and TLR6 (P249S) were associated with an increased susceptibility to 
cSSSIs. No association with susceptibility to cSSSIs was observed for polymorphisms 
TLR2 (R753Q), TLR4 (D299G and T399I), NOD2 (P268S) and TIRAP (S180L). In the functional 
analysis, individuals bearing the TLR1 248N or 80T allele showed lower IL-6 secretion upon 
stimulation with S. aureus. 
Conclusions. Polymorphisms in TLR1, TLR2 and TLR6 are associated with increased 
susceptibility to cSSSIs. For TLR1, impaired proinflammatory cytokine production due to 
the polymorphism is most likely the mechanism mediating this effect.
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Introduction
Complicated skin and skin structure infections (cSSSIs) involve deeper soft tissue, require 
substantial surgical intervention, or occur in a compromised host with a comorbid 
condition which may affect the response to treatment [1]. Common examples of cSSSIs are 
soft-tissue abscesses, diabetic foot infections, surgical-site and trauma-induced wound 
infections [1, 2]. Gram-positive and gram-negative aerobic or anaerobic bacteria, alone or 
as part of a polymicrobial infection, are the causative agents of cSSSIs, with Staphylococcus 
aureus and β-hemolytic streptococci being most frequent [1-3]. The infection location, the 
clinical situation, and the medical history of the patient are important characteristics that 
determine the type of pathogens involved [1, 2]. 
cSSSIs are associated with significant morbidity and mortality leading to prolonged and 
expensive hospitalizations, with a considerably impact on healthcare resource utilization 
[4]. cSSSIs often require surgical debridement of the infection in combination with antibiotic 
therapy [2]. However, the increasing ability of bacteria to resist antibiotic treatment, such 
as methicillin-resistant S. aureus and vancomycin-resistant enterococci, complicates 
management of these infections [5]. In addition, differences in severity and occurrence of 
cSSSIs in patients are not solely explained by comorbidities or the virulence of a certain 
pathogen, as previously healthy young individuals can develop a severe infection caused 
by components of the commensal flora [6]. For these reasons, there is a need to identify 
host factors that predispose to development of cSSSIs, to define a predictive profile for 
persons at risk of developing these infections and potential individualized diagnosis and 
treatment. 
One of the most significant discoveries to help understand the role of the host defense 
system against invading pathogens is the identification of germ-line-encoded pattern-
recognition receptors (PRRs) able to recognize conserved structures of microbial species 
called pathogen-associated molecular patterns (PAMPs) [7]. Currently, 5 major PRR classes 
have been described: Toll-like receptors (TLRs), nucleotide-binding domain leucine-rich 
repeat containing receptors (NLRs), C-type lectins, RNA helicase RIG-I-like receptors and 
cytoplasmic DNA receptor AIM2-like receptors [8, 9]. Of these PRR families, TLRs were the 
first to be discovered, and 10 TLRs have since been characterized in humans. TLRs recognize 
PAMPs by N-terminal leucine-rich repeats followed by a transmembrane region leading to 
the cytoplasmic Toll/Interleukin-1R homology (TIR) domain, which interacts with several 
adaptor proteins, such as myeloid differentiation primary response gene 88 (MyD88) and 
MyD88 adaptor-like/Toll-interleukin 1 receptor domain-containing adaptor protein (Mal/
TIRAP), activating transcription factors, resulting in pro- and antiinflammatory cytokine 
production and generation of an adaptive immune response [8]. 
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Several TLRs have been implicated as important in the host defense against cSSSI 
pathogens. Gram-positive bacteria such as S. aureus contain cell wall components 
that initiate immune responses through TLR2 [10], most often by the formation of 
heterodimers with either TLR1 or TLR6 [11, 12]. In contrast, lipopolysaccharide derived 
from the gram-negative bacterium Escherichia coli is recognized by TLR4 [13]. Furthermore, 
peptidoglycans of both gram-positive and gram-negative bacteria (S. aureus and E. coli) 
are recognized by NOD2, a member of the NLR family of cytoplasmic receptors [14]. 
Genetic variants of TLRs [15-25], NOD2 [26-28] and the signaling adaptor TIRAP [29, 30] 
have previously been associated with susceptibility to infections. However, none of these 
studies have systematically investigated the role of these PRRs in the susceptibility to 
cSSSIs. In this study, we hypothesized that polymorphisms in genes encoding PRRs or their 
signaling adaptors may influence the host susceptibility to cSSSIs. To test this hypothesis, 
we determined the prevalence of 7 nonsynonymous single-nucleotide polymorphisms 
(SNPs) in TLR genes, 1 in the NLR (NOD2) gene and 1 in the gene encoding the signaling 
adaptor TIRAP, in a cohort of 318 patients with cSSSI and 328 healthy controls. The genetic 
studies were supported by functional assays investigating the influence of the specific 
polymorphisms on the capacity to induce interleukin 6 (IL-6) cytokine responses after 
stimulation of human peripheral blood mononuclear cells (PBMCs).
Materials and methods
Subjects 
From a total population of 813 patients with cSSSI included in a large, randomized, 
multicenter, clinical trial [6], 389 patients gave informed consent to participate in this 
genetic substudy. Reasons for noninclusion in the genetic substudy were absence of an 
invitation to participate in the genetic substudy (the major reason) or refusal to participate. 
Of the 389 patients, 71 were excluded because they were not white (n=2) or not of Eastern 
European ethnicity (n=69), resulting in 318 white patients with cSSSI from 7 East European 
countries who were eligible to participate in this study.
Inclusion of patients in the trial was performed from September 2006 to June 2008, in 
compliance with Food and Drug Administration (FDA) guidance, in which the term 
“uncomplicated and complicated skin and skin structure infections” was used [31]. The 
FDA issued a new guidance document in 2010, which used the term “acute bacterial skin 
and skin structure infections” [32]. We used the term “cSSSI” in this study because not only 
terminology but also criteria for satisfying the definition of these infections have changed.
Inclusion criteria and definition of cSSSIs (subtype/diagnosis: major abscess, diabetic 
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foot infection, wound infection, or infected ischemic ulcer) are described in detail in the 
trial report [6]. A total of 89% of patients with cSSSI had community-acquired infections, 
and the remaining 11% had nosocomial infections. Seventy percent of the patients with 
cSSSI had polymicrobial infections. In 97% of the infections, at least 1 gram-positive 
microorganism was isolated. The prevalence of the predominant pathogens, mainly S. 
aureus, β-haemolytic Streptococcus group A-G and Enterococcus faecalis, causing these 
infections in patients with cSSSI are displayed in Table 1. 
A total of 328 Eastern European, white, healthy controls recruited from the community, 
the majority of whom where males, were selected to geographically match the patients 
with cSSSI. In addition, 74 Dutch, white, healthy individuals were recruited from the 
community to correlate their genotype with IL-6 secretion upon stimulation of PBMCs. All 
subjects gave informed consent for genetic analysis.
Table 1. Prevalence of baseline causative organisms isolated from patients with complicated skin and skin 
structure infections.
Causative organism Percentage of all causative organisms
Staphylococcus aureus 31.5
Enterococcus faecalis 12.1
Streptococcus pyogenes 6.9
Streptococcus agalactiae 5.8
Streptococcus equisimilis 3.9
Escherichia coli 12.1
Enterobacter cloacae 4.3
Bacteroides fragilis 3.9
Acinetobacter baumannii 3.2
Other gram-positive organisms 3.6
Other gram-negative organisms 12.7
Data are limited to organisms isolated ≥3% of all causative organisms.
Genotyping
DNA from patients with cSSSI was extracted from blood collected in PAXgene DNA tubes 
(Qiagen, Hildesheim, Germany) according to the PLUS XL manual kit (LGC genomics GmbH, 
Berlin, Germany). DNA from healthy controls was isolated using the Gentra Pure Gene 
blood kit (Qiagen), according to the manufacturer’s protocol. Nonsynonymous SNPs of the 
analyzed PRR genes were selected from the National Center for Biotechnology Information 
SNP database if they had previously described associations with human disease or known 
functional effects on gene expression or protein function. In total, 9 nonsynonymous 
missense SNPs in genes TLR1, TLR2, TLR4, TLR6, NOD2, and TIRAP were genotyped (Table 
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2). Gene fragments were amplified by commercially available TaqMan SNP genotyping 
assays according to manufacturer’s protocol on a 7300 real-time polymerase chain 
reaction system (Applied Biosystems, Foster City, CA, USA). Quality control was performed 
by the incorporation of positive and negative controls and duplication of random samples 
across different plates. 
Table 2. Genotyped nonsynonymous missense single-nucleotide polymorphisms (SNPs) in genes coding for 
pattern-recognition receptors and the signaling adaptor TIRAP. 
Gene SNP ID Mutation Nucleotide change# Amino acid change# Taqman Assay ID
TLR1 rs4833095 Missense C > T S248N C__44103606_10
TLR1 rs5743611 Missense G > C R80T C__27855269_10
TLR2 rs5743704 Missense C > A P631H C__27855269_10
TLR2 rs5743708 Missense G > A R753Q C__27860663_10
TLR4 rs4986790 Missense A > G D299G C__11722238_20
TLR4 rs4986791 Missense C > T T399I C__11722237_20
TLR6 rs5743810 Missense C > T P249S C___1180648_20
NOD2 rs2066842 Missense C > T P268S C__11717470_20
TIRAP rs8177374 Missense C > T S180L C__25983622_10
# The first nucleotide (and corresponding amino acid) is the ancestral and therefore is considered the wild-type 
allele. ID, identification number.
In vitro PBMC stimulation and cytokine detection assays
Venous blood was obtained from 74 healthy controls. PBMCs were isolated and stimulated 
as described earlier [33], with minor modifications. In brief, PBMCs were isolated by density 
gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden). Next, 
PBMCs were washed twice with phosphate-buffered saline (pH=7.4), and concentrations 
were adjusted to 5 x 106 cells/mL for experiments in Roswell Park Memorial Institute 1640 
Dutch Modified culture medium (supplemented with 2 mM L-glutamine, 1 mM pyruvate 
and 50 μg/mL gentamicin; GIBCO Invitrogen, Carlsbad, CA, USA).
PBMCs (5 x 105 cells) were added to 96-well round-bottom plates (Greiner, Nurnberg, 
Germany) and stimulated with either 1 x 106 colony forming units/mL of heat-killed S. 
aureus ATCC 29213 or specific TLR ligands (10 μg/mL Pam3Cys or 1 μg/mL FSL-1; EMC 
Microcollections, Tϋbingen, Germany) in a final volume of 200 μL. PBMCs were incubated 
for 24 hours at 37°C and 5% CO2 to induce IL-6 production, after which the plates were 
centrifuged and supernatants were collected. All supernatants were stored at -20°C. IL-6 
concentrations were measured in supernatants by a commercially available enzyme-
linked immunosorbent assay (ELISA) kit according to manufacturer’s instructions (Sanquin 
Reagents, Amsterdam, The Netherlands). 
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Statistical analysis
Chi-square analysis of deviation from Hardy-Weinberg equilibrium (HWE) was performed 
for all 9 SNPs separately in healthy controls, using a web-based HWE calculator [34]. The 
association between susceptibility to cSSSIs and a SNP were investigated by means of 
univariate logistic regression models, using IBM SPSS 18 software (IBM, Armonk, NY, 
USA). SNPs were evaluated using dominant model analysis (in which heterozygotic and 
homozygotic individuals for the allelic variant are combined and compared to wild-
type individuals) and recessive model analysis (in which wild-type and heterozygotic 
individuals are combined and compared to homozygotic individuals for the allelic variant). 
No correction for multiple testing was performed. Pairwise linkage disequilibrium (LD), 
D’ and r2, were calculated using IBM SPSS 18 software. Multivariate logistic regression 
analyses were performed assuming a dominant model. Model reduction was done via 
forward and backward model selection methods, and in the most complex model all 9 
genotyped SNPs were considered. P-values <0.05 were considered to be statistically 
significant. Odds ratios (ORs) and 95% confidence intervals (CIs) were reported for these 
tests of association. 
All statistical analyses and graphs of the IL-6 concentrations in the in vitro PBMC 
stimulation assays were performed and created, respectively, using GraphPad Prism 5.00 
software (GraphPad Software, La Jolla, CA, USA). Results were stratified by genotype, and 
differences in IL-6 secretion between genotypes were analyzed by Mann-Whitney U tests. 
Results
Univariate logistic regression of single polymorphisms in PRR and signaling adaptor 
TIRAP genes in patients with cSSSI and healthy controls
Polymorphisms in genes of TLR1, TLR2, TLR4, TLR6, NOD2 and TIRAP were genotyped in 
318 patients with cSSSI and 328 healthy controls for the analyses of genetic association 
with susceptibility to cSSSIs. In the dominant model, genotyping revealed an association 
between susceptibility to cSSSIs and 3 TLR polymorphisms: TLR1 S248N (P=0.03; OR=1.78 
[95% CI, 1.04-3.05]), TLR2 P631H (P=0.04; OR=1.86 [95% CI, 1.02-3.40]), TLR6 P249S (P=0.03; 
OR=1.41 [95% CI, 1.03-1.93]), in patients with cSSSI, compared to healthy controls (Table 
3). Polymorphism TLR1 R80T was borderline insignificant (P=0.06; OR=1.41 [95% CI, 0.98-
2.03]). In contrast to healthy controls, patients with cSSSI were more often heterozygous 
or homozygous for the allelic variant of these SNPs. No association with susceptibility to 
cSSSIs was observed in individuals carrying polymorphisms in TLR2 R753Q, TLR4 D299G 
and T399I, NOD2 P268S and TIRAP S180L (Table 3). In addition, recessive model analysis 
confirmed the association between susceptibility to cSSSIs and TLR1 S248N (P=0.01; 
OR=1.54 [95% CI, 1.13-2.11]) and showed borderline insignificance for TLR6 P249S (P=0.06; 
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OR=1.60 [95% CI, 0.98-2.61]) whereas TLR2 P631H, TLR1 R80T, TLR2 R753Q, TLR4 D299G 
and T399I, NOD2 P268S and TIRAP S180L did not influence susceptibility to cSSSIs (data 
not shown).
All genotyped SNPs were in HWE for the healthy controls (data not shown). LD analyses 
indicated that polymorphisms TLR1 S248N and TLR1 R80T (P<0.0001; r2=0.27; D’=0.53), 
Table 3. Distribution of pattern-recognition receptor and signaling adaptor TIRAP genotypes in 318 patients 
with complicated skin and skin structure infections (cSSSIs) and 328 healthy controls.
Polymorphism Wild-type, 
No. (%)
Heterozygous, 
No. (%)
Homozygous, 
No. (%)
P-value# Odds ratio (95% CI)#
TLR1 S248N CC CT TT 0.03 1.78 (1.04-3.05)
Patients with cSSSI 23 (7.2) 120 (37.7) 175 (55.0)
Healthy controls 40 (12.2) 143 (43.6) 145 (44.2)
TLR1 R80T GG GC CC 0.06 1.41 (0.98-2.03)
Patients with cSSSI 231 (72.6) 81 (25.5) 6 (1.9)
Healthy controls 259 (79.0) 63 (19.2) 6 (1.8)
TLR2 P631H CC CA AA 0.04 1.86 (1.02-3.40)
Patients with cSSSI 287 (90.3) 31 (9.7) 0 (0.0)
Healthy controls 310 (94.5) 18 (5.5) 0 (0.0)
TLR2 R753Q GG GA AA 0.76 0.89 (0.42-1.90)
Patients with cSSSI 305 (95.9) 13 (4.1) 0 (0.0)
Healthy controls 313 (95.4) 15 (4.6) 0 (0.0)
TLR4 D299G AA AG GG 0.37 0.81 (0.51-1.29)
Patients with cSSSI 280 (88.3) 35 (11.0) 2 (0.6)
Healthy controls 282 (86.0) 43 (13.1) 3 (0.9)
TLR4 T399I CC CT TT 0.37 0.81 (0.51-1.29)
Patients with cSSSI 280 (88.3) 35 (11.0) 2 (0.6)
Healthy controls 282 (86.0) 43 (13.1) 3 (0.9)
TLR6 P249S CC CT TT 0.03 1.41 (1.03-1.93)
Patients with cSSSI 130 (40.9) 144 (45.3) 44 (13.8)
Healthy controls 162 (49.4) 136 (41.5) 30 (9.1)
NOD2 P268S CC CT TT 0.87 0.98 (0.71-1.33)
Patients with cSSSI 179 (56.3) 107 (33.6) 32 (10.1)
Healthy controls 182 (55.7) 119 (36.4) 26 (8.0)
TIRAP S180L CC CT TT 0.43 1.16 (0.80-1.68)
Patients with cSSSI 240 (75.7) 66 (20.8) 11 (3.5)
Healthy controls 257 (78.4) 65 (19.8) 6 (1.8)
# Data are based on a dominant model analysis. CI, confidence interval.
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TLR1 S248N and TLR6 P249S (P<0.0001; r2=0.47; D’=0.59), TLR1 R80T and TLR6 P249S 
(P<0.0001; r2=0.26; D’=0.48) were not independent from another, although the strength 
of their correlation was observed to be low. In contrast, LD analyses for TLR4 D299G and 
TLR4 T399I revealed these SNPs were perfectly correlated (P<0.0001; r2=1.00; D’=1.00).
Multivariate logistic regression of polymorphisms in PRR and signaling adaptor 
TIRAP genes in patients with cSSSI and healthy controls
All 9 genotyped SNPs were considered for inclusion as explanatory variables in the 
multivariate logistic regression model with cSSSI status as main outcome. On the basis of 
results from univariate analyses, a dominant model analysis was performed. Forward and 
backward selection procedures resulted in the same final model, with SNPs TLR1 R80T, 
TLR2 P631H and TLR6 P249S best explaining the susceptibility to cSSSIs. The SNPs TLR1 
R80T (P=0.01; OR=1.60 [95% CI, 1.10-2.34]), TLR2 P631H (P=0.03; OR=1.94 [95% CI, 1.06-
3.56]) and TLR6 P249S (P=0.01; OR=1.55 [95% CI, 1.12-2.15]) independently influenced 
susceptibility to cSSSIs. Incorporation of the remaining 6 SNPs in the analysis did not 
improve the prediction of cSSSI status (P>0.3).
Functional effects of TLR1 S248N and R80T, TLR2 P631H, and TLR6 P249S 
polymorphisms on cytokine production
Functional consequences of the TLR polymorphisms associated with susceptibility to 
cSSSIs were studied by stimulation of PBMCs obtained from an additional cohort of 74 
healthy volunteers. PBMCs were stimulated with S. aureus, the pathogen most frequently 
causing cSSSIs, or with the following specific TLR ligands: Pam3Cys for TLR1 and TLR2 and 
FSL-1 for TLR6. IL-6 secretion was assessed in cell culture supernatants after 24 hours of 
stimulation and was stratified based on the particular TLR genotype. Unstimulated PBMCs 
did not induce detectable IL-6 cytokine responses (data not shown). Homozygosity 
(TT; n=41) for the TLR1 S248N polymorphism was associated with dramatically lower 
IL-6 cytokine responses, compared to wild-type (CC; n=3) and heterozygous (CT; n=29) 
genotypes after S. aureus and Pam3Cys stimulation (Figure 1A and 1E, respectively). Also, 
heterozygosity (GC; n=13) for the TLR1 R80T polymorphism resulted in significantly lower 
IL-6 cytokine responses, compared to the wild-type (GG; n=58) genotype after S. aureus 
but not Pam3Cys stimulation (Figure 1B and 1F, respectively). This decreased IL-6 cytokine 
response after S. aureus stimulation was not observed in individuals homozygous for the 
variant allele (CC; n=2), most likely because of its low prevalence. 
No significant differences in IL-6 response could be detected between the wild-type (CC; 
n=71) and heterozygous (CA; n=2) genotypes of the TLR2 P631H polymorphism (Figure 
1C and 1G), again most likely because of the low prevalence of the allelic variant among 
the study participants. No homozygotes (AA; n=0) for TLR2 P631H were present among 
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the 74 individuals. A decreasing trend in IL-6 response was observed in PBMCs stratified 
for the TLR6 P249S polymorphism (CC; n=22, CT; n=39, TT; n=11) after S. aureus but not 
FSL-1 stimulation, although results were not statistically significant (Figure 1D and 1H).
PRR SNPs and susceptibility to cSSSIs | 83
4
Discussion
This study demonstrates that polymorphisms in PRRs genes TLR1, TLR2 and TLR6 are 
associated with an increased susceptibility to cSSSIs. In the univariate logistic regression 
analysis, 3 polymorphisms were found to be associated with an increased susceptibility 
to cSSSIs: TLR1 S248N, TLR2 P631H and TLR6 P249S, with borderline insignificance for 
TLR1 polymorphism R80T. When studying the predictive power of a combination of SNPs 
by means of a multivariate logistic regression analysis, TLR1 polymorphism S248N is 
not included in the model. The combination of polymorphisms TLR1 R80T, TLR2 P631H, 
and TLR6 P249S better explains the susceptibility to cSSSIs than models including TLR1 
polymorphism S248N. In addition, PBMCs of individuals carrying the TLR1 allele 248N 
or 80T produced significantly less IL-6 in response to the cSSSI pathogen S. aureus. No 
association was observed with susceptibility to cSSSIs for polymorphisms in TLR2 R753Q, 
TLR4 D299G and T399I, NOD2 P268S, and TIRAP S180L.
The patients included in this study had predominantly gram-positive bacterial infections 
caused by Staphylococcus, Streptococcus, and Enterococcus species [6]. It is important to 
observe that TLR1, TLR2, and TLR6 are the main innate immune receptors for recognition 
of gram-positive bacteria. For instance TLR2, as a homodimer, or in heterodimeric 
combination with either TLR1 or TLR6, recognizes cell wall components of S. aureus [11, 
12]. 
All these cSSSI-associated polymorphisms have been previously linked to infectious 
disease. The TLR1 polymorphism S248N has been demonstrated to result in increased 
susceptibility to gram-positive infection in sepsis [25], candidemia [21] and leprosy [22]. 
The other TLR1 polymorphism R80T is associated with pancolitis [35], invasive aspergillosis 
after hematopoietic stem cell transplantation [18], and candidemia [21]. Furthermore, the 
TLR2 polymorphism P631H is significantly overrepresented in patients with tuberculosis, 
compared with contact controls [36], whereas the TLR6 polymorphism P249S is associated 
with malaria [37] and invasive aspergillosis [18]. 
Figure 1. Correlation of complicated skin and skin structure-associated pattern-recognition receptor genotypes 
with interleukin 6 (IL-6) levels after 24 hours of peripheral blood mononuclear cell stimulation. Left, stimulation 
with heat-killed Staphylococcus aureus (1x106 colony-forming units/mL). Right, stimulation with specific Toll-like 
receptor (TLR) agonists. Specific TLR agonists were Pam3Cys (10 μg/mL) for TLR1 and TLR2 and FSL-1 (1 μg/mL) 
for TLR6 stimulation. Results are stratified by genotype (A, E) TLR1 S248N, (B, F) TLR1 R80T, (C, G) TLR2 P631H, 
(D, H) TLR6 P249S. Dark grey represents individuals homozygous for the wild-type allele, light grey individuals 
heterozygous for the allelic variant, and white individuals homozygous for the allelic variant. Data were analyzed 
by Mann-Whitney U tests. Boxes represents the median and interquartile ranges; whiskers represent minimal 
and maximal values.
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In addition to the genetic association between PRR polymorphisms and cSSSIs, we also 
studied the functional consequences of these polymorphisms. Presence of the TLR1 
248N or 80T allele results in significantly lower IL-6 secretion, and a similar trend was 
observed for the TLR6 249S allele. IL-6 blockade by tocilizumab has been recently related 
to staphylococcal infections [38], illustrating the potential relevance of the effects of 
TLR1 SNPs on IL-6 production. No differences in IL-6 response were detected in groups 
stratified for the TLR2 polymorphism P631H, most likely because of the rare occurrence of 
heterozygotes and the absence of homozygotes for the allelic variant. 
In a recent paper by Ben-Ali et al., functional characterization of genetic variants in the 
TLR1-2-6 family were studied by transfection of various TLR constructs in HEK 293T cells 
containing a NF-κB luciferase reporter construct. Transfection of alleles TLR1 248N or 
80T, TLR2 631H and TLR6 249S all led to decreased NF-κB activation, compared to their 
ancestral variant, supporting our findings on the functional consequences of these 
polymorphisms. In addition, computational PolyPhen algorithm studies to predict the 
impact of nonsynonymous variants suggested that the TLR2 polymorphism P631H is a 
damaging mutation, whereas the TLR1 polymorphisms S248N and R80T, as well as the 
TLR6 polymorphism P249S, were classified as benign for protein function [39]. 
This study showed that polymorphisms TLR1 S248N and TLR1 R80T, TLR1 S248N and 
TLR6 P249S, and TLR1 R80T and TLR6 P249S were in LD, although the strength of their 
correlation was observed to be low. In contrast, the TLR1 polymorphism S248N is in strong 
linkage with the nonsynonymous TLR1 polymorphism I602S (rs5743618; not studied). This 
polymorphism is associated with impaired trafficking of the receptor to the cell surface, 
leading to decreased cell membrane expression of TLR1 [25]. These findings may imply 
that the polymorphism I602S is causing the functional effects observed. 
Presence of the TLR2 631H allele has been shown to decrease internalization of the 
TLR2 complex from the plasma membrane after recognition of its ligand [36]. Although 
internalization of the wild-type TLR2 complex is not necessary for intracellular signaling 
[40], one can expect that inhibition of internalization by this polymorphism still could 
modulate functional responses as described by reduced NF-κB activation [39].
Although the TLR2 R753Q, TLR4 D299G and T399I, NOD2 P268S, and TIRAP S180L 
polymorphisms were previously associated with infectious disease, no correlation between 
these polymorphisms and susceptibility to cSSSIs was observed here. The absence of an 
effect of these polymorphisms could in part be due to the type of pathogens present in 
patients with cSSSI, of which the majority are gram-positive bacteria. 
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To our knowledge this is the first study investigating the role of SNPs in PRR genes in 
disease susceptibility to cSSSIs. Unfortunately, a confirmation cohort was not available 
and future studies should validate the findings reported here.
In conclusion, this study demonstrates that 4 polymorphisms in genes TLR1, TLR2 and 
TLR6 are associated with an increased susceptibility to cSSSIs. These infections are 
predominantly caused by gram-positive bacteria, in which specifically these TLRs are of 
major importance for innate immune recognition. Functional characterization showed 
impaired TLR function and decreased cytokine responses. Although gram-positive 
bacterial infection and impaired TLR function strengthen the genetic associations 
observed, further studies are warranted to elucidate whether characterization of a 
predictive profile using TLR polymorphisms in TLR1, TLR2 and TLR6 can play a beneficial 
role for individuals at risk of developing cSSSIs.
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Abstract
Background. Toll-like receptors (TLRs) play a central role in the innate immune response to 
complicated skin and skin structure infections (cSSSIs), with TLR10 being the first family 
member known to have an inhibitory function. This study assessed the role of TLR10 in 
recognition of cSSSI-related pathogens and whether genetic variation in TLR10 influences 
susceptibility to cSSSIs.
Methods. Human peripheral blood mononuclear cells (PBMCs) preincubated with anti-
TLR10 antibody and HEK-293 cells overexpressing TLRs were exposed to cSSSI pathogens, 
and cytokine secretion was determined by enzyme-linked immunosorbent assay. A total 
of 318 patients with cSSSI and 328 healthy controls were genotyped for 4 nonsynonymous 
single-nucleotide polymorphisms in TLR10, and functional consequences of the TLR10 
SNPs were assessed via in vitro stimulation assays. 
Results. PBMC stimulation with cSSSI pathogens in the presence of TLR10 neutralizing 
antibody significantly increased interleukin 6 (IL-6) secretion. Overexpression of TLR10 
completely abrogated TLR2-induced IL-8 secretion of HEK-293 cells in response to cSSSI 
pathogens. Three polymorphisms in TLR10, I775L, I369L and N241H, were associated 
with reduced susceptibility to cSSSIs. The presence of TLR10 alleles 775L, 369L or 241H 
increased IL-6 secretion by PBMCs in response to cSSSI pathogens. 
Conclusions. TLR10 is a modulatory receptor of innate immune responses to cSSSI-related 
pathogens, and genetic variants in TLR10 are associated with protection against cSSSIs.
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Introduction
Complicated skin and skin structure infections (cSSSIs) were termed by the Food and 
Drug Administration as infections involving the deeper soft tissue that require significant 
surgical intervention, such as major abscesses, diabetic foot infections, surgical-site 
and trauma-induced wound infections, and infections in individuals with a significant 
underlying disease state that complicates the response to treatment. Also included are 
infections located in an anatomical site in which the chance of involvement of anaerobic 
or gram-negative pathogens is high [1, 2]. Gram-positive bacteria such as Staphylococcus 
aureus (S. aureus) and β-hemolytic streptococci are the predominant causative organisms, 
but presence of gram-negative bacteria (e.g. Escherichia coli) and anaerobes (e.g. 
Bacteroides fragilis), as well as a polymicrobial etiology, is frequent [2-4].
Cells of the innate immune system recognize pathogen-associated molecular patterns 
(PAMPs) on the surface of invading microorganisms through distinct families of pattern-
recognition receptors (PRRs). Toll-like receptors (TLRs) are the best-documented family 
of PRRs and 10 members have been characterized in humans [5]. In general, binding of 
ligands to TLRs results in interaction with downstream adaptor proteins and activation 
of transcription factors, followed by the production of inflammatory cytokines and 
chemokines and induction of an immune response.
TLRs are essential in the host defense against cSSSI pathogens. Cell wall components 
of gram-positive bacteria such as S. aureus are ligands for TLR2, in combination with 
TLR1 and TLR6 [6]. Malfunction of TLRs may lead to an inappropriate overactivation or 
underactivation of the immune response, resulting in the development of cSSSIs. Our 
group has recently observed that genetic variants in TLR1, TLR2 and TLR6 were associated 
with an increased susceptibility to cSSSIs. In addition, functional studies of these 
genetic variants showed an effect on interleukin 6 (IL-6) secretion by peripheral blood 
mononuclear cells (PBMCs) after exposure to S. aureus [7]. TLR1, TLR2, and TLR6 form a 
cluster on chromosome 4, together with TLR10.
First described by Chuang and Ulevitch in 2001, TLR10 was found to be closely related 
to TLR1, TLR6, and to a lesser extent, TLR2 (50%, 49%, and 30% amino acid identity, 
respectively) [8]. TLR10 was predominantly expressed in lymphoid tissues including 
spleen, lymph node, thymus and tonsil specimens [8]. Expression of TLR10 has mainly 
been observed in immune cells, such as B cells, dendritic cells, monocytes, neutrophils, 
and eosinophils [9-13], but also in nonimmune cells such as trophoblasts [14]. TLR10, 
similar to TLR1 and TLR6, forms heterodimers with TLR2 [9, 15, 16] but differs in its lack of 
downstream signaling [17]. Recent studies suggest TLR10 is an unusual PRR, with mainly 
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inhibitory functions on TLR2-driven immune responses [17-20], whereas its involvement 
in the recognition of cSSSI pathogens is unknown.
Genetic variation in the TLR10 gene has previously been associated with inflammatory 
diseases [21-23] and cancer [24-26], while its role in susceptibility to cSSSIs and 
consequences to cSSSI pathogen-induced immune responses remain to be elucidated.
In this study, we hypothesized that TLR10 influences recognition of cSSSI pathogens 
and that genetic variation in TLR10 may result in an altered immune response to cSSSI 
pathogens, hence influencing susceptibility to infection.
Materials and methods
Subjects and blood samples
A total of 646 white East European individuals were included in our association study, 
among whom were 318 patients with cSSSI from a randomized, multicenter clinical 
trial [27] (subtype/diagnosis: major abscess, diabetic foot infection, wound infection 
or infected ischemic ulcer) and 328 healthy controls recruited from the community. 
Detailed information on inclusion criteria in the study cohort are described elsewhere [7]. 
In addition, 74 white, healthy Dutch individuals were recruited from the community to 
correlate their genotype with IL-6 secretion upon stimulation of PBMCs. All subjects gave 
informed consent for genetic analysis. PBMCs were isolated from buffy coats of healthy 
individuals for experiments regarding antibody blocking of TLR10.
In vitro PBMC stimulation assays
PBMC isolation and stimulation assays were performed as described earlier [28], with 
minor modifications. PBMCs were isolated by density gradient centrifugation using 
Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden) from venous blood. Next, PBMCs 
were washed twice with phosphate-buffered saline (pH=7.4) and resuspended in Roswell 
Park Memorial Institute 1640 Dutch modified culture medium (supplemented with 2 mM 
L-glutamine, 1 mM pyruvate and 50 µg/mL gentamicin; GIBCO Invitrogen, Carlsbad, CA, 
USA) for experiments.
PBMCs (5 x 105 cells) were added to 96-well round-bottom plates (Greiner, Nurnberg, 
Germany) in the presence of either 1 x 106 colony-forming units/mL of heat-killed S. aureus 
ATCC 29213, Bacteroides fragilis NCTC 10584 or ATCC 25285, Escherichia coli ATCC 25922 or 10 
µg/mL TLR2 ligand Pam3Cys (EMC Microcollections, Tϋbingen, Germany) in a final volume 
of 200 µL. After incubation for 24 hours at 37°C and 5% CO2, supernatants were collected 
and stored at -20°C. For the TLR10 blocking experiments, PBMCs were preincubated for 1 
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hour with 10 µg/mL anti-TLR10 antibody (Novus Biologicals, Cambridge, United Kingdom) 
or IgG1κ isotype control (R&D Systems, Minneapolis, MN, USA) before exposure to cSSSI 
pathogens or Pam3Cys.
Transfection and stimulation of human embryonic kidney (HEK)-293 cells
Transfection of HEK-293 cells with human TLR10, TLR2 or both was performed as 
previously described [18, 20]. HEK-293 cells were cultured in Dulbecco’s modified Eagle’s 
medium, supplemented with 7.5% fetal bovine serum (Hyclone, Thermo Scientific, Logan, 
UT, USA), 100 U/mL penicillin, and 100 µg/mL streptomycin (Invitrogen), at 37°C and 5% 
CO2. The plasmid-selecting agents G418 (1 mg/mL; Sigma-Aldrich, St Louis, MO, USA) for 
TLR2, blasticidin (5 µg/mL; Invivogen) for TLR10 and a combination of both for TLR2/10 
were added to the culture medium to ensure presence of these specific TLRs in HEK-293 
cells. Correct TLR expression was confirmed by reverse transcription-polymerase chain 
reaction (PCR) and flowcytometry. When 80% confluency was reached, the HEK-293 cells 
were passaged and used in stimulation experiments. Nontransfected, TLR10-transfected, 
TLR2-transfected, and TLR2/10-transfected HEK-293 cells (1 x 106) were added to 96-well 
flat-bottom plates (Greiner) in the presence of either 1 x 107 cfu/mL of heat-killed S. aureus 
ATCC 29213, B. fragilis ATCC 25285, E. coli ATCC 25922, or TLR ligands Pam3Cys (TLR2; 1 µg/
mL; EMC Microcollections) and lipopolysaccharide (LPS; TLR4; 10 ng/mL; Sigma-Aldrich) in 
a final volume of 200 µL. After incubation for 24 hours at 37°C and 5% CO2, supernatants 
were collected and stored at -20°C.
Cytokine detection assays
IL-6 secretion was selected as the primary read-out cytokine after PBMCs stimulation 
because it is crucial in the response against cSSSI pathogens, as blockage of IL-6 by 
tocilizumab has been recently related to staphylococcal infections [29]. In supernatants 
from the HEK-293 cells IL-8 was determined. IL-6 secretion and IL-8 secretion were 
determined in supernatants by commercially available enzyme-linked immunosorbent 
assay (ELISA) kits according to manufacturer’s protocol (Sanquin Reagents, Amsterdam, 
The Netherlands).
Genotyping of TLR10 polymorphisms
Genomic DNA from patients with cSSSI was isolated using the PLUS XL manual kit (LGC 
genomics GmbH, Berlin, Germany). Genomic DNA from healthy controls was isolated 
using the Gentra Pure Gene Blood kit (Qiagen). Four nonsynonymous TLR10 single-
nucleotide polymorphisms (SNPs; Table 1), with previously described associations with 
human diseases and a minor allele frequency of at least 5% among different populations, 
were selected from the National Center for Biotechnology Information SNP database. 
TLR10 gene fragments were amplified using commercially available TaqMan SNP 
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genotyping assays according to manufacturer’s protocol on a 7300 Real-Time PCR system 
(Applied Biosystems, Foster City, CA, USA). Quality control of the assay was warranted by 
incorporating positive and negative controls and duplicating random samples across 
different plates. Correct assessment of TLR10 SNPs by Taqman SNP genotyping assays 
was validated by whole-exome sequencing on a selection of the cohort of healthy, white, 
Dutch individuals. 
Table 1. Genotyped nonsynonymous single-nucleotide polymorphisms (SNPs) in TLR10. 
Gene SNP ID Mutation Nucleotide change# Amino acid change# Taqman Assay ID
TLR10 rs4129009 Missense A > C I775L C____309084_10
TLR10 rs11096955 Missense A > C I369L C____309086_10
TLR10 rs11096957 Missense A > C N241H C____309088_10
TLR10 rs11466653 Missense T > C M326T C__25643406_10
# The first nucleotide (and corresponding amino acid) is the ancestral and therefore is considered the wild-type 
allele. ID, identification number.
Statistical analysis
Chi-square analysis of deviation from Hardy-Weinberg equilibrium (HWE) were performed 
for all 4 TLR10 SNPs in healthy controls, using a web-based HWE calculator [30]. The 
association between susceptibility to cSSSIs and a SNP were investigated by means of 
univariate logistic regression models with IBM SPSS 18 software (IBM, Armonk, NY, USA). 
SNPs were evaluated using a dominant model analyses and P-values of <0.05 were 
considered to be statistically significant. Odds ratios including 95% confidence intervals 
were reported for these tests of association. Pairwise linkage disequilibrium (LD), D’ and r2, 
were calculated using IBM SPSS 18 software.
The statistical analyses and graphical presentation of the cytokine concentrations in the 
PBMC and HEK-293 cells stimulation assays were performed using GraphPad Prism 5.00 
software (GraphPad Software, La Jolla, CA, USA).
Results
Blocking TLR10 increases IL-6 secretion by human PBMCs after exposure to cSSSI 
pathogens
To determine the biological function of TLR10 in the innate immune response to cSSSI 
pathogens, human PBMCs were preincubated with TLR10 neutralizing antibody or isotype 
control followed by stimulation with heat-killed S. aureus, B. fragilis, E. coli, or TLR1/2 ligand 
Pam3Cys (Figure 1). Blocking of TLR10 significantly increased IL-6 secretion after exposure 
to Pam3Cys (P=0.0078), S. aureus (P=0.0195), and B. fragilis (P=0.0039) and approached 
TLR10 and cSSSIs | 95
5
Figure 1. Blocking Toll-like receptor 10 (TLR10) increases interleukin 6 (IL-6) secretion in human peripheral blood 
mononuclear cells (PBMCs) after exposure to common complicated skin and skin structure (cSSSI) pathogens. 
PBMCs (5 x 106/mL) were preincubated for 1 hour with 10 µg/mL anti-TLR10 (α-TLR10) antibody or isotype 
control, followed by incubation for 24 hours with 10 µg/mL Pam3Cys (A), 1 x 10
6 colony-forming units/mL heat-
killed cSSSI pathogens Staphylococus aureus ATCC 29213 (B), Bacteroides fragilis ATCC 25285 (C), Escherichia coli 
ATCC 25922 (D). IL-6 secretion was determined in supernatants by an enzyme-linked immunosorbent assay. 
Data are presented of 9 different buffy-coats performed in 3 separate experiments. *P<0.05, and **P<0.01, by 
the Wilcoxon signed-rank test.
significance after E. coli stimulation (P=0.0547). No differences were observed for PBMCs 
exposed to TLR4 ligand LPS in the presence or absence of TLR10 neutralizing antibody 
(Supplementary figure 1).
Overexpression of TLR10 abrogates TLR2-mediated cytokine secretion in HEK-293 
cells after exposure to cSSSI pathogens
To investigate how TLR10 exerts its inhibitory effect on the recognition of cSSSI pathogens, 
HEK-293 cells were transfected with human TLR2, TLR10 or both TLR2 and TLR10. All 
combinations were cultured for 24 hours in the presence of the PRR ligands Pam3Cys 
(TLR1/2) and LPS (TLR4) and cSSSI pathogens S. aureus, B. fragilis and E. coli. Thereafter, 
IL-8 secretion was determined in supernatant by ELISA (Figure 2). Unstimulated cells did 
not induce significant levels of IL-8. Nontransfected HEK-293 cells or transfected with 
only TLR10 were unable to induce significant IL-8 secretion in response to any of the 
stimuli (Figure 2). HEK-293 cells transfected with TLR2 alone did not respond to LPS but 
demonstrated a strong induction of IL-8 secretion in the presence Pam3Cys, as well as cSSSI 
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pathogens S. aureus, B. fragilis and E. coli (Figure 2). In contrast, the presence of TLR2 in 
combination with TLR10 resulted in a significant reduction of IL-8 secretion after exposure 
to Pam3Cys (P=0.0022) and cSSSI pathogens S. aureus (P=0.0050), B. fragilis (P=0.0022) and 
E. coli (P=0.0022) in HEK-293 cells (Figure 2).
Figure 2. Overexpression of Toll-like receptor 10 (TLR10) abrogates TLR2-mediated cytokine secretion in human 
embryonic kidney (HEK)-293 cells after exposure to common complicated skin and skin structure infection 
(cSSSI) pathogens. HEK-293 cells transfected with TLR10, TLR2, or both were stimulated for 24 hours with TLR 
ligands lipopolysaccharide (LPS; 10 ng/mL), Pam3Cys (1 µg/mL) or 1 x 10
7 colony-forming units/mL of the heat-
killed cSSSI pathogens Staphylococcus aureus ATCC 29213, Bacteroides fragilis ATCC 25285, or Escherichia coli 
ATCC 25922. Interleukin 8 (IL-8) secretion was determined in supernatants by an enzyme-linked immunosorbent 
assay. Boxes represent median values and interquartile ranges; whiskers represent minimum and maximum 
values from 6 separate experiments. **P<0.01, by Mann-Whitney U test.
Table 2. Distribution of TLR10 genotypes in 318 patients with complicated skin and skin structure infection 
(cSSSI) and 328 healthy controls.
Polymorphism Wild-type, 
No. (%)
Heterozygous, 
No. (%)
Homozygous, 
No. (%)
P-value# Odds ratio (95% CI)# 
TLR10 I775L AA AC CC 0.002 0.603 (0.438-0.831)
Patients with cSSSI 214 (67.3) 89 (28.0) 15 (4.7)
Healthy controls 180 (55.4) 119 (36.6) 26 (8.0)
TLR10 I369L AA AC CC 0.019 0.676 (0.487-0.937)
Patients with cSSSI 123 (38.7) 145 (45.6) 50 (15.7)
Healthy controls 98 (29.9) 156 (47.6) 74 (22.6)
TLR10 N241H AA AC CC 0.019 0.676 (0.487-0.937)
Patients with cSSSI 123 (38.7) 145 (45.6) 50 (15.7)
Healthy controls 98 (29.9) 156 (47.6) 74 (22.6)
TLR10 M326T TT TC CC 0.174 0.667 (0.370-1.200)
Patients with cSSSI 298 (93.7) 20 (6.3) 0 (0.0)
Healthy controls 298 (90.9) 29 (8.8) 1 (0.3)
# Data are based on a dominant model analysis. CI, confidence interval.
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Genetic variation in TLR10 is associated with reduced susceptibility to cSSSIs
Data from 318 patients with cSSSI and 328 healthy controls were included to assess the 
role of TLR10 polymorphisms I775L, I369L, N241H, and M326T in susceptibility to cSSSIs 
(Table 2). All TLR10 polymorphisms were in HWE for the healthy controls. LD analyses 
revealed that I369L and N241H were in complete linkage (P<0.0001, r2=1.00, D’=1.00), 
whereas moderate LD was observed for I775L with I369L and N241H (P<0.0001, r2=0.64, 
D’=0.82) and weak LD was observed for M326T with I775L (P<0.001, r2=0.01, D’=0.47) and 
M326T with I369L and N241H (P<0.0001, r2=0.25, D’=0.52).
Univariate logistic regression analysis indicated that 3 TLR10 polymorphisms were 
associated with susceptibility to cSSSIs (Table 2): I775L (P=0.002) and I369L and N241H 
(P=0.019). For all 3 TLR10 polymorphisms, patients with cSSSI were significantly less 
often heterozygous and homozygous for the allelic variant, compared with the healthy 
controls. The TLR10 polymorphism M326T was not associated with susceptibility to cSSSIs 
(P=0.167).
Figure 3. Correlation of the TLR10 I775L genotype with interleukin 6 (IL-6) secretion by human peripheral blood 
mononuclear cells (PBMCs) after exposure for 24 hours to common complicated skin and skin structure infection 
(cSSSI) pathogens. PBMCs were exposed to 10 μg/mL Pam3Cys (A), 1 x 10
6 colony-forming units/mL of the heat-
killed cSSSI pathogens Staphylococcus aureus ATCC 29213 (B), Bacteroides fragilis NCTC 10584 (C), or Escherichia 
coli ATCC 25922 (D). Boxes represent the median values and interquartile ranges; whiskers represent minimum 
and maximum values. IL-6 secretion was determined in supernatants by an enzyme-linked immunosorbent assay, 
and results were stratified for the TLR10 I775L genotype. Dark grey represents individuals with the AA genotype 
(n=47), light grey represents individuals with the AC genotype (n=22), and white represents individuals with the 
CC genotype (n=1). *P<0.05, **P<0.01, and ***P<0.001, by the Mann-Whitney U test.
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TLR10 polymorphisms modulate immune response to cSSSI pathogens
To study the functional consequences of TLR10 polymorphisms, PBMCs were obtained from 
an additional cohort of 74 healthy volunteers. PBMCs were exposed to cSSSI pathogens 
S. aureus, B. fragilis, and E. coli and the PRR ligands Pam3Cys (TLR1/2) and LPS (TLR4). After 
24 hours, IL-6 secretion was measured by ELISA and stratified by TLR10 genotype (Figure 
3-5). Unstimulated PBMCs did not induce detectable IL-6 secretion (data not shown). No 
differences were observed between genotypes for all TLR10 polymorphisms after PBMC 
exposure to LPS (Supplementary figure 2). Heterozygosity for TLR10 polymorphism I775L 
(AC; n=22) significantly increased IL-6 secretion, compared with the wild-type genotype 
(AA; n=47), after PBMC exposure to Pam3Cys, S. aureus, and B. fragilis, and a similar trend 
was observed for E. coli stimulation. Homozygosity for TLR10 polymorphism I775L (CC; 
n=1) induced even higher IL-6 secretion compared with the wild-type and heterozygous 
genotype after exposure to Pam3Cys, S. aureus, B. fragilis, and E. coli, but only 1 volunteer 
carried this genotype (Figure 3).
Figure 4. Correlation of the TLR10 I369L/N241H genotype with interleukin 6 (IL-6) secretion by human peripheral 
blood mononuclear cells (PBMCs) after exposure for 24 hours to common complicated skin and skin structure 
infection (cSSSI) pathogens. PBMCs were exposed to 10 μg/mL Pam3Cys (A), 1 x 10
6 colony-forming units/
mL of the heat-killed cSSSI pathogens Staphylococcus aureus ATCC 29213 (B), Bacteroides fragilis NCTC 10584 
(C), or Escherichia coli ATCC 25922 (D). Boxes represent the median values and interquartile ranges; whiskers 
represent minimum and maximum values. IL-6 secretion was determined in supernatants by an enzyme-linked 
immunosorbent assay, and results were stratified for the TLR10 I369L/N241H genotype. Dark grey represents 
individuals with the AA genotype (n=26), light grey represents individuals with the AC genotype (n=38), and 
white represents individuals with the CC genotype (n=9). *P<0.05, **P<0.01, ***P<0.001, by Mann-Whitney U 
test.
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The TLR10 polymorphisms I369L and N241H were also in complete linkage for the cohort 
of 74 healthy volunteers, and therefore results were combined in Figure 4. Homozygosity 
(CC/CC; n=9) and heterozygosity (AC/AC; n=38) for TLR10 polymorphism I369L/N241H 
significantly increased IL-6 secretion, compared with the wild-type genotype (AA/AA; 
n=26) after exposure to Pam3Cys and B. fragilis. A similar increasing trend was observed 
for S. aureus and E. coli stimulation (Figure 4).
No differences in IL-6 secretion were detected between heterozygous and wild-type 
genotypes for TLR10 polymorphism M326T after PBMC exposure to Pam3Cys, S. aureus, 
B. fragilis and E. coli. In addition, no homozygotes for TLR10 polymorphism M326T were 
present among the 74 individuals (Figure 5). Secretion of IL-1β and IL-8 by PBMCs showed 
similar patterns as IL-6 for all TLR10 polymorphisms (Supplementary figures 3 and 4).
Figure 5. Correlation of the TLR10 M326T genotype with interleukin 6 (IL-6) secretion by human peripheral blood 
mononuclear cells (PBMCs) after exposure for 24 hours to common complicated skin and skin structure infection 
(cSSSI) pathogens. PBMCs were exposed to 10 μg/mL Pam3Cys (A), 1 x 10
6 colony-forming units/mL of the heat-
killed cSSSI pathogens Staphylococcus aureus ATCC 29213 (B), Bacteroides fragilis NCTC 10584 (C), or Escherichia 
coli ATCC 25922 (D). Boxes represent the median values and interquartile ranges; whiskers represent minimum 
and maximum values. IL-6 secretion was determined in supernatants by an enzyme-linked immunosorbent 
assay, and results were stratified for the TLR10 M326T genotype. Dark grey represents individuals with the TT 
genotype (n=70), light grey represents individuals with the TC genotype (n=3). Data were analyzed by Mann-
Whitney U test.
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Discussion
The present study demonstrates that TLR10 is an inhibitory receptor of TLR2-driven 
immune activation by the common cSSSI pathogens S. aureus, E. coli, and B. fragilis. 
Genetic variants I775L, I369L, and N241H in TLR10 were significantly associated with a 
reduced susceptibility to cSSSIs, and the presence of the TLR10 alleles 775L, 369L or 241H 
increased cytokine secretion in response to cSSSI pathogens. 
Since its discovery, much effort has been put in delineating the ligand and function 
of TLR10. Coimmunoprecipitation and molecular modeling studies have repeatedly 
suggested TLR10’s ability to form homodimers and heterodimers with TLR2, but also 
combinations with TLR1 and TLR6 have been described [9, 15-17]. Downstream, TLR10 was 
found to associate with MyD88 [9], but it failed to activate typical TLR signaling pathways 
via nuclear factor-κB [17]. Molecular modeling of the TLR10/2 complex suggested that 
Pam3Cys might be the ligand [16]. To study the involvement of TLR10 in the recognition 
of cSSSI pathogens, we first neutralized the function of TLR10 on human PBMCs following 
exposure to cSSSI pathogens or Pam3Cys and observed increased IL-6 secretion. Second, 
we overexpressed TLR2, TLR10, or both in HEK-293 cells, to model the responses of primary 
immune cells. TLR10 abrogated the TLR2-mediated cytokine secretion after exposure to 
cSSSI pathogens. Similar effects for TLR10 were observed after exposure to TLR1/2 ligand 
Pam3Cys, TLR6/2 ligand FSL-1 and pathogens Borrelia burgdorferi and Yersinia pestis [18, 
20]. These results were further underscored by in vivo experiments using human TLR10 
transgenic (TLR10tg) mice, as mice do not have a functional TLR10 [17]. TLR10tg mice 
injected intraperitoneally with Pam3Cys produced lower cytokine levels than their wild-
type counterparts, confirming the suppressive effect of TLR10 [20]. 
In contrast to the inhibitory function reported here, 2 recent studies have suggested 
that TLR10 acts as a stimulatory receptor in the innate immune recognition of Listeria 
monocytogenes and influenza virus [31, 32]. Possible reasons for the dissimilarity might lay 
in different engagement of the TLR10 receptor by these pathogens, or differences in the 
experimental setup. Both studies mainly base these conclusions on experiments involving 
small interfering RNA (siRNA), using epithelial and macrophage cell lines, which hampers 
a direct comparison with our findings. Inhibition of TLR10 expression in primary human 
cells using a siRNA approach has previously been shown to have varying efficiency, but this 
approach also revealed upregulation of IL-6 secretion by TLR10-silenced macrophages, 
confirming our results [20].
All 4 studied TLR10 polymorphisms have previously been associated with other diseases. 
TLR10 polymorphisms I775L, I369L, and N241H all influenced susceptibility to prostate 
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cancer [24, 25] and Crohn’s disease [23]. In addition, TLR10 polymorphism I775L was 
associated with susceptibility to asthma [21, 22]. TLR10 polymorphism I369L was also 
associated with susceptibility to Ménière’s disease [33] and sarcoidosis [34], whereas TLR10 
polymorphism M326T was only found to be associated with small tumor size of papillary 
thyroid carcinoma [26]. We found TLR10 polymorphisms I775L, I369L, and N241H but 
not M326T to be significantly associated with susceptibility to cSSSIs. For all 3 associated 
TLR10 polymorphisms, healthy controls were more often heterozygous and homozygous 
for the allelic variant (775L, 369L or 241H), compared with patients with cSSSI, indicating 
a reduced risk of cSSSIs. Similar findings were reported in most other TLR10 association 
studies, and the type of disease possibly explains findings in which this was not the case. 
Genetic variation in the TLR10 gene may modulate the balance between the 
proinflammatory and antiinflammatory responses and as such explain the influence on 
susceptibility to cSSSIs. The presence of the TLR10 alleles 775L, I369L or 241H increased 
IL-6 secretion after exposure to the cSSSI pathogens S. aureus, E. coli, and B. fragilis. In 
line with our results, recent publications indicate the same genetic variants increased pro-
inflammatory cytokine secretion in response to TLR1/2 ligand Pam3Cys and pathogens B. 
burgdorferi (Lyme disease) and Y. pestis (plague) [18-20].
In conclusion, the present study demonstrates that TLR10 has a suppressive function 
on TLR2-driven immune activation by cSSSI-related pathogens. Furthermore, genetic 
variation in the TLR10 gene influences the susceptibility to cSSSIs and results in an impaired 
TLR10 function and enhanced immune response to cSSSI pathogens. Further studies are 
warranted to decipher the exact mechanism by which TLR10 induces its inhibitory effect 
and to elucidate the potential of these TLR10 polymorphisms in risk assessment, individual 
diagnosis, and treatment for patients with cSSSI. 
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Supplementary figures
Supplementary figure 1. Blocking Toll-like receptor 10 
(TLR10) does not influence interleukin 6 (IL-6) secretion in 
human peripheral blood mononuclear cells (PBMCs) after 
exposure to Escherichia coli lipopolysaccharide (LPS). PBMCs 
(5 x 106/mL) were preincubated for 1 hour with 10 µg/mL 
anti-TLR10 (α-TLR10) antibody or isotype control, followed 
by incubation for 24 hours with E. coli LPS (10 ng/mL). IL-6 
secretion was determined in supernatants by an enzyme-
linked immunosorbent assay. Data are presented of 6 
different buffy coats performed in 3 separate experiments. 
Data were analyzed by Wilcoxon signed-rank test.
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Supplementary figure 2. Correlation of TLR10 genotypes with interleukin 6 (IL-6) secretion by human peripheral 
blood mononuclear cells (PBMCs) after exposure for 24 hours to Escherichia coli lipopolysaccharide (LPS; 10 ng/
mL). Boxes represent the median values and interquartile ranges; whiskers represent minimum and maximum 
values. IL-6 secretion was determined in supernatants by enzyme-linked immunosorbent assay and the results 
were stratified for TLR10 genotype; TLR10 I775L, AA (n=47), AC (n=22), and CC (n=1) (A); TLR10 N241H/I369L, AA 
(n=26), AC (n=38) and CC (n=9) (B); TLR10 M326T, TT (n=70), TC (n=3) (C). Data were analyzed by Mann-Whitney 
U test.
Supplementary figure 3. Correlation of TLR10 genotypes with interleukin 1β (IL-1β) secretion by human 
peripheral blood mononuclear cells (PBMCs) after exposure for 24 hours to common complicated skin and skin 
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structure (cSSSI) pathogens. PBMCs were exposed to 10 μg/mL Pam3Cys (A, E, I), 1 x 10
6 colony forming units/
mL of the heat-killed cSSSI pathogens Staphylococcus aureus ATCC 29213 (B, F, J), Bacteroides fragilis NCTC 10584 
(C, G, K), or Escherichia coli ATCC 25922 (D, H, L). Boxes represent the median values and interquartile ranges; 
whiskers represent minimum and maximum values. IL-1β secretion was determined in supernatants by an 
enzyme-linked immunosorbent assay and results were stratified for TLR10 genotype; TLR10 I775L, AA (n=47), AC 
(n=22) and CC (n=1) (A-D); TLR10 I369L/N241H, AA (n=26), AC (n=38) and CC (n=9) (E-H); TLR10 M326T, TT (n=70), 
TC (n=3) (I-L). *P<0.05, **P<0.01, ***P<0.001, by Mann-Whitney U test.
Supplementary figure 4. Correlation of TLR10 genotypes with interleukin 8 (IL-8) secretion by human peripheral 
blood mononuclear cells (PBMCs) after exposure for 24 hours to common complicated skin and skin structure 
(cSSSI) pathogens. PBMCs were exposed to 10 μg/mL Pam3Cys (A, E, I), 1 x 10
6 colony forming units/mL of the 
heat-killed cSSSI pathogens Staphylococcus aureus ATCC 29213 (B, F, J), Bacteroides fragilis NCTC 10584 (C, G, K), 
or Escherichia coli ATCC 25922 (D, H, L). Boxes represent the median values and interquartile ranges; whiskers 
represent minimum and maximum values. IL-8 secretion was determined in supernatants by an enzyme-linked 
immunosorbent assay and results were stratified for TLR10 genotype; TLR10 I775L, AA (n=47), AC (n=22) and CC 
(n=1) (A-D); TLR10 I369L / N241H, AA (n=26), AC (n=38) and CC (n=9) (E-H); TLR10 M326T, TT (n=70), TC (n=3) (I-L). 
*P<0.05, **P<0.01, ***P<0.001, by Mann-Whitney U test.
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Abstract
Complicated skin and skin structure infections (cSSSIs) are caused by gram-positive 
and gram-negative, aerobic and anaerobic pathogens, with a polymicrobial etiology 
being frequent. Recognition of invading pathogens by the immune system results in 
the production of pro- and anti-inflammatory cytokines, which are extremely important 
for intercellular communication and control of infection. This study assessed whether 
genetic variation in genes encoding cytokines influences the susceptibility to cSSSIs. For 
the association study, 318 patients with cSSSI and 328 healthy controls were genotyped 
for single-nucleotide polymorphisms (SNPs) in cytokine genes IL1A, IL1B, IL1RN, TNF, IL10, 
IL17A, IL17F and IFNG. For immunological validation, peripheral blood mononuclear cells 
(PBMCs) from 74 healthy individuals, genotyped for SNPs of interest, were stimulated with 
Staphylococcus aureus or Escherichia coli and corresponding cytokine levels were determined 
by enzyme-linked immunosorbent assay (ELISA). Polymorphisms IL6 rs1800797, TNF 
rs1800629, IL10 rs1800871, IL17A rs8193036 and IFNG rs2069705 influenced susceptibility 
to cSSSIs. No differences in cytokine responses, stratified for genotype, were detected 
after PBMC stimulation. No association with cSSSIs was observed for polymorphisms IL1A 
rs17561 and rs1800587, IL1B rs16944 and rs1143627, IL1RN rs4251961, TNF rs361525, IL10 
rs1800896, IL17A rs2275913 and IL17F rs763780. In conclusion, polymorphisms in IL6, TNF, 
IL10, IL17A and IFNG are associated with susceptibility to cSSSIs.
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Introduction
Complicated skin and skin structure infections (cSSSIs) include infections involving the 
deeper soft tissue, requiring substantial surgical intervention, or occur in individuals 
with a significant underlying disease state that may affect the response to treatment [1]. 
Superficial infections located in an anatomical site in which the chance of involvement 
of anaerobic or gram-negative pathogens is high should also be considered cSSSIs. 
Predominant types of cSSSIs are major abscesses, diabetic foot infections, surgical-site 
and trauma-induced wound infections [1, 2]. Causative organisms, gram-positive or 
gram-negative, aerobic or anaerobic, alone or as part of a polymicrobial infection, vary 
depending on the clinical situation, location of the infection and medical background of 
the patient [1-3].
cSSSIs frequently lead to hospitalization and are associated with considerable morbidity, 
mortality and healthcare resource utilization [4]. The management of cSSSIs often 
requires a combination of surgical debridement and antibiotic therapy [2]. Due to 
increasing antimicrobial resistance, the latter is becoming a clinical challenge [5]. In 
addition, differences in prevalence and severity of cSSSIs cannot be solely explained by 
the virulence of a pathogen or co-morbidities of the patient, as even healthy individuals 
can develop severe skin and soft tissue infections due to organisms of the commensal 
microflora [6]. Hence, there is a need to identify host characteristics that predispose to the 
development of cSSSIs, in order to delineate a predictive profile for individuals at risk and 
possible individualized diagnosis and treatment for cSSSIs. 
When a pathogen enters normally sterile parts of the body, cells of the innate immune 
system recognize pathogen-associated molecular patterns (PAMPs) on the surface of these 
invading microorganisms through pattern-recognition receptors (PRRs). Recognition 
by these receptors leads to activation of internal signaling pathways, resulting in the 
induction of pro- and anti-inflammatory cytokines, and finally the generation of an 
adaptive immune response [7]. Cytokines, small proteins that are produced by a variety of 
cells and which exert their effect through binding to specific cellular membrane receptors, 
are extremely important for intercellular communication and control of infection. Each 
pathogen induces the production of a variety of pro- and anti-inflammatory cytokines 
by immune cells. For example, gram-positive bacteria induce stronger stimulation of 
IFNγ, TNFα and IL-1β than gram-negative bacteria, which instead induce more IL-6 and 
IL-10 [8]. In addition to the beneficial effects on the activation of the host defense, the 
overproduction of cytokines can result in tissue damage that can have damaging effects 
to the host.
110 | Chapter 6
Genetic variation in cytokine genes is known to affect susceptibility to a variety of 
infectious diseases, such as bacterial sepsis [9, 10], mycobacterial infection [11, 12] and 
malaria [13], while their role in susceptibility to cSSSIs remains to be elucidated. In the 
present study, we hypothesized that polymorphisms in genes encoding cytokines 
may influence the host susceptibility to cSSSIs. To test this hypothesis, we analyzed the 
distribution of single-nucleotide polymorphisms (SNPs) in genes coding for cytokines 
in a cohort of patients with cSSSI and compared them with healthy controls. In order to 
determine the mechanistic effects for the observed genetic associations, functional assays 
were performed investigating the consequences of specific cytokine polymorphisms on 
the ability of human peripheral blood mononuclear cells (PBMCs) to produce cytokines 
after stimulation with cSSSI pathogens.
Materials and methods
Subjects
A total of 646 Eastern European individuals were included in the association study; 318 
patients with cSSSI (subtype/diagnosis: major abscess, diabetic foot infection, wound 
infection or infected ischemic ulcer) from a randomized, multicentre clinical trial [6] and 328 
healthy controls recruited from the community. Inclusion criteria in the study cohort are 
described elsewhere [14]. Eighty-nine percent of patients with suffered from community-
acquired infections and the remaining 11% had nosocomial infections. Seventy percent 
of the patients with cSSSI had polymicrobial infections. In 97% of the infections, at 
least 1 gram-positive microorganism was isolated. The most prevalent pathogens were 
Staphylococcus aureus, β-hemolytic Streptococcus group A-G, Enterococcus faecalis and 
Escherichia coli [14]. An additional cohort of 74 European healthy individuals was recruited 
from the community to correlate the genotype with cytokine secretion upon stimulation 
of PBMCs. All subjects gave informed consent for genetic analysis.
Genotyping
DNA from patients with cSSSI was extracted from blood collected in PAXgene DNA tubes 
(Qiagen, Hildesheim, Germany) according to the PLUS XL manual kit (LGC genomics 
GmbH, Berlin, Germany). DNA from healthy individuals was isolated using the Gentra Pure 
Gene Blood kit (Qiagen), according to the manufacturer’s protocol. SNPs of the analyzed 
cytokine genes were selected from the National Center for Biotechnology Information SNP 
database (http://www.ncbi.nlm.nih.gov/snp/) upon previously described associations 
with human diseases, located in either the exonic or 5’ gene region, with a minor allele 
frequency of at least 5% among different populations. In total, 15 SNPs in IL1A, IL1B, IL1RN, 
TNF, IL10, IL17A, IL17F and IFNG were selected and genotyped (Table 1). Gene fragments 
were amplified by commercially available TaqMan SNP genotyping assays according to 
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manufacturer’s protocol on a 7300 Real-Time PCR system (Applied Biosystems, Foster City, 
CA, USA). Quality control was performed by the incorporation of positive and negative 
controls and duplication of random samples across different plates.
Table 1. Genotyped single-nucleotide polymorphisms (SNPs) in genes coding for cytokines. 
Gene SNP ID Mutation Nucleotide change# Amino acid change# Taqman Assay ID
IL1A rs17561 Missense G > T A114S C___9546471_10
IL1A rs1800587 5’ UTR C > T - C___9546481_20
IL1B rs16944 5’ near gene A > G - C___1839943_10
IL1B rs1143627 5’ near gene C > T - C___1839944_10
IL1RN rs4251961 5’ near gene T > C - C__32060323_10
IL6 rs1800796 5’ near gene G > C - C__11326893_10
IL6 rs1800797 5’ near gene G > A - C___1839695_20
TNF rs361525 5’ near gene G > A - C___2215707_10
TNF rs1800629 5’ near gene G > A - C___7514879_10
IL10 rs1800871 5’ near gene C > T - C___1747362_10
IL10 rs1800896 5’ near gene A > G - C___1747360_10
IL17A rs2275913 5’ near gene A > G - C___1747360_10
IL17A rs8193036 5’ near gene T > C - C___1799585_10
IL17F rs763780 Missense T > C H161R C___2234166_10
IFNG rs2069705 5’ near gene C > T - C__15944115_20
# The first nucleotide (and corresponding amino acid) is the ancestral and therefore is considered the wild-type 
allele. ID, identification number.
In vitro PBMC stimulation and cytokine detection assays
PBMCs were isolated and stimulated as described previously [15], with minor modifications. 
In brief, PBMCs were isolated by density gradient centrifugation using Ficoll-Paque PLUS 
(GE Healthcare, Uppsala, Sweden). Next, PBMCs were washed and resuspended in Roswell 
Park Memorial Institute 1640 Dutch Modified culture medium (supplemented with 2 
mM L-glutamine, 1 mM pyruvate and 50 μg/mL gentamicin; GIBCO Invitrogen, Carlsbad, 
CA, USA). 5 x 105 PBMCs were added to 96-well round-bottom plates (Greiner, Nurnberg, 
Germany) and stimulated with heat-killed 1 x 106 colony-forming units (cfu)/mL S. aureus 
ATCC 29213 or E. coli ATCC 25922 in a final volume of 200 µL. PBMCs were incubated at 
37°C and 5% CO2 for 24 hours to induce IL-6, TNFα and IL-10 or 7 days for IFNγ or IL-17 
production, after which supernatants were collected. Cytokine concentrations were 
measured in supernatants by commercially available enzyme-linked immunosorbent 
assay (ELISA) kits according to manufacturer’s instructions (IL-6, IL-10 and IFNγ, Sanquin 
Reagents, Amsterdam, The Netherlands; TNFα and IL-17, R&D Systems, Minneapolis, MN, 
USA).
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Statistical analysis
Chi-square analyses of deviation from Hardy-Weinberg equilibrium (HWE) were performed 
for all 15 SNPs in healthy controls using a web-based HWE calculator [16]. SNPs deviating 
from HWE were excluded for further analysis. The association between susceptibility to 
cSSSIs and a SNP were investigated by means of univariate logistic regression models 
with IBM SPSS 18 software (IBM, Armonk, NY, USA). SNPs were evaluated using dominant 
(heterozygotic and homozygotic individuals for the allelic variant were combined and 
compared to wild-type individuals) and recessive (wild-type and heterozygotic individuals 
were combined and compared to homozygotic individuals for the allelic variant) model 
analyses. Pairwise linkage disequilibrium (LD), D’ and r2, were calculated using IBM SPSS 
18 software (IBM). Multivariate logistic regression analyses were performed assuming a 
dominant or recessive model. Model reduction was done via forward and backward model 
selection methods. P-values below 0.05 were considered to be statistically significant, and 
odds ratios including 95% confidence intervals were reported. 
All statistical analyses and graphical presentation of the cytokine concentrations in the 
in vitro PBMC stimulation assays were performed using GraphPad Prism 5.00 software 
(GraphPad Software, La Jolla, CA, USA). The results were stratified by cytokine genotype 
and differences in cytokine secretion between genotypes were analyzed by Mann-
Whitney U tests. 
Results
Univariate logistic regression of SNPs in cytokine genes in patients with cSSSI versus 
healthy controls
Genetic variation in IL1A, IL1B, IL1RN, IL6, TNF, IL10, IL17A, IL17F and IFNG was investigated 
in 318 patients with cSSSI and 328 healthy controls to assess their role in the susceptibility 
to cSSSIs. All genotyped polymorphisms were in HWE (data not shown) except for IL6 
rs1800796, which led to the exclusion of this polymorphism for further analyses.
Dominant model analyses resulted in a significantly different distribution for cytokine 
polymorphisms IL6 rs1800797 (P=0.001), TNF rs1800629 (P=0.013), IL10 rs1800871 
(P=0.012), IL17A rs8193036 (P=0.001) in patients with cSSSI versus healthy controls (Table 
2). Patients were significantly more often heterozygous and homozygous for the allelic 
variant of IL6 rs1800797, TNF rs1800629 and IL17A rs8193036 than healthy controls. In 
contrast, patients with cSSSI were significantly less often heterozygous and homozygous 
for the allelic variant of IL10 rs1800871 than healthy controls.
Recessive model analyses confirmed the association between IL6 rs1800797 and 
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susceptibility to cSSSIs (P=0.009; OR=1.773 [95% CI, 1.152-2.727]), whereas TNF rs1800629, 
IL10 rs1800871, IL17A rs8193036 did not influence susceptibility in this model. In addition, 
recessive model analysis identified IFNG rs2069705 to be associated with susceptibility 
to cSSSIs (p=0.003, OR=0.619 [95% CI, 0.452-0.847]). Patients were significantly less often 
homozygous for the allelic variant of IFNG rs2069705 than healthy controls.
No significant association with susceptibility to cSSSIs was observed for both dominant 
and recessive model analysis in individuals carrying polymorphisms in IL1A rs17561 and 
rs1800587, IL1B rs16944 and rs1143627, IL1RN rs4251961, TNF rs361525, IL10 rs1800896, 
IL17A rs2275913 and IL17F rs763780.
Analyses of LD revealed that cSSSI-associated polymorphisms IL6 rs1800797 and TNF 
rs1800629 were not independent, but their correlation was weak: P<0.05, r2=0.09, 
D’=0.13. In addition, cSSSI-associated polymorphism IL10 rs1800871 correlated with IL10 
rs1800896 (P<0.0001, r2=0.51, D’=0.75). cSSSI-associated polymorphism IL17A rs8193036 
weakly correlated with IL17A rs2275913 (P<0.0001, r2=0.34, D’=0.41) and IL17F rs763780 
(P<0.01, r2=0.11, D’=0.17).
Multivariate logistic regression of SNPs in cytokine genes in patients with cSSSI 
versus healthy controls
All genotyped polymorphisms, except for IL6 rs1800796, which failed HWE, were 
considered for inclusion as explanatory variables in the multivariate logistic regression 
model with outcome cSSSI status. 
In the dominant model analysis, the final model consisted of IL6 rs1800797, TNF rs1800629, 
IL10 rs1800871, IL17A rs8193036 best explaining susceptibility to cSSSIs. Polymorphisms 
IL6 rs1800797 (P=0.002, OR=1.679 [95% CI, 1.211-2.327]), TNF rs1800629 (P=0.027, 
OR=1.512 [95% CI, 1.049-2.179]), IL10 rs1800871 (P=0.014, OR=0.671 [95% CI, 0.488-0.922]) 
and IL17A rs8193036 (P=0.002, OR=1.674 [95% CI, 1.209-2.317]) independently influenced 
susceptibility to cSSSIs.
In the recessive model analysis, the final model consisted of IL6 rs1800797 and IFNG 
rs2069705 best explaining susceptibility to cSSSIs. Polymorphisms IL6 rs1800797 (P=0.009, 
OR=1.777 [95% CI, 1.152-2.742]) and IFNG rs2069705 (P=0.003, OR=0.621 [95% CI, 0.452-
0.853]) were independently associated with susceptibility to cSSSIs.
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Table 2. Distribution of cytokine genotypes in 318 patients with complicated skin and skin structure infections 
(cSSSI) and 328 healthy controls.
Polymorphism Wild-type, 
No. (%)
Heterozygous, 
No. (%)
Homozygous, 
No. (%)
P-value# Odds ratio (95% CI)#
IL1A rs17561 GG GT TT 0.518 0.903 (0.663-1.230)
Patients with cSSSI 170 (53.5) 118 (37.1) 30 (9.4)
Healthy controls 167 (50.9) 132 (40.2) 29 (8.8)
IL1A rs1800587 CC CT TT 0.565 0.913 (0.670-1.244)
Patients with cSSSI 172 (54.1) 116 (36.5) 30 (9.4)
Healthy controls 170 (51.8) 129 (39.3) 29 (8.8)
IL1B rs16944 AA AG GG 0.789 0.938 (0.589-1.495)
Patients with cSSSI 41 (12.9) 132 (41.5) 145 (45.6)
Healthy controls 40 (12.2) 155 (47.3) 133 (40.5)
IL1B rs1143627 CC CT TT 0.981 0.994 (0.618-1.601)
Patients with cSSSI 38 (11.9) 135 (42.5) 145 (45.6)
Healthy controls 39 (11.9) 157 (47.9) 132 (40.2)
IL1RN rs4251961 TT TC CC 0.631 0.927 (0.680-1.264)
Patients with cSSSI 147 (46.2) 144 (45.3) 27 (8.5)
Healthy controls 145 (44.3) 147 (45.0) 35 (10.7)
IL6 rs1800796* GG GC CC
Patients with cSSSI 278 (87.4) 39 (12.3) 1 (0.3)
Healthy controls 281 (85.7) 38 (11.6) 9 (2.7)
IL6 rs1800797 GG GA AA 0.001 1.791 (1.300-2.466)
Patients with cSSSI 103 (32.4) 152 (47.8) 63 (19.8)
Healthy controls 151 (46.2) 136 (41.6) 40 (12.2)
TNF rs361525 GG GA AA 0.661 1.163 (0.593-2.279)
Patients with cSSSI 299 (94.0) 18 (5.7) 1 (0.3)
Healthy controls 311 (94.8) 17 (5.2) 0 (0.0)
TNF rs1800629 GG GA AA 0.013 1.570 (1.099-2.244)
Patients with cSSSI 223 (70.1) 88 (27.7) 7 (2.2)
Healthy controls 258 (78.7) 66 (20.1) 4 (1.2)
IL10 rs1800871 CC CT TT 0.012 0.671 (0.492-0.915)
Patients with cSSSI 177 (55.7) 124 (39.0) 17 (5.3)
Healthy controls 150 (45.7) 152 (46.3) 26 (7.9)
IL10 rs1800896 AA AG GG 0.345 0.851 (0.610-1.189)
Patients with cSSSI 104 (32.7) 152 (47.8) 62 (19.5)
Healthy controls 96 (29.3) 178 (54.3) 54 (16.5)
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Functional consequences of IL6 rs1800797, TNF rs1800629, IL10 rs1800871, IL17A 
rs8193036 and IFNG rs2069705 on cytokine production
The effect of cytokine polymorphisms, associated with susceptibility to cSSSIs, on cytokine 
production was studied in an additional cohort of 74 healthy volunteers. PBMCs were 
isolated and stimulated with S. aureus and E. coli, prominent pathogens of cSSSIs, after 
which cytokines were measured by ELISA in cell culture supernatants. Cytokine responses 
were displayed stratified by genotype of interest (Figure 1). Unstimulated PBMCs did 
not induce detectable cytokine responses (data not shown). S. aureus proved to be a 
poor inducer of TNFα, IL-10 and IFNγ (Figure 1B,C,E), whereas E. coli did not induce IL-17 
production (Figure 1I). With cytokine levels for most individuals around the threshold of 
detection for these stimulations, we were unable to draw conclusions solely on these data 
(Figure 1B,C,E,I). 
No significant differences in cytokine responses between the allelic variants after both S. 
aureus and E. coli stimulation could be detected for all 5 SNPs associated with susceptibility 
to cSSSIs (Figure 1A,D,F,G,H,J).
Discussion
This study identifies 5 polymorphisms in cytokine genes: IL6 rs1800797, TNF rs1800629, IL10 
rs1800871, IL17A rs8193036 and IFNG rs2069705 to be associated with the susceptibility 
to cSSSIs. Although clearly induced after in vitro PBMC stimulation with prevalent cSSSI 
pathogens S. aureus or E. coli, the corresponding cytokine levels were not modulated by 
the presence of these cSSSI-associated polymorphisms.
IL17A rs2275913 AA AG GG 0.886 1.032 (0.672-1.584)
Patients with cSSSI 48 (15.1) 139 (43.8) 130 (41.0)
Healthy controls 51 (15.5) 138 (42.1) 139 (42.4)
IL17A rs8193036 TT TC CC 0.001 1.727 (1.256-2.375)
Patients with cSSSI 171 (53.8) 125 (39.3) 22 (6.9)
Healthy controls 219 (66.8) 94 (28.7) 15 (4.6)
IL17F rs763780 TT TC CC 0.869 1.048 (0.600-1.831)
Patients with cSSSI 292 (91.8) 26 (8.2) 0 (0.0)
Healthy controls 300 (91.5) 28 (8.5) 0 (0.0)
IFNG rs2069705 CC CT TT 0.183 0.729 (0.457-1.162)
Patients with cSSSI 46 (14.5) 155 (48.7) 117 (36.8)
Healthy controls 36 (11.0) 133 (40.5) 159 (48.5)
# Data are based on a dominant model analysis. CI, confidence interval. * Significant deviation from Hardy-
Weinberg Equilibrium (HWE) in controls was observed for IL6 rs1800796. All other genotyped SNPs were in HWE.
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These 5 cSSSI-associated polymorphisms have previously been correlated with other 
infectious diseases. The IL6 polymorphism rs1800797 influenced susceptibility to leprosy 
[11]. The TNF polymorphism rs1800629 has previously been associated with susceptibility 
to sepsis [9, 10], malaria [13], and tuberculosis [17]. Furthermore, IL10 polymorphism 
rs1800871 is associated with susceptibility to leprosy [11], whereas IFNG polymorphism 
rs2069705 was involved in susceptibility to sepsis [18] and tuberculosis [12]. The IL17 
polymorphism rs8193036 was approaching significance for susceptibility to gram-
positive infection in sepsis [19], but has been associated with inflammatory disorders like 
asthma [20] and Behcet’s disease [21]. However, in other studies on infectious diseases no 
association was found for some of these polymorphisms [22-25]. 
To determine whether the observed genetic associations also resulted in mechanistic 
effects, the genetic studies were supplemented by functional assays investigating the 
consequences of cSSSI-associated cytokine polymorphisms. The gram-positive bacteria 
S. aureus and gram-negative E. coli, prevalent pathogens of cSSSIs, were chosen to 
ensure potent induction of cytokines of interest by PBMCs. No significant differences 
in corresponding cytokine responses were detected between the allelic variants of all 5 
cSSSI-associated polymorphisms after stimulation of PBMCs. Functional consequences 
of cSSSI-associated polymorphisms have previously been studied. Firstly, the A allele of 
IL6 polymorphism rs1800797 resulted in significantly up-regulated baseline expression 
levels compared to the G allele in HEK and HeLa cell lines using a luciferase reporter assay 
[11]. Also, serum IL-6 levels were found to be higher in the presence the AA genotype 
of IL6 polymorphism rs1800797 [26]. We did not observe differences in baseline IL-6 
secretion by unstimulated PBMCs possibly due to IL-6 levels not reaching the detection 
limit. Secondly, the precise effect of TNF polymorphism rs1800629 on gene expression 
and TNFα production remains controversial. Recently, a large meta-analyses reported the 
absence of an association between TNF polymorphism rs1800629 and TNFα production 
[27], confirming our findings described here. Thirdly, we observed no differences in IL-10 
production by PBMCs after stimulation with S. aureus and E. coli, whereas PBMCs from 
individuals carrying the T allele of IL10 polymorphism rs1800871 were shown to produce 
lower levels of IL-10 after stimulation with Mycobacterium leprae antigens compared to 
Figure 1. Correlation of complicated skin and skin structure infection-associated cytokine genotypes with 
corresponding cytokine measurements after 24 hours of peripheral blood mononuclear cell stimulation. Left 
panel, heat-killed Staphylococcus aureus (1 x 106 colony-forming units [cfu]/mL); Right panel, Escherichia coli (1 
x 106 cfu/mL). Corresponding cytokine measurements were stratified by genotype: IL-6 for IL6 rs1800797 (A, 
F), TNFα for TNF rs1800629 (B, G), IL-10 for IL10 rs1800871 (C, H), IL-17 for IL17 rs8193036 (D, I) and IFNγ for IFNG 
rs2069705 (E, J). Dark grey represents individuals homozygous for the wild-type allele, light grey represents 
individuals heterozygous for the allelic variant and white represents individuals homozygous for the allelic 
variant. Data were analyzed by Mann-Whitney U tests and presented in a box-and-whisker plot; the box 
represents the median with the interquartile range; the whiskers represent the minimal and maximal value.
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non-carriers [28]. Fourthly, identical to our results after PBMC stimulation, the different 
genotypes of polymorphism IL17A rs8193036 were found to have similar levels of IL-
17A in the serum [29]. Finally, 1 study reported similar serum IFNγ levels for the different 
genotypes of IFNG polymorphism rs2069705 [26]. 
Polymorphisms in IL1A rs17561 and rs1800587, IL1B rs16944 and rs1143627, IL1RN 
rs4251961, TNF rs361525, IL10 rs1800896, IL17A rs2275913 and IL17F rs763780 did not 
influence susceptibility to cSSSIs. The presence of these polymorphisms did not affect 
levels of corresponding cytokines after in vitro PBMC stimulation (data not shown). 
To our knowledge, this is the first study investigating the role of genetic variation in 
genes encoding cytokines and susceptibility to cSSSIs. This study demonstrates that 5 
polymorphisms in cytokine genes, IL6, TNF, IL10, IL17 and IFNG, modulate susceptibility 
to cSSSIs. Although these genes are involved in the immune response against cSSSI 
pathogens, indicated by the production of their corresponding cytokines after in vitro 
stimulation, polymorphisms in these genes did not influence the cytokine production 
capacity. In contrast, we have recently described genetic variants in Toll-like receptors 
which dramatically alter IL-6 cytokine responses by PBMCs after stimulation for 24 hours 
with S. aureus [14]. As the cytokine polymorphisms are located in the promoter region, and 
as such could influence gene expression levels, it was surprising to find no differences in 
secreted cytokine levels. We cannot exclude the fact that the kinetics of cytokine secretion 
were different in the presence of the cSSSI-associated polymorphisms, because levels were 
only measured after 24 hours. Furthermore, measurement of total concentration does not 
allow for conclusions to be drawn on altered biological function of the protein due to 
the polymorphism. Though this effect is unlikely the result of promoter polymorphisms, 
they could be in strong linkage with an exonic polymorphism which causes the altered 
biological function. 
Unfortunately, we did not have access to a confirmation cohort and the data on 
predisposing factors in the healthy control cohort, which may act as confounders in the 
associations between polymorphisms in cytokine genes and susceptibility to cSSSIs, were 
not available. We did not correlate polymorphisms with specific infection types or specific 
pathogens, because this would result in the analysis of small subgroups with possibly 
insufficient power to detect differences. Future studies are warranted to determine how 
these cytokine polymorphisms in IL6, TNF, IL10, IL17 and IFNG influence susceptibility to 
cSSSIs and whether they can play a role in the characterization of a predictive profile, 
individualized diagnosis and treatment for individuals at risk of developing cSSSIs.
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Abstract
Major abscesses and diabetic foot infections (DFIs) are predominant subtypes of 
complicated skin and skin structure infections (cSSSIs), and are mainly caused by 
Staphylococcus aureus and β-hemolytic streptococci. This study evaluates the potential 
benefit of direct pathogen-specific real-time polymerase chain reaction (PCR) assays in the 
identification of causative organisms of cSSSIs. One-hundred fifty major abscess and 128 
DFI biopsy samples were collected and microbial DNA was extracted by using the Universal 
Microbe Detection kit for tissue samples. Pathogen-specific PCRs were developed for S. 
aureus and its virulence factor Panton-Valentine leukocidin (PVL), Streptococcus pyogenes, 
S. agalactiae, S. dysgalactiae, and the S. anginosus group. Identification by pathogen-
specific PCRs was compared to routine culture and both methods were considered as the 
gold standard for determination of the sensitivity and specificity of each assay. Direct real-
time PCR assays of biopsy samples resulted in a 34% higher detection of S. aureus, 37% 
higher detection of S. pyogenes, 18% higher detection of S. agalactiae, 4% higher detection 
of S. dysgalactiae subspecies equisimilis, and 7% higher detection of the S. anginosus 
group, compared to routine bacterial culture. The presence of PVL was mainly confined 
to S. aureus isolated from major abscess but not DFI biopsy samples. In conclusion, our 
pathogen-specific real-time PCR assays had a higher yield than culture methods and could 
be an additional method for the detection of relevant causative pathogens in biopsies.
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Introduction
Major abscesses and diabetic foot infections (DFIs) are the predominant subtypes of a 
spectrum of infections termed complicated skin and skin structure infections (cSSSIs). 
The Food and Drug Administration (FDA) defined cSSSIs as infections of the deeper 
soft tissues, involving surgical intervention or a significant underlying disease state that 
complicates the response to treatment. Superficial infections located in an anatomical 
site in which the chance of involvement of anaerobic or gram-negative pathogens is high 
should also be considered as cSSSIs [1, 2]. cSSSIs are associated with significant morbidity 
and mortality, as well as prolonged and expensive hospitalizations [3]. The management 
of cSSSIs involves surgical debridement of the infection, combined with antibiotic therapy 
[4]. 
Gram-positive cocci, in particular Staphylococcus aureus and β-hemolytic streptococci, 
are the leading causative organisms of cSSSIs [2, 4]. In a recent multicenter randomized 
clinical trial, 65% of the cultured isolates consisted of gram-positive cocci (of which S. 
aureus 33% and β-hemolytic streptococci 15%), whereas gram-negative bacilli (28%) and 
anaerobes (7%) were found to a lesser extent [5], but geographical differences exist in the 
type and amount of species isolated [6]. 
Correct and rapid identification of pathogens is crucial for clinical decision-making and 
optimal antibiotic therapy. Up to now, routine bacteriological assessment of biopsies from 
cSSSIs relies upon culture, which, in order to be successful, requires viable pathogens in 
tissue and the use of suitable culture conditions for growth. Difficult to culture pathogens, 
those present in low numbers or that died before/during sampling of the infected tissue 
make detection by culture complicated and time-consuming. This may result in low 
sensitivity and underestimated bacterial prevalence. Several molecular assays, such as 
pathogen-specific, broad-range and multiplex polymerase chain reaction (PCR) assays, 
either directly on clinical samples or cultured isolates, have been developed in recent 
years to improve bacterial detection [7, 8]. This study evaluates the potential benefit of 
direct, pathogen-specific real-time PCR assays on clinical samples in the identification of 
the causative organisms of cSSSIs. 
Biopsy samples of 150 major abscesses and 128 DFIs were collected during a multicenter 
clinical trial involving patients with cSSSIs [5]. Detection of the pathogens S. aureus and 
Streptococcus species by real-time PCR directly on DNA isolated from these clinical cSSSI 
samples was compared to routine cultures.
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Materials and methods
Definitions 
cSSSIs were characterized as infections of bacterial origin that required hospitalization, 
initial parenteral therapy for ≥48 hours, and which met at least 1 of the following criteria: 
deep soft tissue involvement; significant surgical intervention, including drainage and/or 
debridement; and association with an underlying comorbid condition. Major abscesses 
were defined as collections of pus associated with extensive cellulitis, requiring surgical 
intervention followed by antibiotic therapy. DFIs were characterized as infections 
occurring below the ankle in patients with confirmed diabetes [5].
Collection of major abscess and DFI biopsy samples
From a population of 813 cSSSI patients included in a large randomized, multicenter clinical 
trial [5], performed from September 2006 to June 2008, 389 patients gave informed consent 
to participate in this substudy. Of these, the first visit, prestudy treatment biopsy samples 
were selected resulting in the inclusion of 150 major abscess and 128 DFIs samples from 
225 cSSSI patients. Samples were collected via biopsy of tissue or bone, curettage of the 
wound, or aspiration of purulent discharge. After collection, samples were directly stored 
in preservation medium (BBL Port-A-Cul Transport vial, Becton Dickinson, Franklin Lakes, 
NJ, USA) and transported within 72 hours to the central laboratory (Eurofins Medinet SAS, 
Plaisir, France) [5]. On arrival, samples were split into 2, 1 part for immediate culture and 
identification by using standard clinical laboratory procedures, and the other part was 
stored at -80°C for subsequent DNA isolation and PCR analysis. 
Bacterial DNA extraction from biopsy samples
Pathogen DNA was manually extracted by using the MolYsis Universal Microbial Detection 
kit for tissue samples (Molzym, Bremen, Germany), following the manufacturer’s 
instructions. Briefly, selective lysis of human cells is performed, followed by degradation of 
human DNA. After washing the pellet, a second round of DNA extraction is performed to 
release DNA from bacterial and fungal cells. This approach enables an increased sensitivity 
and specificity for pathogen DNA, since interfering non-target human DNA is no longer 
present [9]. Pathogen DNA extraction was carried out in a laminar flow cabinet to prevent 
contamination. Prior to further handling, the DNA samples were stored at -20°C.
Real-time PCR primer and probe design 
To detect S. agalactiae, both subspecies of S. dysgalactiae, and S. pyogenes the recA gene 
was chosen as the target, based on the results from previous studies [10, 11]. Partial recA 
sequences of clinically relevant Streptococcus species were extracted from GenBank 
(accession numbers EU156792-EU156872), an alignment was generated in MEGA v6 [12], 
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and primer and probe sets were developed to make sure that there was no overlap with 
other Streptococcus species. The specificity of the primers and probes were in silico tested 
by a BLAST search in GenBank. 
A previously described multiplex real-time PCR assay was used to detect the S. aureus-
specific fragment Sa442 and the Panton-Valentine leukocidin gene [13]. The duplex real-
time PCRs were performed in reaction volumes of 20 µL consisting of 10 µL 2× LC480 
Probe Master Mix (Roche Diagnostics), 0.1 µL of each primer and 0.04 µL of both probes 
(100 pmol/µL; Eurogentec, Brussels, Belgium), 1.72 µL ddH2O and 8 µL sample-DNA. The 
PCRs were performed with the following settings: Initial denaturation step for 10 min at 
95°C, 50 cycles of 1 s at 95°C, 12 s at 60°C followed by measuring the fluorescence signal, 
and a cooldown step for 30 s at 40°C.
For detection of members of the S. anginosus group (S. anginosus, S. constellatus, and S. 
intermedius, also termed the S. milleri group), a set of primers was developed based on 
an alignment made in MEGA v6 of the recN sequences EU917226–EU917315 [12, 14]. The 
PCRs were performed in 10 µL reaction volumes, containing 5 µL 2× LC480 Probe Master 
Mix (Roche Diagnostics, Almere, the Netherlands), 0.5 µL of each primer (10 pmol/µL; 
Eurogentec), 0.5 µL SYTO82 (40 μM; Molecular Probes, Eugene, OR, USA), 2.5 µL ddH2O, 
and 1 µL sample DNA. The following PCR program was used: initial denaturation for 10 
min at 95°C, 35 cycles 5 s at 95°C, 5 s at 60°C, 10 s at 72°C, followed by a melting curve 
analysis at 65°C to 95°C. Fluorescence was measured after each extension step. 
The primer and probe sequences of all assays are provided in Table 1. 
Table 1. Primer and probe sequences.
Specificity Forward primer Probe Reverse primer
S. aureus* 5’-ACGACTARATAA
ACGCTCATTCG-3’
5’-HEX-TGAAATCTCATTA
CGTTGCATCGGA-BHQ1-3’
5’-GACGGCTTTTAC
ATACAGAACACA-3’
PVL* 5’-AAAAAGGCTCAG
GAGATACAAGTG-3’
5’-Cy5-TGGCAGAAATATGG
ATGTTACTCATGC-BHQ2-3’
5’-TGCCATAGTGTG
TTGTTCTTCTAGT-3’
S. pyogenes 5’-TTGGAAACGAT
AGCTAATACCG-3’
5’-HEX-CGCATGTTAGTAAT
TTAAAAGGGGCA-BHQ1-3’
5’-CGCAGGTCCA
TCTCATAGTG-3’
S. agalactiae 5’-TTGGAAACGAT
AGCTAATACCG-3’
5’-FAM-TGTTAGTTATTTAAA
AGGAGCAATTGC-BHQ1-3’
5’-CGCAGGTCCA
TCTCATAGTG-3’
S. dysgalactiae 
equisimilis
5’-TTGGAAACGAT
AGCTAATACCG-3’
5’-HEX-CCCATGTTAAACAT
TTAAAAGGTGCA-BHQ1-3’
5’-CGCAGGTCCA
TCTCATAGTG-3’
S. dysgalactiae
dysgalactiae
5’-TTGGAAACGAT
AGCTAATACCG-3’
5’-FAM-AATGGAGGACCC
ATGTCTTTCATTT-BHQ1-3’
5’-CGCAGGTCCA
TCTCATAGTG-3’
S. anginosus group 5’-TGGACAGCAT
TTGGTGGATA-3’
n/a 5’-GCTTACGCAAC
TGACGATACTG-3’
* This assay was previously published by Hopman et al. [13].
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Real-time PCR assays and analysis
The analytic specificity was tested by applying the newly developed Streptococcus assays 
on a set of 62 clinically relevant Streptococcus reference strains. The sensitivity of the 
Streptococcus assays was performed by applying 2-step dilution series of the relevant type 
strains, starting with an input ranging from 0.01 ng to 4.9 fg per reaction. The equivalent 
of genomic copies per reaction was calculated based on the genome sizes for each of the 
Streptococcus species [15, 16].
Statistical analysis
McNemar’s test was performed to study differences between real-time PCR and culture-
based assessment of pathogenic presence, for major abscesses and DFIs separately. 
The results for major abscesses and DFIs were combined for the determination of the 
sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). 
Both culture and real-time PCR were considered as the gold standard.
Results
Validation of species-specific Streptococcus real-time PCR assays and analysis
The S. agalactiae real-time PCR assay was found to be positive for the included strains, 
however, atypical amplification curves were observed for 2 S. anginosus strains. The S. 
pyogenes assay, included in the duplex with S. agalactiae, was found to be exclusively 
positive for strains that belong to this species. The S. dysgalactiae duplex real-time PCR 
assay was positive for the included subspecies dysgalactiae and equisimilis. However, the 
assay for subspecies equisimilis showed an atypical amplification curve for 1 strain of S. 
constellatus and S. cristatus. 
The lower limit of detection was found to be at the 9th dilution step for the targets S. 
agalactiae, both subspecies of S. dysgalactiae and S. pyogenes, equivalent of ~39 fg DNA 
per reaction, equal to ~17 genomic copies per reaction. For the intercalating dye-based 
assay for S. anginosus, S. constellatus and S. intermedius assay, the lower limit of detection 
was found to be at the 8th dilution step, equal to 78 fg or ~37 genomic copies per reaction.
Real-time PCR versus culture-based assessment of S. aureus prevalence in major 
abscesses and DFIs
The first visit biopsy samples of 150 major abscesses and 128 DFIs were collected, and the 
identification of S. aureus was performed by real-time PCR and culture. Of the 150 major 
abscess samples, 81% were positive for S. aureus by real-time PCR, whereas 44% were 
culture-positive for S. aureus. None of the culture-positive samples were real-time PCR-
negative (Table 2). Of the 128 DFI samples, 88% were positive for S. aureus by real-time 
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PCR, whereas 57% were culture-positive for S. aureus. One culture-positive sample was 
found to be real-time PCR-negative (Table 2). Subsequent real-time PCR determination 
of the cultured strain from the culture-positive, real-time PCR-negative biopsy sample 
confirmed the presence of S. aureus. Statistical analysis using McNemar’s test showed a 
significant difference between S. aureus real-time PCR and culture-based assessment for 
major abscesses (P<0.001) and DFIs (P<0.001). The sensitivity, specificity, PPV, and NPV for 
the S. aureus real-time PCR and culture are shown in Table 3.
Table 2. Real-time polymerase chain reaction (real-time PCR) versus culture-based assessment of gram-positive 
coccal prevalence in major abscesses and diabetic foot infections. 
Major abscesses Diabetic foot infections
Real-time 
PCR-positive
Real-time 
PCR-negative
Total Real-time 
PCR-positive
Real-time 
PCR-negative
Total
S. aureus
Culture-
positive
66 0 66 Culture-
positive
72 1 73
Culture-
negative
55 29 84 Culture-
negative
41 14 55
Total 121 29 150 Total 113 15 128
S. pyogenes
Culture-
positive
23 0 23 Culture-
positive
1 0 1
Culture-
negative
104 23 127 Culture-
negative
18 109 127
Total 127 23 150 Total 19 109 128
S. agalactiae
Culture-
positive
5 3 8 Culture-
positive
18 10 28
Culture-
negative
42 100 142 Culture-
negative
21 79 100
Total 47 103 150 Total 39 89 128
S. dysgalactiae subspecies equisimilis
Culture-
positive
3 1 4 Culture-
positive
16 1 17
Culture-
negative
0 146 146 Culture-
negative
12 99 111
Total 3 147 150 Total 28 100 128
S. anginosus group
Culture-
positive
16 7 23 Culture-
positive
6 1 7
Culture-
negative
13 114 127 Culture-
negative
13 108 121
Total 29 121 150 Total 19 109 128
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Real-time PCR-based assessment of PVL versus S. aureus prevalence in major 
abscesses and DFIs
The presence of S. aureus virulence factor PVL was determined by real-time PCR and 
correlated to S. aureus real-time PCR-positive biopsies. Of interest, the majority of S. aureus 
real-time PCR-positive major abscess samples were also PVL real-time PCR-positive (89%). 
In contrast, a minority of S. aureus real-time PCR-positive DFI samples were PVL real-time 
PCR-positive (14%). In both groups of major abscesses and DFIs, 2 samples were PVL real-
time PCR-positive but not S. aureus real-time PCR-positive (Table 4). 
Table 3. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of real-time 
polymerase chain reaction (real-time PCR) and culture-based assessment of gram-positive coccal prevalence in 
major abscesses and diabetic foot infections.
Species Reference Assay Sensitivity (%) Specificity (%) PPV (%) NPV (%)
S. aureus Culture
Real-time PCR
Real-time PCR
Culture
99
59
31
98
59
99
98
31
S. pyogenes Culture
Real-time PCR
Real-time PCR
Culture
100
16
86
100
16
100
100
86
S. agalactiae Culture
Real-time PCR
Real-time PCR
Culture
64
27
74
93
27
64
93
74
S. dysgalactiae 
equisimilis
Culture
Real-time PCR
Real-time PCR
Culture
91
61
95
99
61
91
99
95
S. anginosus 
group
Culture
Real-time PCR
Real-time PCR
Culture
73
46
90
97
46
73
97
90
Table 4. Real-time polymerase chain reaction (real-time PCR)-based assessment of Panton-Valentine leukocidin 
(PVL) versus Staphylococcus aureus prevalence in major abscesses and diabetic foot infections.
Major abscesses Diabetic foot infections
S. aureus
real-time 
PCR-positive
S. aureus
real-time 
PCR-negative
Total S. aureus
real-time 
PCR-positive
S. aureus
real-time 
PCR-negative
Total
PVL real-time 
PCR-positive
108 2 110 PVL real-time 
PCR-positive
16 2 18
PVL real-time 
PCR-negative
13 27 40 PVL real-time 
PCR-negative
97 13 110
Total 121 29 150 Total 113 15 128
Real-time PCR versus culture-based assessment of S. pyogenes prevalence in major 
abscesses and DFIs
Of the 150 major abscess samples, 85% were positive for S. pyogenes by real-time PCR, 
whereas 15% was culture-positive for S. pyogenes. None of the culture-positive samples 
were real-time PCR-negative (Table 2). Of the 128 DFI samples, 15% were positive for S. 
pyogenes by real-time PCR, whereas 1% were culture-positive for S. pyogenes. The only 
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culture-positive sample was also real-time PCR-positive (Table 2). Statistical analysis 
showed a significant difference between S. pyogenes real-time PCR and culture-based 
assessment for major abscesses (P<0.001) and DFIs (P<0.001). The sensitivity, specificity, 
PPV, and NPV for the S. pyogenes real-time PCR and culture are shown in Table 3.
Real-time PCR versus culture-based assessment of S. agalactiae prevalence in major 
abscesses and DFIs
Of the 150 major abscess samples, 31% were positive for S. agalactiae by real-time 
PCR, whereas 5% were culture-positive for S. agalactiae. Three culture-positive samples 
were real-time PCR-negative (Table 2). Of the 128 DFI samples, 30% were positive for 
S. agalactiae by real-time PCR, whereas 22% were culture-positive for S. agalactiae. Ten 
culture-positive samples were real-time PCR-negative (Table 2). Subsequent real-time PCR 
determination of the cultured strains from the 13 culture-positive, real-time PCR-negative 
biopsy samples, confirmed presence of S. agalactiae of 4 strains. The other 9 strains 
were negative for S. agalactiae real-time PCR. Statistical analysis showed a significant 
difference between S. agalactiae real-time PCR and culture-based assessment for major 
abscesses (P<0.001) but not DFIs (P>0.05). The sensitivity, specificity, PPV, and NPV for the 
S. agalactiae real-time PCR and culture are shown in Table 3.
Real-time PCR versus culture-based assessment of S. dysgalactiae prevalence in 
major abscesses and DFIs
Of the 150 major abscess samples, 2% were positive for S. dysgalactiae subspecies 
equisimilis by real-time PCR, whereas 3% were culture-positive for S. dysgalactiae subspecies 
equisimilis. One of the culture-positive samples was real-time PCR-negative (Table 2). Of 
the 128 DFI samples, 22% were positive for S. dysgalactiae subspecies equisimilis by real-
time PCR, whereas 13% were culture-positive for S. dysgalactiae subspecies equisimilis. 
One DFI sample was found to be culture-positive samples but real-time PCR-negative 
(Table 2). Subsequent real-time PCR determination of the cultured strains from the 
2 culture-positive, real-time PCR-negative biopsy samples confirmed the presence 
of S. dysgalactiae subspecies equisimilis of 1 strain. The other strain was negative for S. 
dysgalactiae subspecies equisimilis real-time PCR. Statistical analysis showed a significant 
difference between S. dysgalactiae subspecies equisimilis real-time PCR and culture-based 
assessment for DFIs (P<0.01) but not major abscesses (P>0.05). The sensitivity, specificity, 
PPV, and NPV for the S. dysgalactiae subspecies equisimilis real-time PCR and culture are 
shown in Table 3.
None of the 150 major abscess samples were real-time PCR or culture-positive for S. 
dysgalactiae subspecies dysgalactiae. Of the 128 DFI samples, only 1 sample was positive 
for S. dysgalactiae subspecies dysgalactiae by real-time PCR, but culture-negative, and, 
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also, 1 sample was culture-positive for S. dysgalactiae subspecies dysgalactiae but real-
time PCR-negative. Subsequent real-time PCR determination of the cultured strain from 
the culture-positive, real-time PCR-negative biopsy sample was negative for S. dysgalactiae 
subspecies dysgalactiae but positive for S. dysgalactiae subspecies equisimilis.
Real-time PCR versus culture-based assessment of S. anginosus group prevalence in 
major abscesses and DFIs
S. anginosus, S. constellatus, and S. intermedius together constitute the S. anginosus group. 
Of the 150 major abscess samples, 19% were positive for members of the S. anginosus 
group by real-time PCR, whereas 15% were culture-positive for members of the S. 
anginosus group. Seven culture-positive samples were real-time PCR-negative (Table 2). 
Of the 128 DFI samples, 15% were positive for members of the S. anginosus group by real-
time PCR, whereas 6% were culture-positive for members of the S. anginosus group. One 
culture-positive sample was real-time PCR-negative (Table 2). Subsequent real-time PCR 
determination of the cultured strains from the 8 culture-positive, real-time PCR-negative 
biopsy samples confirmed identification of S. anginosus group of 6 strains. Of the 2 other 
strains, 1 was negative for S. anginosus group real-time PCR and the other strain was not 
viable. Statistical analysis showed a significant difference between S. anginosus group 
real-time PCR and culture-based assessment, for DFIs (P<0.01) but not major abscesses 
(P>0.05). The sensitivity, specificity, PPV, and NPV for the S. anginosus group real-time PCR 
and culture are shown in Table 3.
Discussion
This study is the first to demonstrate that the use of direct real-time PCR versus culture-
based assessment for the determination of pathogens in clinical biopsy samples of 
patients with major abscesses and DFIs resulted in an increased detection of all studied 
cSSSI pathogens: S. aureus, S. pyogenes, S. agalactiae, S. dysgalactiae, and S. anginosus 
group. 
The current routine practice for detection and identification of bacterial pathogens in 
cSSSI is culture of biopsy samples collected from the site of infection. Development of 
direct real-time PCR assays on bacterial DNA isolated from biopsy samples resulted in 
a higher detection of 34% for S. aureus, 37% for S. pyogenes, 18% for S. agalactiae, 4% 
for S. dysgalactiae subspecies equisimilis, and 7% for the S. anginosus group compared 
to standard cultures. No differences were observed for S. dysgalactiae subspecies 
dysgalactiae, which could be due to its low prevalence in human infections [17]. Significant 
differences were found between real-time PCR and culture-assesment for S. aureus 
(major abscesses and DFIs), S. pyogenes (major abscesses and DFIs), S. agalactiae (major 
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abscesses), S. dysgalactiae subspecies equisimilis (DFIs), and S. anginosus group (DFIs). 
Possible explanations for the real-time PCR-positive, culture-negative biopsy samples are: 
culture is less sensitive than real-time PCR for the detection of organisms, real-time PCR 
detects nonviable organisms in contrast to culture, splitting of the biopsy sample into 2 
parts for culture and real-time PCR, contamination of the real-time PCR reagents, cross-
reactivity of the real-time PCR assay with DNA from other organisms or human origin not 
controlled for during the development of the assay inducing false-positives. 
In contrast, our real-time PCR assays did not identify some pathogens that were grown 
in culture. Possible explanations for the culture-positive, real-time PCR-negative biopsy 
samples are: real-time PCR is less sensitive than culture for the detection of organisms, 
incorrect determination during culture, low prevalence of bacterial DNA in the biopsy 
sample, splitting of the biopsy sample into 2 parts for culture and real-time PCR, low DNA 
yield or poor quality DNA after extraction or the presence of factors that inhibit the real-
time PCR assay, poor target specificity, and/or competition between primers and probes 
within the developed real-time PCR not controlled for during the development of the 
assay.
Other studies evaluating the potential of direct real-time PCR in the detection of the 
organisms studied here frequently found comparable or increased detection rates 
compared to culture methods. The detection of (methicillin-resistant) S. aureus by real-time 
PCR was similar to culture in samples from skin and soft tissue infections and osteoarticular 
infections [18, 19], and increased in a screening for MRSA colonization [20]. In addition, 
the detection of S. pyogenes by real-time PCR was similar to culture in throat swabs from 
suspected pharyngitis [21, 22]. Furthermore, similar and increased detection rates of S. 
agalactiae were found in screening samples of vaginal and neonatal colonization [23-25], 
and increased detection was observed by real-time PCR for S. agalactiae in cerebrospinal 
fluid and blood from patients suspected of meningitis and sepsis [26]. 
Overall, combined detection by either culture and/or real-time PCR resulted in 85% of 
samples positive for S. aureus, 68% positive for S. pyogenes, 36% positive for S. agalactiae, 
12% positive for S. dysgalactiae subspecies equisimilis, 0.7% positive for S. dysgalactiae 
subspecies dysgalactiae, and 20% positive for S. anginosus group. This again underlines 
the importance of gram-positive cocci in cSSSIs. Interestingly, there are differences in the 
species present in major abscesses and DFIs. S. pyogenes was mainly detected in biopsies 
from major abscesses, whereas S. dysgalactiae subspecies equisimilis was mainly found in 
biopsies from diabetic foot infections. Other identified pathogens were similarly present 
in both major abscesses and DFIs. In addition, a clear distinction was observed between 
major abscesses and DFIs for PVL positive S. aureus. 73% of the major abscesses, but 
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only 14% of the DFIs, were positive for PVL. PVL is a bi-component pore-forming toxin, 
encoded by the lukS-PV and lukF-PV genes, and is associated with lysis of leukocytes [27]. 
A recent meta-analysis confirmed the association between PVL and S. aureus skin and 
skin structure infections, which was not present for S. aureus invasive infections, such as 
pneumonia, musculoskeletal infections, and bacteremia [28]. 
In an attempt to evaluate the reliability of the real-time PCR and culture, we have calculated 
the sensitivity, specificity, PPV, and NPV. Both techniques were separately considered as 
the gold standard, as it is unknown which technique represents the “true” presence of 
pathogens in the biopsy samples. 
In conclusion, current routine bacteriological assessment of biopsies by culture is time-
consuming, requires viable pathogens, culture conditions suitable for growth, and results 
in lower detection sensitivity and may underestimate bacterial prevalence. However, given 
the fast and superior detection of cSSSI pathogens by real-time PCR, our study indicates 
that molecular analysis can be an additional method for the detection of bacteria in 
clinical samples. 
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Abstract 
Direct determination by pathogen-specific real-time PCR assay for B. fragilis was compared 
to culture in major abscess and DFI biopsy samples. Real-time PCR resulted in an increased 
detection rate of 12% for B. fragilis, and could improve the detection of B. fragilis in clinical 
samples.
B. fragilis real-time PCR in cSSSI biopsy samples | 141
8
Major abscesses and diabetic foot infections (DFIs) are prevalent subtypes of a spectrum 
of clinical conditions termed complicated skin and skin structure infections (cSSSIs) [1, 
2]. The microbiology of cSSSIs is diverse, as demonstrated during a recent clinical trial 
in patients with cSSSIs, 65% of the isolates contained gram-positive cocci, while 28% 
contained gram-negative bacilli. Anaerobes (7%) were found to a lesser extent and 
consisted mainly of the species Bacteroides fragilis (5.2%) [3].
B. fragilis is a gram-negative, obligate anaerobic rod present within the colon as part of 
the commensal microflora [4]. Both beneficial and harmful features have been described, 
depending on presence of virulence factors. B. fragilis strains producing polysaccharide A 
(PSA), exhibit immunomodulatory properties in the colon and have been shown to protect 
against the development of colitis in animal models [5]. In contrast, enterotoxigenic B. 
fragilis strains produce B. fragilis toxin (BFT) which is associated with diarrhoea in humans 
and led to development of colitis and colon cancer in animal models [6].
For accurate clinical decision-making and optimal antibiotic therapy, correct and fast 
determination of pathogens and their susceptibility is crucial. In routine practice, 
determination of Bacteroides species relies on culture of the clinical sample, during which 
they are easily overlooked, e.g. pathogens died before/during sampling and handling of 
the specimen, are present in mixed cultures, growth requires specific anaerobic conditions 
and requires longer periods of time. Different molecular assays, characterized by high 
sensitivity and fast turnaround times, have been developed in recent years to improve 
bacteriological detection [7, 8]. In this study, we evaluated the potential benefit of direct 
detection on clinical cSSSI samples by pathogen-specific real-time PCR assays for B. fragilis 
(and presence of enterotoxigenic B. fragilis). 
A total of 150 major abscess and 128 DFI, first visit, pre-study treatment samples of 225 
cSSSI patients were collected during a clinical trial [3]. Definitions and inclusion criteria of 
the study cohort are described elsewhere [3]. Samples were collected via biopsy of tissue 
or bone, curettage of the wound or aspiration of purulent discharge. After collection, 
samples were directly stored in preservation medium (BBL Port-A-Cul Transport vial, 
Becton Dickinson, Franklin Lakes, NJ, USA) and transported within 72 hours to the central 
laboratory (Eurofins medinet SAS, Plaisir, France). On arrival, samples were split in 2, 1 part 
for immediate culture and identification using standard clinical laboratory procedures, 
and another part was stored at -80°C for molecular analysis. Culture was performed 
according to CLSI guidelines and is described elsewhere [3].
Pathogen DNA was manually extracted by using the MolYsis Universal Microbial 
Detection kit for tissue samples (Molzym, Bremen, Germany) following the manufacturer’s 
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instructions, to improve sensitivity and specificity for pathogen DNA since interfering 
human DNA is removed [9]. Pathogen DNA extraction was carried out in a laminar flow 
cabinet to prevent contamination. Primers and hydrolysis probe (Table 1) to detect 
B. fragilis were designed for this study based on the recA gene using Primer3 [10]. To 
differentiate the 3 BFT-types a melting-curve real-time PCR approach was designed, 
based on a previously described gene locus [11] , with specific melting-curve peaks at 
74°C, 76°C and 78°C for BFT-type 1, 2 and 3, respectively [12, 13]. Real-time PCR reactions 
were performed as recently described by Stappers et al. [14]. 
Table 1. Primer and probe sequences. 
Specificity Forward primer Probe Reverse primer
B. fragilis 5’-GCTTTTGACC
GCTTCTATGC-3’
5’-FAM-CCTGTTCATCT
CGCAACCCGA-BHQ1-3’
5’-CAATTTCCAA
CGCCTGTTCT-3’
Enterotoxigenic
B. fragilis
5’-CAAGGACAAG
AAGTGCTGGA-3’
n/a 5’-TCGCATTCAG
GAAGATTCAA-3’
In silico analysis revealed a high-specificity for B. fragilis with no cross-specificity for other 
Bacteroides species. Of 29 well-characterized Bacteroides clinical isolates, including B. 
fragilis type-strain ATCC 25285, only the 11 B. fragilis isolates were positive for the B. fragilis 
real-time PCR. The BFT melting-curve PCR correctly identified 6 BFT-1, 5 BFT-2 and 1 BFT-3 
of 12 sequencing confirmed BFT-positive B. fragilis strains. The limit-of-detection (LoD) of 
both assays was determined by 2-fold DNA dilution series. Based on the average B. fragilis 
genome size of 5.3Mbp [15] the LoD was determined as being 156 and 625 genomic 
copies per reaction for the B. fragilis PCR and BFT melting-curve PCR, respectively.
Of the 278 major abscess and DFI samples, 60 were positive for B. fragilis by real-time PCR, 
compared to 26 B. fragilis positive culture samples. Real-time PCR detected B. fragilis in 
36 culture negative samples, but did not detect B. fragilis in 2 culture positive samples 
(Table 2). Subsequent 16S rRNA sequencing of the 2 cultured strains from the culture 
positive, real-time PCR negative biopsy samples identified them as being Escherichia coli 
and Streptococcus agalactiae. Of all 60 real-time PCR positive samples for B. fragilis, only 2 
were positive for BFT real-time PCR. Both samples were of DFI origin and contained BFT-2 
(data not shown).
Direct real-time PCR on DNA isolated from major abscess and DFI samples, resulted in 
an increased detection rate of 12% for B. fragilis, compared to culture. Statistical analysis 
using McNemar’s test confirmed a significant difference between B. fragilis real-time PCR 
and culture-based assessment for both major abscesses (P<0.001) and DFIs (P<0.05). 
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The added value of direct real-time PCR for the detection of B. fragilis has been studied 
previously in different clinical samples [16-19]. Increased detection of B. fragilis has been 
reported using direct conventional and real-time PCR in intra-abdominal and pelvic 
samples [16], real-time PCR in postoperative or traumatic wound infections [17], whereas 
detection was similar using conventional [18] or nested PCR [19] in various clinical samples. 
Both culture and real-time PCR were considered as gold standard for identification of 
B. fragilis. Sensitivity, specificity, positive predictive value (PPV) and negative predictive 
value (NPV) are shown in Table 2. Considering culture as a gold standard resulted in a high 
NPV and a poor PPV for our real-time PCR assay. Possible reasons for this discrepancy are 
real-time PCR is probably more sensitive than culture, real-time PCR may detect nonviable 
B. fragilis, contamination or cross-reactivity of the real-time PCR assay, or splitting of the 
biopsy sample for culture and real-time PCR, resulting in loss of the organism in 1 of the 
aliquots. 
According to the BFT melting-curve PCR, B. fragilis enterotoxin was not frequent in our 
cSSSI samples. Other studies have demonstrated 6% - 33% of extraintestinal isolates 
positive for B. fragilis enterotoxin [6].
In conclusion, this study demonstrated that the use of pathogen-specific real-time PCR 
assays for B. fragilis, directly on clinical samples from patients with major abscesses and 
DFIs, resulted in an increased detection of B. fragilis compared to culture and could be an 
additional method for detection in clinical samples. In the future, the high NPV of our real-
time PCR could be helpful in ruling out the presence of B. fragilis, the most frequent and 
virulent species of gram-negative anaerobic pathogens in cSSSI. When combined with 
Table 2. Real-time polymerase chain reaction (real-time PCR) versus culture-based assessment of Bacteroides 
fragilis prevalence in major abscesses and diabetic foot infections.
Major abscesses Diabetic foot infections
Real-time 
PCR-positive
Real-time 
PCR-negative
Total Real-time 
PCR-positive
Real-time 
PCR-negative
Total
B. fragilis
Culture-
positive
19 2 21 Culture-
positive
5 0 5
Culture-
negative
28 101 129 Culture-
negative
8 115 123
Total 47 103 150 Total 13 115 128
Species Reference Assay Sensitivity (%) Specificity (%) PPV (%) NPV (%)
B. fragilis Culture
Real-time PCR
Real-time PCR
Culture
92
40
86
99
40
92
99
86
PPV, positive predictive value; NPV, negative predictive value.
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PCR approaches that simultaneously detect (functional) antibiotic resistance genes this 
diagnostic strategy would support the clinical decision to add or delete antibiotics with 
an effective anaerobic spectrum. 
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Summary and discussion
 
The skin is our first line of defence against pathogens. Breaching this barrier may result 
in the invasion of microorganisms and the development of complicated skin and skin 
structure infections (cSSSIs), depending on the immune response of the host and the 
virulence of the pathogen. This thesis describes several studies investigating the innate 
immune response, as well as the presence of relevant pathogens and specific virulence 
factors for the development of cSSSIs.
The host innate immune diversity and response in cSSSIs 
In the first part of this thesis we focused on the role and diversity of the innate immune 
system of the host in cSSSIs. Cells of the innate immune system express pattern-
recognition receptors (PRRs), which recognize conserved pathogen-associated molecular 
patterns, and result in production of cytokines and activation of the immune response 
[1]. In Chapter 2, we review the different PRR families: Toll-like receptors, C-type lectin 
receptors, NOD-like receptors, RIG-I-like receptors and AIM2-like receptors and describe 
their signalling pathways and functions in response to infection. In addition, we reviewed 
how genetic variation in genes encoding these receptors influences their function and 
susceptibility to infectious disease, emphasizing the fact that infections are strongly 
influenced by the genetic make-up of each individual [2].
Each microbe activates a distinct set of PRRs, resulting in tailored immune responses 
for each pathogen. Bacteroides fragilis, although a commensal to the human intestinal 
microflora, is the most frequently isolated anaerobic microorganism in skin and soft 
tissue infections [3]. Depending on its location in the body and virulence factors, both 
protective and detrimental effects have been described. One the one hand, B. fragilis 
capsular polysaccharide A (PSA) exhibits immunomodulatory properties in the colon 
and is associated with protection against colitis in animal models. On the other hand, 
extraintestinal presence of B. fragilis PSA upon breach of the mucosal or skin barrier is 
associated with abscess formation [4]. Furthermore, enterotoxigenic B. fragilis strains 
expressing B. fragilis toxin (BFT) induce diarrhoea in humans and led to the development 
of colitis and colon cancer in animal models [5]. In Chapter 3, we investigated the PRRs 
involved in the recognition of B. fragilis and characterized its induced cytokine profile in 
peripheral blood mononuclear cells (PBMCs). Using a set of complementary approaches, 
including cell lines expressing specific PRRs, as well as antibody-blockage and genetic 
variants of PRRs in PBMCs, we were able to demonstrate that TLR2, TLR1 and NOD2, but 
not TLR4, TLR6, Dectin-1 or NOD1, mediate pattern recognition of B. fragilis. This was 
supported a previously described role for TLR2 and NOD2 in the recognition of B. fragilis 
[6-10], but contrasted with 1 study indicating TLR4 as a PRR for B. fragilis LPS [11]. TLR1 
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is through heterodimeric association with TLR2 involved in the recognition of various 
ligands of microbial origin, but the role for TLR1 in recognition of B. fragilis was described 
for the first time in our study. In addition, we demonstrated that B. fragilis is a strong 
inducer of IL-6 and IL-8 production, a moderate inducer of IL-1β and TNFα and a poor 
inducer of IL-10, IFNγ, IL-23 and IL-17 cytokine responses in human PBMCs. Another study 
confirmed the production of IL-6 and TNFα upon stimulation of human mononuclear cells 
with B. fragilis [12], whereas others focused on specific cell wall components in the murine 
setting [10, 13-17]. 
Besides gram-negative microorganisms such as B. fragilis, the vast majority of SSSIs are 
caused by gram-positive bacteria, mainly Staphylococcus aureus and Streptococcus species 
[18]. Based on the findings in Chapter 3 and the previously described role of TLRs and NLRs 
in recognition of these gram-positive bacteria [19-21], we aimed to investigate whether 
genetic variation in genes encoding these PRRs would affect the susceptibility to cSSSIs. 
Presence of genetic variants was determined in a cohort of patients with the important 
cSSSI subtypes: major abscess, diabetic foot infection, wound infection or infected 
ischemic ulcers and compared to healthy controls [22]. In Chapter 4, we demonstrated that 
genetic variants in TLR1 (S248N and R80T), TLR2 (P631H) and TLR6 (P249S) were associated 
with an increased susceptibility to cSSSIs. In contrast to healthy controls, patients with 
cSSSI were more often heterozygous or homozygous for the allelic variant. The fact that 
these variants in TLR1, TLR2 and TLR6 have also been linked to other infectious diseases 
[23-29] and that specifically these receptors are of major importance for innate immune 
recognition of gram-positive bacteria [19-21] further underlines their significance in the 
innate immune response to cSSSIs. Moreover, presence of allelic variants (248N and 80T) 
in TLR1 is associated with decreased activation of transcription factor NF-κB [30] and we 
demonstrated that these variants were associated with decreased cytokine responses of 
PBMCs after stimulation with S. aureus or specific TLR agonists, linking the impaired TLR 
function with the increased risk of the development of cSSSIs.
TLR1, TLR2 and TLR6 are located in a cluster on chromosome 4, together with TLR10. In 
Chapter 5, we investigated the role of the innate immune response to cSSSI pathogens 
and the effect of genetic variation in TLR10 on the susceptibility to cSSSIs. In contrast to 
the other members of the TLR2 gene cluster, TLR10 was demonstrated to function as an 
inhibitory receptor in the innate immune response to cSSSIs. Using a cell line which over-
expressed TLR2, TLR10 or both TLR2 and TLR10, we demonstrated that TLR10 inhibited 
the TLR2-mediated cytokine secretion after exposure to cSSSI pathogens S. aureus, 
B. fragilis and Escherichia coli. Neutralization the function of TLR10 on human PBMCs, 
using TLR10 antibodies, resulted in increased cytokine responses following exposure 
to cSSSI pathogens. Genetic variants I775L, I369L and N241H in TLR10 were associated 
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with a reduced susceptibility to cSSSIs, as patients with cSSSI were significantly less often 
heterozygous and homozygous for the allelic variants compared to the healthy controls. 
Moreover, presence of these allelic variants in TLR10 was associated with increased 
cytokine responses of PBMCs after stimulation with cSSSI pathogens or specific TLR 
agonists. These findings support the concept that TLR10 functions as a anti-inflammatory 
PRR [31-34], although 2 contrasting studies suggested a pro-inflammatory effect of this 
receptor [35, 36].
PRR recognition of a pathogen results in activation of an immune response and production 
of pro- and anti-inflammatory cytokines [1]. In Chapter 6, we investigated the influence 
of sequence variants in genes encoding cytokines on the susceptibility to cSSSIs, and 
studied their functional consequences on the innate immune response to these cSSSI 
pathogens. We demonstrated that genetic variants in IL6 rs1800797, TNF rs1800629 and 
IL17A rs8193036 increased susceptibility to cSSSIs, whereas IL10 rs1800871 and IFNG 
rs2069705 were associated with decreased susceptibility to cSSSIs, confirming their 
previously described importance in susceptibility to infectious disease [37-42]. Patients 
with cSSSI were more often heterozygous or homozygous for the allelic variant of IL6, 
TNF and IL17A and less often heterozygous and homozygous for the allelic variant of IL10 
and IFNG, compared to healthy controls. In contrast to previously described effects for 
IL6 rs1800797 [43] and IL10 rs1800871 [44], we were unable to demonstrate differences 
in cytokine responses of PBMCs from individuals carrying the associated genetic variants 
after stimulation with cSSSI pathogens. As the associated genetic variants are located in 
the promoter region of the gene, and therefore could impact on gene expression levels, 
we expected to observe differences in cytokine secretion. Possible reasons how the 
associated genetic variants can still influence susceptibility to cSSSIs are different kinetics 
of cytokine secretion, or altered biological function of the protein due to the genetic 
variant itself or linkage with an exonic variant which causing the effect.
Detection of pathogens in cSSSIs
In the second part of this thesis we focussed on the detection of common cSSSI pathogens, 
comparing routine culture with direct, pathogen-specific real-time PCR assays in clinical 
samples of patients with diabetic foot infections and major abscesses. In Chapter 7, we 
determined the presence of S. aureus, Streptococcus pyogenes, Streptococcus agalactiae, 
Streptococcus dysgalactiae, and the Streptococcus anginosus group. In comparison to 
culture, the direct real-time PCR assays resulted in a higher detection of 34% for S. aureus, 
37% for S. pyogenes, 18% for S. agalactiae, 4% for S. dysgalactiae subspecies equisimilis and 
7% for the S. anginosus group, whereas no differences were observed for S. dysgalactiae 
subspecies dysgalactiae. Differences were significant between real-time PCR and culture 
for in both major abscesses and DFIs for S. aureus and S. pyogenes, only major abscesses 
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for S. agalactiae, and only diabetic foot infections for S. dysgalactiae subspecies equisimilis 
and S. anginosus group. In Chapter 8, we determined the presence of B. fragilis and 
the direct real-time PCR assay resulted in 12% higher detection compared to culture, 
which was both significant in major abscesses and diabetic foot infections. These 
findings confirm for cSSSIs, which previously has been shown for other infections [45], 
that molecular detection is a fast, simple and sensitive alternative for the detection of 
pathogens compared to culture methods. In addition, we also determined the presence 
of S. aureus virulence factor Panton-Valentine leukocidin (PVL) and B. fragilis toxin (BFT), 
in Chapter 7 and Chapter 8 respectively. PVL is a pore-forming toxin, secreted by S. aureus 
and is associated with lysis of leukocytes [46]. We demonstrated that 73% of the major 
abscesses, but only 14% of the diabetic foot infections, were positive for PVL by real-time 
PCR, which aligns with a previously described association for PVL with S. aureus skin and 
skin structure infections [47]. BFT-producing B. fragilis strains have mainly been associated 
with diarrhoea in humans, but extraintestinal presence of enterotoxigenic B. fragilis has 
been reported [5]. In our study less than 1% of clinical cSSSI samples contained BFT-
producing B. fragilis, suggesting BFT does not play a role in cSSSIs.
General conclusions and future perspectives
In this thesis we have investigated the contribution of the innate immunity diversity of 
the host and presence of relevant pathogens in the development of cSSSIs. The advances 
presented here provide several additional pieces necessary for understanding the puzzle 
of skin and skin structure infections. On the side of the host, we have demonstrated a 
role for several PRRs in the recognition of cSSSI pathogens. We have shown the effect of 
genetic variation in PRRs of innate immune cells, as well as their effector molecules, the 
cytokines, on susceptibility to cSSSIs. These findings increase our understanding of the 
biological mechanisms involved in cSSSI pathogenesis. Furthermore, these host factors 
that predispose to development of cSSSIs, potentially provides opportunities to define a 
predictive profile for the screening of persons at risk of these infections and individualized 
diagnosis and treatment. On the side of the pathogen, we have demonstrated that 
molecular detection is a fast, simple and sensitive method for the detection of prevalent 
cSSSI pathogens, compared to routine culture methods. The true value of this method 
and the impact on clinical decision making and disease outcome for the patient remains 
to be determined, but the increased detection over culture is promising.
On both the side of the host and the pathogen we focussed on molecular methods that 
either detected a single genetic variant or a single pathogen. With the development and 
increasing accessibility of techniques such as next-generation sequencing, future studies 
should aim to comprehensively study the role of the genetic variants in the entire genome 
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for susceptibility to cSSSIs. On the side of the pathogen, next-generation sequencing 
would not only allow for the detection of all pathogens, but also the presence of virulence 
factors and antibiotic resistance genes in 1 assay. The combination of both approaches 
has the potential to revolutionize our understanding of the pathogenesis of cSSSIs.
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Samenvatting en discussie
De huid is de eerste verdedigingslinie tegen pathogenen. Indien deze barrière 
doorbroken wordt kan dit leiden tot invasie van micro-organismen en het ontstaan van 
huid en weke delen infecties. Deze infecties kunnen opgedeeld worden in 2 categorieën: 
ongecompliceerde (uSSSIs) en gecompliceerde huid en weke delen infecties (cSSSIs). 
cSSSIs betreft infecties die vaak dieper gelegen zijn en chirurgische behandeling vereisen, 
of komen voor in een gastheer die aan een aandoening(en) lijdt die de uitkomst van de 
behandeling kan beïnvloeden. Oppervlakkige infecties in gebieden waar de kans op 
anaerobe en gram-negatieve pathogenen groot is worden ook beschouwd als cSSSIs. Veel 
voorkomende cSSSIs zijn: diabetische voetinfecties (DFIs), majeure abcessen van de weke 
delen en infecties na chirurgie of trauma [1]. 
De kans op, en ernst van cSSSIs is afhankelijk van de immuunrespons van de gastheer 
alsmede de virulentie van het pathogeen. In dit proefschrift beschrijven we verschillende 
studies die aan de ene kant de rol van het aangeboren immuunsysteem en aan de andere 
kant de aanwezigheid van relevante pathogenen en specifieke virulentiefactoren, in de 
ontwikkeling van cSSSIs bestuderen. 
De aangeboren immuunrespons van de gastheer in cSSSIs
In het eerste deel van dit proefschrift ligt de nadruk op het bestuderen van de 
rol en diversiteit van het aangeboren immuunsysteem van de gastheer in cSSSIs. 
Cellen van het aangeboren immuunsysteem bevatten gespecialiseerde pathogeen 
herkenningsreceptoren (PRRs), waarmee ze pathogeen specifieke moleculaire patronen 
(PAMPs) kunnen herkennen van binnengedrongen micro-organismen. Deze herkenning 
leidt tot de productie van signaalstoffen, zogenaamde cytokines, en de activatie van de 
immuunrespons [2]. Hoofdstuk 2 geeft een overzicht van de verschillende PRR families: 
Toll-like receptoren, C-type lectine receptoren, NOD-like receptoren, RIG-I-like receptoren 
en AIM2-like receptoren en beschrijft de signaalroutes en functies van deze PRRs tijdens 
infectie. Daarnaast toont het hoe variatie in genen, die coderen voor deze receptoren, 
de functie en gevoeligheid voor infectieziekten beïnvloeden. Dit hoofdstuk benadrukt 
het feit dat infectieziekten sterk beïnvloed worden door de genetische opmaak van het 
individu [3].
Elk micro-organisme activeert een eigen combinatie van PRRs, resulterend in een 
specifieke immuunrespons voor ieder pathogeen. Bacteroides fragilis, een commensaal 
van de humane darmmicroflora, is het meest frequent geïsoleerde anaerobe micro-
organisme in cSSSIs [4]. Afhankelijk van de locatie in het lichaam en de aanwezigheid 
van virulentiefactoren, zijn zowel beschermende als schadelijke effecten beschreven 
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voor B. fragilis. Aan de ene kant heeft het capsulair polysaccharide A (PSA) van B. 
fragilis immuunmodulerende eigenschappen in het colon en is het geassocieerd met 
bescherming tegen colitis in diermodellen. Aan de andere kant is aanwezigheid van 
PSA buiten de darm, na het doorbreken van de mucosa of de huid, geassocieerd met 
de vorming van abcessen [5]. Daarnaast produceren enterotoxigene B. fragilis stammen 
een toxine (B. fragilis toxin; BFT) dat diarree veroorzaakt in mensen en leidt tot colitis en 
colonkanker in diermodellen [6]. In Hoofdstuk 3 word onderzocht welke PRRs betrokken 
zijn bij de herkenning van B. fragilis en het door B. fragilis geïnduceerde cytokineprofiel in 
perifeer bloed mononucleaire cellen (PBMCs) gekarakteriseerd. Door gebruik te maken 
van onder andere cellijnen die specifieke PRRs tot expressie brengen, alsmede blokkade 
van PRRs met antilichamen en genetische varianten van PRRs, konden wij aantonen dat 
TLR2, TLR1 en NOD2, maar niet TLR4, TLR6, Dectine-1 en NOD1 betrokken zijn bij de 
herkenning van B. fragilis. Dit werd ondersteund door een eerder beschreven rol voor 
TLR2 en NOD2 in de herkenning van B. fragilis [7-11], maar contrasteerde met een studie 
waarin TLR4 beschreven wordt als PRR voor B. fragilis LPS [12].
Via de vorming van een heterodimeer met TLR2, is TLR1 betrokken bij de herkenning van 
verschillende microbiële liganden, maar de rol van TLR1 in de herkenning van B. fragilis 
is voor het eerst beschreven in onze studie. Verder hebben we aangetoond dat B. fragilis 
een hoge productie van cytokines IL-6 en IL-8, een gematigde productie van cytokines 
IL-1β en TNFα en een lage productie van cytokines IL-10, IFNγ, IL-23 en IL-17 induceert in 
humane PBMCs. Een andere studie bevestigde de productie van IL-6 en TNFα na stimulatie 
van humane mononucleaire cellen met B. fragilis [13], terwijl andere studies zich richtten 
op specifieke celwand componenten van B. fragilis in diermodellen [11, 14-18].
Naast gram-negatieve micro-organismen zoals B. fragilis, wordt de meerderheid van de 
SSSIs veroorzaakt door gram-positieve bacteriën, met name Staphylococcus aureus en 
Streptococcus species [19]. Op basis van de bevindingen in Hoofdstuk 3 en de eerder 
beschreven rol voor TLRs en NLRs in de herkenning van deze gram-positieve bacteriën [20-
22], hebben we de relatie tussen genetische variatie in genen die coderen voor deze PRRs 
en de gevoeligheid voor cSSSIs onderzocht. Aanwezigheid van genetische varianten werd 
bepaald in een cohort van patiënten met de cSSSI subtypes: majeure abcessen, diabetische 
voetinfecties, wondinfecties of geïnfecteerde ischemische ulcera en vergeleken met 
gezonde controles [23]. In Hoofdstuk 4, wordt aangetoond dat genetische varianten in 
TLR1 (S248N en R80T), TLR2 (P631H) en TLR6 (P249S) geassocieerd zijn met een verhoogde 
gevoeligheid voor cSSSIs. In tegenstelling tot gezonde controles, zijn patiënten met cSSSI 
vaker heterozygoot of homozygoot voor de allelische variant. Het feit dat deze varianten 
in TLR1, TLR2 en TLR6 ook geassocieerd zijn met andere infectieziekten [24-30], en specifiek 
deze PRRs van groot belang zijn voor de herkenning van gram-positieve bacteriën [20-22], 
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onderstreept de belangrijke rol van deze receptoren in de aangeboren immuunrespons 
bij cSSSIs. Bovendien is de aanwezigheid van allelische varianten (248N en 80T) in TLR1 
geassocieerd met een verlaagde activatie van transcriptiefactor NF-κB [31] en hebben wij 
kunnen aantonen dat aanwezigheid van deze varianten na stimulatie van PBMCs met S. 
aureus en specifieke TLR agonisten leidt tot lagere cytokineresponsen, welke mogelijk de 
verhoogde gevoeligheid voor cSSSIs verklaren. 
TLR1, TLR2 en TLR6 liggen in een cluster op chromosoom 4, samen met TLR10. In 
Hoofdstuk 5 wordt de rol van de aangeboren immuunrespons op cSSSI pathogenen en 
het effect van genetische variatie in TLR10 op de gevoeligheid voor cSSSIs onderzocht. In 
tegenstelling tot de overige TLRs in het TLR2-gencluster, konden wij aantonen dat TLR10 
als een remmende receptor functioneert in de aangeboren immuunrespons tegen cSSSIs. 
Met behulp van een cellijn die TLR2, TLR10, of beide tot overexpressie brengt, hebben we 
aangetoond dat TLR10 de door TLR2-gemedieerde cytokinesecretie remt na blootstelling 
aan cSSSI pathogenen S. aureus, B. fragilis en Escherichia coli. Het neutraliseren van de functie 
van TLR10 in humane PBMCs, met behulp TLR10-antilichamen, resulteerde in verhoogde 
cytokine responsen na blootstelling aan cSSSI pathogenen. Genetische varianten I775L, 
I369L en N241H in TLR10 zijn geassocieerd met een verminderde gevoeligheid voor 
cSSSIs, wat betekent dat patiënten met cSSSI significant minder vaak heterozygoot 
en homozygoot zijn voor het allelische varianten vergeleken met gezonde controles. 
Bovendien konden wij aantonen dat de aanwezigheid van deze allelische varianten in 
TLR10 geassocieerd is met verhoogde cytokineresponsen door PBMCs na stimulatie 
met cSSSI pathogenen of specifieke TLR-agonisten. Deze bevindingen ondersteunen 
de consensus dat TLR10 functioneert als een anti-inflammatoire PRR [32-35], hoewel 2 
contrasterende studies suggereren dat TLR10 een pro-inflammatoire receptor is [36, 37].
PRR herkenning van een pathogeen resulteert in activatie van een immuunrespons en 
de productie van pro- en anti-inflammatoire cytokines [2]. In Hoofdstuk 6 wordt het 
effect van genetische varianten in genen die coderen voor cytokines op de gevoeligheid 
voor de ontwikkeling van cSSSIs onderzocht, en de functionele gevolgen van deze 
varianten voor de aangeboren immuunrespons op cSSSI pathogenen. We konden 
aantonen dat genetische varianten in IL6 rs1800797, TNF rs1800629 en IL17A rs8193036 
geassocieerd zijn met een verhoogde gevoeligheid voor cSSSIs, terwijl IL10 rs1800871 
en IFNG rs2069705 geassocieerd zijn met een verminderde gevoeligheid voor cSSSIs. Dit 
onderstreept nogmaals de eerder beschreven rol voor deze genetische varianten in de 
vatbaarheid voor infectieziekten [38-43]. Patiënten met cSSSI waren vaker heterozygoot of 
homozygoot voor de allelische variant van IL6, TNF en IL17A en minder vaak heterozygoot 
en homozygoot voor de allelische variant van IL10 en IFNG, vergeleken met gezonde 
controles. In tegenstelling tot de eerder beschreven effecten voor IL6 rs1800797 [44] en 
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IL10 rs1800871 [45], waren wij niet in staat verschillen in cytokineresponsen van PBMCs 
van individuen met en zonder de geassocieerde genetische varianten aan te tonen na 
stimulatie met cSSSI pathogenen. Aangezien de geassocieerde genetische varianten 
gelokaliseerd zijn in het promotorgebied van het gen, en daarom van invloed kunnen zijn 
op genexpressie, hadden we verwacht verschillen in de cytokinesecretie te observeren. 
Mogelijk kunnen de geassocieerde genetische varianten de gevoeligheid voor cSSSIs 
beïnvloeden door een afwijkende kinetiek van cytokinesecretie, of een veranderde 
biologische functie van het eiwit als gevolg van de genetische variant zelf of gelinkt aan 
een exon-variant die het effect veroorzaakt.
Detectie van pathogenen in cSSSIs
In het tweede deel van dit proefschrift hebben we ons gericht op de detectie van veel 
voorkomende cSSSI pathogenen, door routine cultuurtechnieken te vergelijken met 
directe, pathogeen-specifieke real-time PCR-assays op klinische monsters van patiënten 
met DFIs en majeure abcessen. In Hoofdstuk 7, beschrijft de detectie van S. aureus, 
Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae en de 
Streptococcus anginosus groep. In vergelijking met de kweek, resulteerde de directe real-
time PCR-assays in een hogere detectie van 34% voor S. aureus, 37% voor S. pyogenes, 
18% voor S. agalactiae, 4% voor S. dysgalactiae subspecies equisimilis en 7% voor de S. 
anginosus groep, terwijl geen verschillen werden waargenomen voor S. dysgalactiae 
subspecies dysgalactiae. De verschillen tussen de real-time PCR en kweek waren 
significant voor zowel majeure abcessen en DFIs voor S. aureus en S. pyogenes, enkel voor 
majeure abcessen voor S. agalactiae, en enkel voor DFIs voor S. dysgalactiae subspecies 
equisimilis en de S. anginosus groep. In Hoofdstuk 8, wordt de aanwezigheid van B. 
fragilis bepaald en de directe real-time PCR resulteerde in een 12% hogere detectie in 
vergelijking met cultuurtechnieken, wat significant was voor zowel majeure abcessen en 
DFIs. Deze bevindingen bevestigen voor cSSSIs, wat al eerder aangetoond is voor andere 
infecties [46], dat moleculaire detectie een snel, eenvoudig en gevoelig alternatief is voor 
de detectie van pathogenen in vergelijking met cultuurtechnieken. Daarnaast hebben we 
ook de aanwezigheid van S. aureus virulentiefactor Panton-Valentine Leukocidine (PVL) 
en B. fragilis toxine (BFT) bepaald in respectievelijk Hoofdstuk 7 en Hoofdstuk 8. PVL is 
een poriënvormend toxine wat uitgescheiden wordt door S. aureus en gepaard gaat met 
de lysis van leukocyten [47]. Met behulp van real-time PCR konden we aantonen dat 73% 
van de majeure abcessen en slechts 14% van de DFIs positief waren voor PVL. Dit komt 
overeen met een eerder beschreven associatie van PVL met S. aureus huid en weke delen 
infecties [48]. BFT-producerende B. fragilis stammen zijn hoofdzakelijk geassocieerd met 
diarree bij de mens, maar aanwezigheid van enterotoxigene B. fragilis buiten de darm is 
eerder beschreven [6]. Echter, in onze studie bevatte minder dan 1% van de klinische cSSSI 
monsters BFT-producerende B. fragilis, wat suggereert dat BFT geen rol speelt in cSSSIs.
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Conclusies en toekomstperspectieven
In dit proefschrift wordt de bijdrage van genetische variatie in de aangeboren immuniteit 
van de gastheer en de aanwezigheid van pathogenen in de ontwikkeling van cSSSIs 
onderzocht. De hier gepresenteerde ontwikkelingen bieden een aantal aanvullende 
stukken die nodig zijn om de ingewikkelde puzzel van de huid en weke infecties op te 
lossen. Aan de kant van de gastheer hebben we de rol voor enkele PRRs in de herkenning 
van cSSSI pathogenen aangetoond. Daarnaast hebben we laten zien dat genetische 
variatie in PRRs van de aangeboren immuniteit, evenals hun effector-moleculen (de 
cytokines), effect hebben op de gevoeligheid voor cSSSIs. Deze bevindingen versterken 
onze kennis van de biologische mechanismen die betrokken zijn bij pathogenese van 
cSSSIs. Bovendien leiden deze factoren van de gastheer tot een predispositie voor cSSSIs, 
wat mogelijk perspectieven biedt voor de ontwikkeling van een voorspellend profiel. 
Toepassingen hiervan zijn het screenen van personen die risico lopen op deze infecties, 
bijvoorbeeld voor een chirurgische ingreep, en voor een geïndividualiseerde diagnose of 
behandeling. Aan de kant van het pathogeen hebben we aangetoond dat moleculaire 
detectie, in vergelijking met routine kweekmethoden, een snelle, eenvoudige en 
gevoelige techniek is voor het detecteren van veel voorkomende cSSSI pathogenen. De 
werkelijke waarde van deze methode en de invloed op de klinische besluitvorming en de 
ziekte uitkomst voor de patiënt zal nog moeten blijken, maar de verhoogde detectie ten 
opzichte van kweektechnieken is veelbelovend.
Zowel in ons onderzoek naar de immuunrespons van de gastheer als het pathogeen 
hebben wij ons gericht op moleculaire methoden die gericht waren enerzijds op het 
detecteren van een genetische variant of anderzijds op een specifiek pathogeen. Met de 
ontwikkeling en de toenemende toegankelijkheid van technieken zoals next-generation 
sequencing dienen toekomstige studies zich te richten op diepgaande analyses van de 
rol van genetische varianten in het gehele menselijke genoom op de gevoeligheid voor 
cSSSIs. Aan de kant van het pathogeen zou next-generation sequencing niet alleen de 
mogelijkheid bieden tot de detectie van micro-organismen, maar ook de aanwezigheid 
van virulentiefactoren en antibiotica resistentiegenen; dit alles gecombineerd in één 
enkel assay. De combinatie van beide benaderingen zal onze kennis van de pathogenese 
van cSSSIs revolutioneren.
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